CN116615440A - 包含修饰的il-2多肽的多肽及其用途 - Google Patents
包含修饰的il-2多肽的多肽及其用途 Download PDFInfo
- Publication number
- CN116615440A CN116615440A CN202180053315.0A CN202180053315A CN116615440A CN 116615440 A CN116615440 A CN 116615440A CN 202180053315 A CN202180053315 A CN 202180053315A CN 116615440 A CN116615440 A CN 116615440A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- binding domain
- modified
- substitution
- antigen binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 634
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 629
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 628
- 108010002350 Interleukin-2 Proteins 0.000 title claims abstract description 89
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 185
- 230000002829 reductive effect Effects 0.000 claims abstract description 38
- 230000027455 binding Effects 0.000 claims description 369
- 108091007433 antigens Proteins 0.000 claims description 352
- 102000036639 antigens Human genes 0.000 claims description 352
- 239000000427 antigen Substances 0.000 claims description 350
- 238000006467 substitution reaction Methods 0.000 claims description 263
- 210000004027 cell Anatomy 0.000 claims description 196
- 238000000034 method Methods 0.000 claims description 107
- 150000001413 amino acids Chemical group 0.000 claims description 92
- 206010028980 Neoplasm Diseases 0.000 claims description 72
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 69
- 230000035772 mutation Effects 0.000 claims description 68
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 66
- 241000282414 Homo sapiens Species 0.000 claims description 62
- 230000014509 gene expression Effects 0.000 claims description 51
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 48
- 210000000822 natural killer cell Anatomy 0.000 claims description 43
- 230000035755 proliferation Effects 0.000 claims description 42
- 102220096696 rs62625272 Human genes 0.000 claims description 41
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 40
- 201000011510 cancer Diseases 0.000 claims description 38
- 102220097722 rs876660020 Human genes 0.000 claims description 34
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 32
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 32
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 32
- 102220497892 NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 11_H16A_mutation Human genes 0.000 claims description 31
- 230000001965 increasing effect Effects 0.000 claims description 27
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 25
- 229960002621 pembrolizumab Drugs 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 23
- 102000039446 nucleic acids Human genes 0.000 claims description 23
- 108020004707 nucleic acids Proteins 0.000 claims description 23
- 150000007523 nucleic acids Chemical class 0.000 claims description 23
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 22
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 22
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 claims description 21
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 claims description 21
- 102200006184 rs11552822 Human genes 0.000 claims description 21
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 238000002560 therapeutic procedure Methods 0.000 claims description 19
- 239000000556 agonist Substances 0.000 claims description 18
- 229940124597 therapeutic agent Drugs 0.000 claims description 18
- 230000037430 deletion Effects 0.000 claims description 17
- 238000012217 deletion Methods 0.000 claims description 17
- 102000017578 LAG3 Human genes 0.000 claims description 16
- 239000002246 antineoplastic agent Substances 0.000 claims description 16
- 102200100726 rs61752874 Human genes 0.000 claims description 16
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 15
- -1 Kabat amino acids Chemical class 0.000 claims description 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 13
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 13
- 101150069255 KLRC1 gene Proteins 0.000 claims description 13
- 101100404845 Macaca mulatta NKG2A gene Proteins 0.000 claims description 13
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 claims description 13
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 13
- 230000001093 anti-cancer Effects 0.000 claims description 13
- 230000004663 cell proliferation Effects 0.000 claims description 13
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 12
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 12
- 238000000338 in vitro Methods 0.000 claims description 12
- 208000014018 liver neoplasm Diseases 0.000 claims description 12
- 101150064015 FAS gene Proteins 0.000 claims description 11
- 102220580198 Non-receptor tyrosine-protein kinase TYK2_L19A_mutation Human genes 0.000 claims description 11
- 238000001727 in vivo Methods 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 102220511328 F-actin-capping protein subunit beta_Q22A_mutation Human genes 0.000 claims description 9
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 claims description 9
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 9
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 9
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 claims description 9
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 claims description 9
- 102220503468 Superoxide dismutase [Cu-Zn]_D84S_mutation Human genes 0.000 claims description 9
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 9
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 9
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 9
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 9
- 102220540040 Alkaline phosphatase, placental type_R38A_mutation Human genes 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 206010014733 Endometrial cancer Diseases 0.000 claims description 8
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 8
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 8
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 8
- 206010038389 Renal cancer Diseases 0.000 claims description 8
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 8
- 206010017758 gastric cancer Diseases 0.000 claims description 8
- 201000010982 kidney cancer Diseases 0.000 claims description 8
- 201000007270 liver cancer Diseases 0.000 claims description 8
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 8
- 201000011549 stomach cancer Diseases 0.000 claims description 8
- 239000004471 Glycine Substances 0.000 claims description 7
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 7
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims description 7
- 108010004222 Natural Cytotoxicity Triggering Receptor 3 Proteins 0.000 claims description 7
- 102100032852 Natural cytotoxicity triggering receptor 3 Human genes 0.000 claims description 7
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims description 7
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims description 7
- 239000005557 antagonist Substances 0.000 claims description 7
- 239000003124 biologic agent Substances 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 244000309459 oncolytic virus Species 0.000 claims description 7
- 102200139516 rs35960830 Human genes 0.000 claims description 7
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical group COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 6
- 210000004072 lung Anatomy 0.000 claims description 6
- 238000001959 radiotherapy Methods 0.000 claims description 6
- 238000002271 resection Methods 0.000 claims description 6
- 102220222423 rs765125459 Human genes 0.000 claims description 6
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 5
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 5
- 102220604965 Killer cell immunoglobulin-like receptor 3DL1_M23V_mutation Human genes 0.000 claims description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 102220608429 Mitogen-activated protein kinase kinase kinase kinase 1_E95V_mutation Human genes 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 102220498123 Protein LRATD2_E95S_mutation Human genes 0.000 claims description 5
- 102220643014 Protein phosphatase 1A_Q22G_mutation Human genes 0.000 claims description 5
- 102220640550 Putative oxidoreductase GLYR1_L19S_mutation Human genes 0.000 claims description 5
- 206010039491 Sarcoma Diseases 0.000 claims description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 5
- 102220547809 Serine/threonine-protein kinase B-raf_N88T_mutation Human genes 0.000 claims description 5
- 102220603562 TYRO protein tyrosine kinase-binding protein_Q22D_mutation Human genes 0.000 claims description 5
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 5
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 5
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 210000004698 lymphocyte Anatomy 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 102220198097 rs121913236 Human genes 0.000 claims description 5
- 102200000390 rs121917859 Human genes 0.000 claims description 5
- 102220056479 rs200635937 Human genes 0.000 claims description 5
- 102200045855 rs72554624 Human genes 0.000 claims description 5
- 102220062675 rs786204152 Human genes 0.000 claims description 5
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 5
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 4
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 4
- 206010005949 Bone cancer Diseases 0.000 claims description 4
- 208000018084 Bone neoplasm Diseases 0.000 claims description 4
- 102100038077 CD226 antigen Human genes 0.000 claims description 4
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 4
- 208000002699 Digestive System Neoplasms Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 4
- 206010019695 Hepatic neoplasm Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 4
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
- 201000000582 Retinoblastoma Diseases 0.000 claims description 4
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims description 4
- 206010061934 Salivary gland cancer Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 4
- 206010057644 Testis cancer Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 4
- 206010047741 Vulval cancer Diseases 0.000 claims description 4
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 4
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 4
- 201000009036 biliary tract cancer Diseases 0.000 claims description 4
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 4
- 201000000220 brain stem cancer Diseases 0.000 claims description 4
- 102220350724 c.68T>A Human genes 0.000 claims description 4
- 201000007455 central nervous system cancer Diseases 0.000 claims description 4
- 201000010918 connective tissue cancer Diseases 0.000 claims description 4
- 208000024558 digestive system cancer Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 208000024519 eye neoplasm Diseases 0.000 claims description 4
- 230000003325 follicular Effects 0.000 claims description 4
- 201000003444 follicular lymphoma Diseases 0.000 claims description 4
- 201000010231 gastrointestinal system cancer Diseases 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 208000020082 intraepithelial neoplasia Diseases 0.000 claims description 4
- 201000005264 laryngeal carcinoma Diseases 0.000 claims description 4
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 4
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 4
- 230000002101 lytic effect Effects 0.000 claims description 4
- 201000000564 macroglobulinemia Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 201000008106 ocular cancer Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 201000002628 peritoneum cancer Diseases 0.000 claims description 4
- 230000004962 physiological condition Effects 0.000 claims description 4
- 206010038038 rectal cancer Diseases 0.000 claims description 4
- 201000001275 rectum cancer Diseases 0.000 claims description 4
- 210000002345 respiratory system Anatomy 0.000 claims description 4
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 4
- 102220227229 rs1064796897 Human genes 0.000 claims description 4
- 102200006515 rs727503110 Human genes 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 201000003120 testicular cancer Diseases 0.000 claims description 4
- 239000004308 thiabendazole Substances 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 230000002485 urinary effect Effects 0.000 claims description 4
- 206010046766 uterine cancer Diseases 0.000 claims description 4
- 201000005102 vulva cancer Diseases 0.000 claims description 4
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 3
- 102220598064 Cell division cycle and apoptosis regulator protein 1_N88A_mutation Human genes 0.000 claims description 3
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 3
- 102220603939 Clathrin heavy chain 1_P65N_mutation Human genes 0.000 claims description 3
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 claims description 3
- 108700004922 F42A Proteins 0.000 claims description 3
- 101150112082 Gpnmb gene Proteins 0.000 claims description 3
- 102100035943 HERV-H LTR-associating protein 2 Human genes 0.000 claims description 3
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 3
- 101001021491 Homo sapiens HERV-H LTR-associating protein 2 Proteins 0.000 claims description 3
- 101000955999 Homo sapiens V-set domain-containing T-cell activation inhibitor 1 Proteins 0.000 claims description 3
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 3
- 206010025312 Lymphoma AIDS related Diseases 0.000 claims description 3
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 3
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 claims description 3
- 102220533967 Protein BEX1_E61S_mutation Human genes 0.000 claims description 3
- 102220495631 Putative uncharacterized protein LOC645739_F42A_mutation Human genes 0.000 claims description 3
- 102220610852 Thialysine N-epsilon-acetyltransferase_L72G_mutation Human genes 0.000 claims description 3
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 3
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 3
- 102220363900 c.182A>C Human genes 0.000 claims description 3
- 102220359607 c.194C>A Human genes 0.000 claims description 3
- 102220344885 c.67A>T Human genes 0.000 claims description 3
- 229940127089 cytotoxic agent Drugs 0.000 claims description 3
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 3
- 229960005386 ipilimumab Drugs 0.000 claims description 3
- 229960003301 nivolumab Drugs 0.000 claims description 3
- 102220234588 rs1114167484 Human genes 0.000 claims description 3
- 102220074162 rs113134544 Human genes 0.000 claims description 3
- 101150046249 Havcr2 gene Proteins 0.000 claims description 2
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 claims description 2
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims description 2
- 239000000710 homodimer Substances 0.000 claims description 2
- 102220223852 rs1060502978 Human genes 0.000 claims description 2
- 102200006514 rs121913236 Human genes 0.000 claims description 2
- 102220308083 rs1462326368 Human genes 0.000 claims description 2
- 102200065860 rs201442000 Human genes 0.000 claims description 2
- 102200105319 rs397514675 Human genes 0.000 claims description 2
- 229950007217 tremelimumab Drugs 0.000 claims description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 23
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 23
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 claims 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 3
- 102200042537 rs121909608 Human genes 0.000 claims 1
- 102200108023 rs199473051 Human genes 0.000 claims 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 abstract description 50
- 102000010789 Interleukin-2 Receptors Human genes 0.000 abstract description 50
- 102000000588 Interleukin-2 Human genes 0.000 abstract description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 140
- 235000001014 amino acid Nutrition 0.000 description 114
- 230000000694 effects Effects 0.000 description 101
- 108020001507 fusion proteins Proteins 0.000 description 75
- 102000037865 fusion proteins Human genes 0.000 description 74
- 230000008685 targeting Effects 0.000 description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 38
- 210000003289 regulatory T cell Anatomy 0.000 description 35
- 238000011282 treatment Methods 0.000 description 34
- 201000010099 disease Diseases 0.000 description 29
- 230000004048 modification Effects 0.000 description 27
- 238000012986 modification Methods 0.000 description 27
- 238000000684 flow cytometry Methods 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 26
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 22
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 22
- 235000018102 proteins Nutrition 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 22
- 230000006052 T cell proliferation Effects 0.000 description 21
- 239000011324 bead Substances 0.000 description 20
- 239000000203 mixture Substances 0.000 description 20
- 230000037396 body weight Effects 0.000 description 19
- 230000000284 resting effect Effects 0.000 description 16
- 230000001225 therapeutic effect Effects 0.000 description 15
- 230000009258 tissue cross reactivity Effects 0.000 description 15
- 230000004913 activation Effects 0.000 description 14
- 102000005962 receptors Human genes 0.000 description 14
- 108020003175 receptors Proteins 0.000 description 14
- 102200013599 rs452472 Human genes 0.000 description 14
- 239000013598 vector Substances 0.000 description 14
- 230000006044 T cell activation Effects 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 239000013074 reference sample Substances 0.000 description 12
- 230000011664 signaling Effects 0.000 description 12
- 230000000903 blocking effect Effects 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 230000009467 reduction Effects 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 210000001519 tissue Anatomy 0.000 description 11
- 230000004071 biological effect Effects 0.000 description 10
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 108091033319 polynucleotide Proteins 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 239000000539 dimer Substances 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 102000016914 ras Proteins Human genes 0.000 description 9
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 8
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 8
- 102000001712 STAT5 Transcription Factor Human genes 0.000 description 8
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 231100000673 dose–response relationship Toxicity 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 7
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 7
- 125000000539 amino acid group Chemical group 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 238000006471 dimerization reaction Methods 0.000 description 7
- 239000000833 heterodimer Substances 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 239000004570 mortar (masonry) Substances 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000009870 specific binding Effects 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 230000003213 activating effect Effects 0.000 description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 238000009099 neoadjuvant therapy Methods 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108010087819 Fc receptors Proteins 0.000 description 4
- 102000009109 Fc receptors Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 4
- 238000009098 adjuvant therapy Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004671 cell-free system Anatomy 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 210000002602 induced regulatory T cell Anatomy 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- 206010061818 Disease progression Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 108700025316 aldesleukin Proteins 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 3
- 210000004443 dendritic cell Anatomy 0.000 description 3
- 230000005750 disease progression Effects 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000005734 heterodimerization reaction Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 210000004882 non-tumor cell Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102220112880 rs370986101 Human genes 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 150000008163 sugars Chemical group 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102220467418 Acyl-coenzyme A thioesterase MBLAC2_E61Q_mutation Human genes 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102220540043 Alkaline phosphatase, placental type_R38G_mutation Human genes 0.000 description 2
- 101150075764 CD4 gene Proteins 0.000 description 2
- 241000282832 Camelidae Species 0.000 description 2
- 241000251730 Chondrichthyes Species 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000935587 Homo sapiens Flavin reductase (NADPH) Proteins 0.000 description 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 2
- 102000037978 Immune checkpoint receptors Human genes 0.000 description 2
- 108091008028 Immune checkpoint receptors Proteins 0.000 description 2
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 229960005310 aldesleukin Drugs 0.000 description 2
- 229960000548 alemtuzumab Drugs 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000005341 cation exchange Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 108091008042 inhibitory receptors Proteins 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000004985 myeloid-derived suppressor cell Anatomy 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 210000003668 pericyte Anatomy 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 210000001995 reticulocyte Anatomy 0.000 description 2
- 102200006183 rs11552822 Human genes 0.000 description 2
- 102220046274 rs587782792 Human genes 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000009450 sialylation Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- XZWXFWBHYRFLEF-FSPLSTOPSA-N Ala-His Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 XZWXFWBHYRFLEF-FSPLSTOPSA-N 0.000 description 1
- IPWKGIFRRBGCJO-IMJSIDKUSA-N Ala-Ser Chemical compound C[C@H]([NH3+])C(=O)N[C@@H](CO)C([O-])=O IPWKGIFRRBGCJO-IMJSIDKUSA-N 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- 102100021266 Alpha-(1,6)-fucosyltransferase Human genes 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 101001007348 Arachis hypogaea Galactose-binding lectin Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- RJUHZPRQRQLCFL-IMJSIDKUSA-N Asn-Asn Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(O)=O RJUHZPRQRQLCFL-IMJSIDKUSA-N 0.000 description 1
- TWXZVVXRRRRSLT-IMJSIDKUSA-N Asn-Cys Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(O)=O TWXZVVXRRRRSLT-IMJSIDKUSA-N 0.000 description 1
- IQTUDDBANZYMAR-WDSKDSINSA-N Asn-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(N)=O IQTUDDBANZYMAR-WDSKDSINSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 229940125565 BMS-986016 Drugs 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 229920002799 BoPET Polymers 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102100038078 CD276 antigen Human genes 0.000 description 1
- 102000049320 CD36 Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- 101100510617 Caenorhabditis elegans sel-8 gene Proteins 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 244000267640 Dendrobium capra Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101100421450 Drosophila melanogaster Shark gene Proteins 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102220510047 FAS-associated death domain protein_E51R_mutation Human genes 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 229910052688 Gadolinium Inorganic materials 0.000 description 1
- JEFZIKRIDLHOIF-BYPYZUCNSA-N Gln-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(O)=O JEFZIKRIDLHOIF-BYPYZUCNSA-N 0.000 description 1
- KOSRFJWDECSPRO-WDSKDSINSA-N Glu-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(O)=O KOSRFJWDECSPRO-WDSKDSINSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000002927 Hamartoma Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- 101000819490 Homo sapiens Alpha-(1,6)-fucosyltransferase Proteins 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 description 1
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 1
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- WMDZARSFSMZOQO-DRZSPHRISA-N Ile-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 WMDZARSFSMZOQO-DRZSPHRISA-N 0.000 description 1
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 description 1
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 101150030213 Lag3 gene Proteins 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000019298 Lipocalin Human genes 0.000 description 1
- 108050006654 Lipocalin Proteins 0.000 description 1
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 101000574441 Mus musculus Alkaline phosphatase, germ cell type Proteins 0.000 description 1
- 239000005041 Mylar™ Substances 0.000 description 1
- 230000006051 NK cell activation Effects 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- FSXRLASFHBWESK-HOTGVXAUSA-N Phe-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 FSXRLASFHBWESK-HOTGVXAUSA-N 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- LZLREEUGSYITMX-JQWIXIFHSA-N Ser-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CO)N)C(O)=O)=CNC2=C1 LZLREEUGSYITMX-JQWIXIFHSA-N 0.000 description 1
- ILVGMCVCQBJPSH-WDSKDSINSA-N Ser-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CO ILVGMCVCQBJPSH-WDSKDSINSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- DSGIVWSDDRDJIO-ZXXMMSQZSA-N Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DSGIVWSDDRDJIO-ZXXMMSQZSA-N 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- VNYDHJARLHNEGA-RYUDHWBXSA-N Tyr-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 VNYDHJARLHNEGA-RYUDHWBXSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000000641 acridinyl group Chemical class C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000009831 antigen interaction Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012761 co-transfection Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 108091008034 costimulatory receptors Proteins 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 210000003162 effector t lymphocyte Anatomy 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000002121 endocytic effect Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009459 flexible packaging Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000027596 immune receptors Human genes 0.000 description 1
- 108091008915 immune receptors Proteins 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000012004 kinetic exclusion assay Methods 0.000 description 1
- 229910052747 lanthanoid Inorganic materials 0.000 description 1
- 150000002602 lanthanoids Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 238000012434 mixed-mode chromatography Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 238000011227 neoadjuvant chemotherapy Methods 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical group [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000000954 titration curve Methods 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 108010020532 tyrosyl-proline Proteins 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Biotechnology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
本文提供了包含修饰的IL‑2的多肽,其中相对于野生型IL‑2,所述修饰的IL‑2具有降低的对IL‑2受体的亲和力。在一些实施方案中,提供了包含修饰的IL‑2的多肽,所述多肽结合并激动激活的T细胞。还提供了所述包含修饰的IL‑2的多肽的用途。
Description
相关申请的交叉引用
本申请要求2020年7月2日提交的美国临时申请号63/047,681的优先权权益,将所述临时申请出于任何目的通过引用以其整体并入本文。
技术领域
本发明涉及具有降低的对CD25和CD122的亲和力的修饰的IL-2以及与靶向部分融合的这种修饰的IL-2。本发明还涉及使用修饰的IL-2和包含修饰的IL-2的多肽的方法,包括但不限于治疗癌症的方法。
背景技术
IL-2是一种有力的细胞因子,可通过由CD25、CD122和CD132构成的异三聚体IL-2受体(IL-2R)或仅由CD122和CD132构成的异二聚体IL-2受体刺激T和NK细胞增殖。两种形式的IL-2R都是T细胞存活、增殖和整体激活状态的有力介导物。IL-2通常由T细胞和NK细胞在激活后产生,并在局部微环境中以顺式和反式介导信号传导。IL-2R信号传导可以诱导幼稚T细胞分化为效应T细胞和记忆T细胞,并且还可以刺激抑制性调节性T细胞。尽管三聚体形式的IL-2R对IL-2的亲和力高于二聚体形式,但两者都具有相当高的亲和力并导致受体介导的快速内化和降解,从而导致极短的半衰期。重组人IL-2(rhIL-2,阿地白介素(Proleukin))在临床上用于治疗肾细胞癌和恶性黑色素瘤;然而,它与严重的毒性相关。由于IL-2信号传导对表达高亲和力IL-2R的内皮细胞的效应,血管渗漏综合征是接受阿地白介素治疗的癌症患者的主要毒性问题。
T细胞通过其TCR与呈递结合了互补肽的MHC的相邻细胞的连接而被激活,从而导致TCR复合物聚集并通过NFAT传导信号。通过CD28对T细胞的共刺激由CD80和CD86驱动,从而增强T细胞激活。在初始激活后,T细胞上调多种蛋白质,包括细胞因子受体以及许多用于调节T细胞应答的共刺激和检查点受体。
最近报道了针对检查点受体(如CTLA-4、PD-1和PD-L1)的拮抗剂抗体具有持久的抗肿瘤临床反应。然而,即使在最具反应性的适应证中,反应率也仅限于约30%的患者。因此,需要改进的T细胞调节疗法。
发明内容
本文提供了包含修饰的IL-2的多肽,所述修饰的IL-2在至少一个氨基酸位置处包含至少一个取代。在一些实施方案中,相对于野生型IL-2,所述修饰的IL-2具有降低的对CD25、CD122和/或IL-2R的结合亲和力。在一些实施方案中,相对于野生型IL-2,所述修饰的IL-2具有降低的对静息或激活T细胞的活性。
在本文中提供以下实施方案:
实施方案1.一种包含修饰的IL-2的多肽,其中所述修饰的IL-2包含D84Y取代。
实施方案2.根据实施方案1所述的多肽,其中相比于野生型IL-2,所述修饰的IL-2具有降低的对CD122的亲和力。
实施方案3.根据实施方案1-2中任一项所述的多肽,其中所述修饰的IL-2在选自H16、L19、M23、N88和E95的至少一个氨基酸位置处包含至少一个取代。
实施方案4.根据实施方案3所述的多肽,其中所述修饰的IL-2在氨基酸位置H16处包含取代。
实施方案5.根据实施方案4所述的多肽,其中所述取代选自H16A、H16N、H16V和H16T。
实施方案6.根据实施方案1-5中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置L19处包含取代。
实施方案7.根据实施方案6所述的多肽,其中所述取代选自L19A、L19P、L19Q、L19Y、L19N、L19S、L19T、L19V。
实施方案8.根据实施方案1-7中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置M23处包含取代。
实施方案9.根据实施方案8所述的多肽,其中所述取代选自M23A、M23G、M23S、M23T、M23V、M23D、M23E、M23I、M23K、M23L、M23N、M23Q、M23R和M23Y。
实施方案10.根据实施方案1-9中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置N88处包含取代。
实施方案11.根据实施方案10所述的多肽,其中所述取代选自N88T、N88A和N88S。
实施方案12.根据实施方案1-11中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置E95处包含取代。
实施方案13.根据实施方案12所述的多肽,其中所述取代选自E95Q、E95G、E95T、E95V、E95P、E95H、E95N和E95Y。
实施方案14.根据实施方案1-13中任一项所述的多肽,其中相比于野生型IL-2,所述修饰的IL-2包含至少一个降低对CD132的亲和力的取代。
实施方案15.根据实施方案1-14中任一项所述的多肽,其中所述修饰的IL-2在选自Q22、R120、T123、Q126、S127、I129和S130的至少一个氨基酸位置处包含至少一个取代。
实施方案16.根据实施方案15所述的多肽,其中所述修饰的IL-2在氨基酸位置Q22处包含取代。
实施方案17.根据实施方案16所述的多肽,其中所述取代选自Q22A、Q22D、Q22G、Q22H、Q22K、Q22N、Q22R、Q22S、Q22T、Q22V和Q22Y。
实施方案18.根据实施方案15-17中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置R120处包含取代。
实施方案19.根据实施方案18所述的多肽,其中所述取代选自R120A、R120D、R120E、R120F、R120G、R120H、R120K、R120N、R120Q、R120S、R120V和R120Y。
实施方案20.根据实施方案15-19中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置T123处包含取代。
实施方案21.根据实施方案20所述的多肽,其中所述取代选自T123D、T123E、T123H、T123K、T123N、T123Q和T123R。
实施方案22.根据实施方案15-21中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置Q126处包含取代。
实施方案23.根据实施方案22所述的多肽,其中所述取代选自Q126N、Q126A和Q126Y。
实施方案24.根据实施方案15-23中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置S127处包含取代。
实施方案25.根据实施方案24所述的多肽,其中所述取代选自S127D、S127E、S127H、S127K、S127N、S127P和S127R。
实施方案26.根据实施方案15-25中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置I129处包含取代。
实施方案27.根据实施方案26所述的多肽,其中所述取代选自I129A、I129H、I129R和I129S。
实施方案28.根据实施方案15-27中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置S130处包含取代。
实施方案29.根据实施方案28所述的多肽,其中所述取代选自S130E、S130K、S130N、S130P、S130Q和S130R。
实施方案30.一种包含修饰的IL-2的多肽,其中所述修饰的IL-2在选自Q22、R120、T123、S127和S130的至少一个氨基酸位置处包含至少一个取代。
实施方案31.根据实施方案30所述的多肽,其中相比于野生型IL-2,所述修饰的IL-2具有降低的对CD132的亲和力。
实施方案32.根据实施方案30-31中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置Q22处包含取代。
实施方案33.根据实施方案32所述的多肽,其中所述取代选自Q22A、Q22D、Q22E、Q22G、Q22H、Q22K、Q22N、Q22P、Q22R、Q22S、Q22T、Q22V和Q22Y。
实施方案34.根据实施方案30-33中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置R120处包含取代。
实施方案35.根据实施方案34所述的多肽,其中所述取代选自R120A、R120D、R120E、R120F、R120G、R120H、R120K、R120N、R120P、R120Q、R120S、R120V和R120Y。
实施方案36.根据实施方案30-35所述的多肽,其中所述修饰的IL-2在氨基酸位置T123处包含取代。
实施方案37.根据实施方案36所述的多肽,其中所述取代选自T123D、T123E、T123H、T123K、T123N、T123Q和T123R。
实施方案38.根据实施方案30-37中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置S127处包含取代。
实施方案39.根据实施方案38所述的多肽,其中所述取代选自S127D、S127E、S127H、S127K、S127N、S127P、S127Q和S127R。
实施方案40.根据实施方案30-39中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置S130处包含取代。
实施方案41.根据实施方案40所述的多肽,其中所述取代选自S130D、S130E、S130H、S130K、S130N、S130P、S130Q和S130R。
实施方案42.根据实施方案30-41中任一项所述的多肽,其中相比于野生型IL-2,所述修饰的IL-2包含至少一个降低对CD122的亲和力的取代。
实施方案43.根据实施方案42所述的多肽,其中所述修饰的IL-2在选自H16、L19、M23、D84、N88和E95的至少一个氨基酸位置处包含至少一个取代。
实施方案44.根据实施方案43所述的多肽,其中所述修饰的IL-2在氨基酸位置H16处包含取代。
实施方案45.根据实施方案44所述的多肽,其中所述取代选自H16A、H16T、H16V和H16N。
实施方案46.根据实施方案43-45中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置L19处包含取代。
实施方案47.根据实施方案46所述的多肽,其中所述取代选自L19A、L19P、L19Q、L19Y、L19N、L19S、L19T、L19V。
实施方案48.根据实施方案43-47中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置M23处包含取代。
实施方案49.根据实施方案48所述的多肽,其中所述取代选自M23A、M23G、M23S、M23T、M23V、M23D、M23E、M23I、M23K、M23L、M23N、M23Q、M23R和M23Y。
实施方案50.根据实施方案43-49中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置D84处包含取代。
实施方案51.根据实施方案50所述的多肽,其中所述取代选自D84S、D84G、D84A、D84T、D84V、D84Y和D84N。
实施方案52.根据实施方案43-51中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置N88处包含取代。
实施方案53.根据实施方案52所述的多肽,其中所述取代选自N88T、N88A和N88S。
实施方案54.根据实施方案43-53中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置E95处包含取代。
实施方案55.根据实施方案54所述的多肽,其中所述取代选自E95Q、E95G、E95T、E95V、E95P、E95H、E95N和E95Y。
实施方案56.根据实施方案1-55中任一项所述的多肽,其中相比于野生型IL-2,所述修饰的IL-2包含至少一个降低对CD25的亲和力的取代。
实施方案57.根据实施方案1-56中任一项所述的多肽,其中所述修饰的IL-2在至少一个选自K43、Y45、E61、I114、P65、F42、R38和L72的氨基酸位置处包含至少一个取代,和/或其中所述修饰的IL-2包含氨基酸F42的缺失。
实施方案58.根据实施方案57所述的多肽,其中所述修饰的IL-2在氨基酸F42处包含取代或包含氨基酸F42的缺失。
实施方案59.根据实施方案58所述的多肽,其中所述修饰的IL-2在氨基酸位置F42处包含选自F42K、F42A、F42R、F42G、F42S和F42T的取代。
实施方案60.根据实施方案58所述的多肽,其中所述修饰的IL-2包含氨基酸F42的缺失。
实施方案61.根据实施方案57-60中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置K43处包含取代。
实施方案62.根据实施方案61所述的多肽,其中所述取代选自K43E和K43D。
实施方案63.根据实施方案57-62中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置Y45处包含取代。
实施方案64.根据实施方案63所述的多肽,其中所述取代选自Y45R和Y45K。
实施方案65.根据实施方案57-64中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置E61处包含取代。
实施方案66.根据实施方案65所述的多肽,其中所述取代选自E61R、E61G、E61H、E61N、E61P、E61S、E61T、E61Y、E61A、E61Q和E61K。
实施方案67.根据实施方案57-66中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置I114处包含取代。
实施方案68.根据实施方案67所述的多肽,其中所述取代是I114F、I114Y或I114W。
实施方案69.根据实施方案57-68中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置P65处包含取代。
实施方案70.根据实施方案69所述的多肽,其中所述取代选自P65R、P65E、P65K、P65H、P65Y、P65Q、P65D和P65N。
实施方案71.根据实施方案57-70中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置R38处包含取代。
实施方案72.根据实施方案71所述的多肽,其中所述在R38处的取代选自R38A和R38G。
实施方案73.根据实施方案57-72中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置L72处包含取代。
实施方案74.根据实施方案73所述的多肽,其中所述在L72处的取代是L72G。
实施方案75.根据实施方案1-74中任一项所述的多肽,其中所述修饰的IL-2包含取代Q22A或取代R120A、或取代Q22A和R120A。
实施方案76.根据实施方案1-75中任一项所述的多肽,其中所述修饰的IL-2包含取代P65R和R38A或取代P65R和E61R。
实施方案77.根据实施方案1-76中任一项所述的多肽,其中所述修饰的IL-2包含至少一个选自H16A、L19A、L19N、M23A、D84S或D84Y、N88S和E95Q的取代。
实施方案78.根据实施方案1-77中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置P65、H16和D84处包含取代。
实施方案79.根据实施方案78所述的多肽,其中所述修饰的IL-2包含取代P65R、H16A和D84S或取代P65R、H16A和D84Y。
实施方案80.根据实施方案1-79中任一项所述的多肽,其中所述修饰的IL-2在至少一个选自T3和C125的氨基酸位置处包含至少一个取代和/或包含IL-2的前五个氨基酸的缺失。
实施方案81.根据实施方案80所述的多肽,其中所述修饰的IL-2包含至少一个选自T3A、C125A、C125V和C125S的取代。
实施方案82.根据实施方案81所述的多肽,其中所述修饰的IL-2包含T3A和C125S取代或T3A和C125V取代。
实施方案83.根据实施方案81所述的多肽,其中所述修饰的IL-2包含IL-2的前五个氨基酸的缺失和C125S取代或C125V取代。
实施方案84.根据前述实施方案中任一项所述的多肽,其中所述修饰的IL-2包含选自以下的取代组:[T3A、H16A、E61R、P65R、D84Y、C125S]、[T3A、H16A、M23T、E61R、P65R、D84Y、E95Q、C125S]、[T3A、H16A、L19N、E61R、P65R、D84Y、C125S]、[T3A、H16A、L19N、M23T、E61R、P65R、D84Y、E95Q、C125S]、[T3A、H16A、E61R、P65R、D84Y、C125S、S127D]、[T3A、H16A、M23T、E61R、P65R、D84Y、E95Q、C125S、S127D]、[T3A、H16A、L19N、E61R、P65R、D84Y、C125S、S127D]以及[T3A、H16A、L19N、M23T、E61R、P65R、D84Y、E95Q、C125S、S127D]。
实施方案85.一种包含修饰的IL-2的修饰的多肽,其中所述修饰的IL-2包含选自以下的取代组:[T3A、H16A、E61R、P65R、D84Y、C125S]、[T3A、H16A、M23T、E61R、P65R、D84Y、E95Q、C125S]、[T3A、H16A、L19N、E61R、P65R、D84Y、C125S]、[T3A、H16A、L19N、M23T、E61R、P65R、D84Y、E95Q、C125S]、[T3A、H16A、E61R、P65R、D84Y、C125S、S127D]、[T3A、H16A、M23T、E61R、P65R、D84Y、E95Q、C125S、S127D]、[T3A、H16A、L19N、E61R、P65R、D84Y、C125S、S127D]以及[T3A、H16A、L19N、M23T、E61R、P65R、D84Y、E95Q、C125S、S127D]。
实施方案86.根据前述实施方案中任一项所述的多肽,其中所述修饰的IL-2包含所指示的取代,并且不包含任何另外的取代。
实施方案87.根据前述实施方案中任一项所述的多肽,其中所述修饰的IL-2是修饰的人IL-2。
实施方案88.根据前述实施方案中任一项所述的多肽,其中所述氨基酸位置对应于SEQ ID NO:1中的氨基酸位置。
实施方案89.根据前述实施方案中任一项所述的多肽,其中所述修饰的IL-2包含与SEQ ID NO:84至少90%、91%、92%、93%、94%、95%、96%、97%、98%或99%相同并且包含选自SEQ ID NO:105-290的氨基酸序列的对应取代的氨基酸序列。
实施方案90.根据前述实施方案中任一项所述的多肽,其中所述修饰的IL-2包含与选自SEQ ID NO:270-277的氨基酸序列至少90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或100%相同的氨基酸序列并且包含取代D84Y。
实施方案91.根据前述实施方案中任一项所述的多肽,其中所述修饰的IL-2包含选自SEQ ID NO:105-290的氨基酸序列。
实施方案92.根据前述实施方案中任一项所述的多肽,其中所述修饰的IL-2包含选自SEQ ID NO:270-277的氨基酸序列。
实施方案93.根据前述实施方案中任一项所述的多肽,其中所述多肽包含Fc区。
实施方案94.根据实施方案93所述的多肽,其中所述修饰的IL-2与所述Fc区的N端或C端融合。
实施方案95.根据实施方案93或实施方案94所述的多肽,其中所述Fc区在Kabat氨基酸位置T366处包含取代。
实施方案96.根据实施方案95所述的多肽,其中所述Fc区包含T366W取代。
实施方案97.根据实施方案93或实施方案94所述的多肽,其中所述Fc区在选自T366、L368和Y407的至少一个Kabat氨基酸位置处包含至少一个取代。
实施方案98.根据实施方案108所述的多肽,其中所述Fc区包含T366S、L368A和Y407V突变。
实施方案99.根据实施方案93-98中任一项所述的多肽,其中所述Fc区在选自S354和Y349的Kabat位置处包含取代。
实施方案100.根据实施方案99所述的多肽,其中所述Fc区包含S354C或Y349C取代。
实施方案101.根据实施方案93-100中任一项所述的多肽,其中所述Fc区在Kabat氨基酸位置H435处包含取代。
实施方案102.根据实施方案101所述的多肽,其中所述Fc区包含选自H435R和H435K的取代。
实施方案103.根据实施方案93-102中任一项所述的多肽,其中所述Fc区在选自M252和M428的至少一个Kabat氨基酸位置处包含至少一个取代。
实施方案104.根据实施方案103所述的多肽,其中所述Fc区包含M252Y和M428V取代。
实施方案105.根据实施方案93-104中任一项所述的多肽,其中所述Fc区包含Kabat氨基酸E233、L234和L235的缺失。
实施方案106.根据实施方案93-104中任一项所述的多肽,其中所述Fc区在选自L234、L235和P329的至少一个氨基酸位置处包含至少一个取代。
实施方案107.根据实施方案106所述的多肽,其中所述Fc区包含L234A、L235A和P329G取代。
实施方案108.根据实施方案93-107中任一项所述的多肽,其中所述Fc区包含与选自SEQ ID NO:47-83、292和293的氨基酸序列至少90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或100%相同的氨基酸序列。
实施方案109.根据实施方案93-108中任一项所述的多肽,其中所述Fc区是重链恒定区的一部分。
实施方案110.根据实施方案109所述的多肽,其中所述重链恒定区是IgG恒定区。
实施方案111.根据实施方案110所述的多肽,其中所述重链恒定区是IgG1、IgG2、IgG3或IgG4恒定区。
实施方案112.根据实施方案93-111中任一项所述的多肽,其中所述修饰的IL-2与所述Fc区或重链恒定区的C端融合。
实施方案113.根据实施方案112所述的多肽,其中所述修饰的IL-2经由包含1-20个氨基酸的接头与所述Fc区或重链恒定区的C端融合。
实施方案114.根据实施方案113所述的多肽,其中所述接头包含甘氨酸氨基酸。
实施方案115.根据实施方案114所述的多肽,其中所述接头包含甘氨酸和丝氨酸氨基酸。
实施方案116.根据实施方案113-115中任一项所述的多肽,其中所述接头中的大部分或全部氨基酸是甘氨酸和丝氨酸。
实施方案117.根据实施方案93-116中任一项所述的多肽,其中所述多肽包含选自SEQ ID NO:105-290的氨基酸序列以及选自SEQ ID NO:48、64、292和293的氨基酸序列。
实施方案118.根据前述实施方案中任一项所述的多肽,其中所述多肽包含至少一个抗原结合结构域。
实施方案119.根据实施方案118所述的多肽,其中所述多肽包含两个、三个或四个抗原结合结构域。
实施方案120.根据实施方案118或实施方案119所述的多肽,其中至少一个抗原结合结构域特异性结合T细胞抗原或自然杀伤细胞抗原。
实施方案121.根据实施方案118-120中任一项所述的多肽,其中至少一个抗原结合结构域特异性结合CD4+T细胞抗原或CD8+T细胞抗原。
实施方案122.根据实施方案121所述的多肽,其中所述至少一个抗原结合结构域特异性结合激活的CD4+T细胞或激活的CD8+T细胞上的抗原。
实施方案123.根据实施方案118-122中任一项所述的多肽,其中至少一个抗原结合结构域是激动剂。
实施方案124.根据实施方案118-122中任一项所述的多肽,其中所述抗原结合结构域是拮抗剂。
实施方案125.根据实施方案118-124中任一项所述的多肽,其中至少一个抗原结合结构域特异性结合PD-1、CTLA-4、LAG3、TIM3、4-1BB、OX40、GITR、CD8a、CD8b、CD4、NKp30、NKG2A、TIGIT、TGFβR1、TGFβR2、Fas、NKG2D、NKp46、PD-L1、CD107a、ICOS、TNFR2、CD16a或γδTCR。
实施方案126.根据实施方案118-124中任一项所述的多肽,其中至少一个抗原结合结构域特异性结合PD-1。
实施方案127.根据实施方案118-126中任一项所述的多肽,其中至少一个抗原结合结构域是人或人源化抗原结合结构域。
实施方案128.根据实施方案127所述的多肽,其中每个抗原结合结构域独立地是人或人源化抗原结合结构域。
实施方案129.根据实施方案118-128中任一项所述的多肽,其中至少一个抗原结合结构域包含VHH结构域。
实施方案130.根据实施方案129所述的多肽,其中每个抗原结合结构域包含VHH结构域。
实施方案131.根据实施方案118-128中任一项所述的多肽,其中至少一个抗原结合结构域包含VH结构域和VL结构域。
实施方案132.根据实施方案131所述的多肽,其中至少一个抗原结合结构域包含选自以下的抗体的VH结构域和VL结构域:派姆单抗、纳武单抗、AMP-514、TSR-042、STI-A1110、伊匹单抗、曲美目单抗、乌瑞鲁单抗、乌托鲁单抗、阿特珠单抗和度伐鲁单抗。
实施方案133.根据实施方案131或132所述的多肽,其中所述至少一个抗原结合结构域包含单链Fv(scFv)。
实施方案134.根据实施方案131或132所述的多肽,其中所述多肽包含重链恒定区,其中所述VH结构域与所述重链恒定区融合,并且其中所述VL结构域与所述VH结构域缔合。
实施方案135.根据实施方案134所述的多肽,其中所述VL结构域与轻链恒定区融合。
实施方案136.根据实施方案135所述的多肽,其中所述轻链恒定区选自κ和λ。
实施方案137.根据实施方案118-136中任一项所述的多肽,其中每个所述抗原结合结构域是相同的。
实施方案138.根据实施方案118-137所述的多肽,其中每个所述抗原结合结构域特异性结合相同的抗原。
实施方案139.根据实施方案118-136所述的多肽,其中至少一个所述抗原结合结构域与至少一个其他抗原结合结构域特异性结合不同的抗原。
实施方案140.根据实施方案139所述的多肽,其中至少一个抗原结合结构域特异性结合PD-1,并且至少一个其他抗原结合结构域特异性结合除PD-1之外的T细胞抗原或自然杀伤细胞抗原。
实施方案141.根据实施方案118-140中任一项所述的多肽,其中至少一个抗原结合结构域结合PD-1、CTLA-4、LAG3、TIM3、4-1BB、OX40、GITR、CD8a、CD8b、CD4、NKp30、NKG2A、TIGIT、TGFβR1、TGFβR2、Fas、NKG2D、NKp46、PD-L1、CD107a、ICOS、TNFR2、CD16a、DNAM1或γδTCR(Vγ9、Vγ2、Vδ1)。
实施方案142.根据实施方案93-141中任一项所述的多肽,其中所述多肽在生理条件下形成同二聚体。
实施方案143.根据前述实施方案中任一项所述的多肽,其中与人野生型IL-2对于IL-2R的亲和力相比,所述修饰的IL-2以低至少2倍、3倍、4倍、5倍、6倍、7倍、8倍、9倍、至少10倍、至少20倍、至少30倍、至少50倍或至少100倍的亲和力结合人IL-2R。
实施方案144.一种包含第一多肽和第二多肽的复合物,其中所述第一多肽是根据前述实施方案中任一项所述的多肽。
实施方案145.根据实施方案144所述的复合物,其中所述第一多肽包含第一Fc区并且所述第二多肽包含第二Fc区。
实施方案146.根据实施方案144或实施方案145所述的复合物,其中每个Fc区是选自人IgG1、IgG2、IgG3、IgG4的同种型的。
实施方案147.根据实施方案146所述的复合物,其中每个Fc区是人IgG1。
实施方案148.根据实施方案144-147中任一项所述的复合物,其中每个Fc区包含氨基酸E233、L234和L235的缺失。
实施方案149.根据实施方案144-148中任一项所述的复合物,其中每个Fc区包含H435R或H435K突变。
实施方案150.根据实施方案155-160中任一项所述的复合物,其中所述Fc区包含突变M252Y和M428L或突变M252Y和M428V。
实施方案151.根据实施方案144-150中任一项所述的复合物,其中所述第一Fc区或所述第二Fc区包含T366W突变,并且另一个Fc区包含突变T366S、L368A和Y407V。
实施方案152.根据实施方案151所述的复合物,其中所述第一Fc区或所述第二Fc区包含S354C突变。
实施方案153.根据实施方案144-152中任一项所述的复合物,其中每个Fc区独立地包含与选自SEQ ID NO:47-83、292和293的氨基酸序列至少90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或100%相同的氨基酸序列。
实施方案154.根据实施方案144-153中任一项所述的复合物,其中所述第二多肽不包含修饰的IL-2。
实施方案155.根据实施方案144-154中任一项所述的复合物,其中所述第一多肽包含至少一个抗原结合结构域。
实施方案156.根据实施方案144-155中任一项所述的复合物,其中所述第二多肽包含至少一个抗原结合结构域。
实施方案157.根据实施方案144-156中任一项所述的复合物,其中所述第一多肽包含第一抗原结合结构域、Fc区和修饰的IL-2。
实施方案158.根据实施方案157所述的复合物,其中所述第一抗原结合结构域与所述Fc区的N端融合,并且所述修饰的IL-2与所述Fc区的C端融合。
实施方案159.根据实施方案157或实施方案158所述的复合物,其中所述第二多肽包含第二抗原结合结构域和Fc区。
实施方案160.根据实施方案159所述的复合物,其中所述第一抗原结合结构域和所述第二抗原结合结构域是相同或不同的。
实施方案161.根据实施方案160所述的复合物,其中:
a.所述第一抗原结合结构域和所述第二抗原结合结构域均结合PD-1;
b.所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合LAG3;
c.所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合CTLA-4;
d.所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合4-1BB;
e.所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合OX40;
f.所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合GITR;
g.所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合CD8a;
h.所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合CD8b;
i.所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合CD4;
j.所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合NKp30;
k.所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合NKG2A;
l.所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合TIGIT;
m.所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合NKG2D;
n.所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合TGFBR2;o.所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合Fas;
p.所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合CD107a;
q.所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合NKp46;
r.所述第一抗原结合结构域结合CD8a,并且所述第二抗原结合结构域结合TGFRβR2;s.所述第一抗原结合结构域结合CD8a,并且所述第二抗原结合结构域结合Fas;
t.所述第一抗原结合结构域结合NKG2D,并且所述第二抗原结合结构域结合TGFRβR2;
u.所述第一抗原结合结构域结合NKG2D,并且所述第二抗原结合结构域结合Fas;
v.所述第一抗原结合结构域结合NKG2A,并且所述第二抗原结合结构域结合TGFRβR2;
w.所述第一抗原结合结构域结合NKG2A,并且所述第二抗原结合结构域结合Fas;
x.所述第一抗原结合结构域结合NKp46,并且所述第二抗原结合结构域结合TGFRβR2;y.所述第一抗原结合结构域结合NKp46,并且所述第二抗原结合结构域结合Fas;
z.所述第一抗原结合结构域结合CTLA-4,并且所述第二抗原结合结构域结合LAG3;aa.所述第一抗原结合结构域结合CTLA-4,并且所述第二抗原结合结构域结合Tim3;
bb.所述第一抗原结合结构域结合CTLA-4,并且所述第二抗原结合结构域结合OX40;cc.所述第一抗原结合结构域结合CTLA-4,并且所述第二抗原结合结构域结合GITR;dd.所述第一抗原结合结构域结合CTLA-4,并且所述第二抗原结合结构域结合CD107a;ee.所述第一抗原结合结构域结合CTLA-4,并且所述第二抗原结合结构域结合NKp46;ff.所述第一抗原结合结构域结合ICOS,并且所述第二抗原结合结构域结合TNFR2;
gg.所述第一抗原结合结构域结合γδTCR,并且所述第二抗原结合结构域结合NKG2D;hh.所述第一抗原结合结构域结合γδTCR,并且所述第二抗原结合结构域结合DNAM1;ii.所述第一抗原结合结构域结合γδTCR,并且所述第二抗原结合结构域结合TIGIT;
jj.所述第一抗原结合结构域结合γδTCR,并且所述第二抗原结合结构域结合4-1BB;
kk.所述第一抗原结合结构域结合γδTCR,并且所述第二抗原结合结构域结合Fas;
ll.所述第一抗原结合结构域结合γδTCR,并且所述第二抗原结合结构域结合NKG2A;或
mm.所述第一抗原结合结构域结合γδTCR,并且所述第二抗原结合结构域结合CD16a。
实施方案162.根据实施方案144-161中任一项所述的复合物,其中与人野生型IL-2对于IL-2R的亲和力相比,所述修饰的IL-2以低至少2倍、3倍、4倍、5倍、6倍、7倍、8倍、9倍、至少10倍、至少20倍、至少30倍、至少50倍或至少100倍的亲和力结合人IL-2R。
实施方案163.一种药物组合物,其包含根据实施方案1-154中任一项所述的多肽或根据实施方案144-162中任一项所述的复合物和药学上可接受的载体。
实施方案164.一种分离的核酸,其编码根据实施方案1-143中任一项所述的多肽或根据实施方案144-162中任一项所述的复合物。
实施方案165.一种表达载体,其包含根据实施方案164所述的核酸。
实施方案166.一种分离的宿主细胞,其包含根据实施方案164所述的核酸或根据实施方案165所述的表达载体。
实施方案167.一种分离的宿主细胞,其表达根据实施方案1-143中任一项所述的多肽或根据实施方案144-162中任一项所述的复合物。
实施方案168.一种产生根据实施方案1-143中任一项所述的多肽或根据实施方案144-162中任一项所述的复合物的方法,其包括在适合表达所述多肽或复合物的条件下孵育根据实施方案166或实施方案167所述的宿主细胞。
实施方案169.根据实施方案168所述的方法,其还包括分离所述多肽或复合物。
实施方案170.一种增加CD4+和/或CD8+T细胞增殖的方法,其包括使T细胞与根据实施方案1-154中任一项所述的多肽或根据实施方案144-162中任一项所述的复合物接触。
实施方案171.根据实施方案170所述的方法,其中所述CD4+和/或CD8+T细胞在体外。
实施方案172.根据实施方案170所述的方法,其中所述CD4+和/或CD8+T细胞在体内。
实施方案173.根据实施方案170-172中任一项所述的方法,其中所述增加为至少1.5倍、至少2倍、至少3倍或至少5倍。
实施方案174.一种增加NK细胞增殖的方法,其包括使NK细胞与根据实施方案1-143中任一项所述的多肽或根据实施方案144-162中任一项所述的复合物接触。
实施方案175.根据实施方案174所述的方法,其中所述增加为至少1.5倍、至少2倍、至少3倍或至少5倍。
实施方案176.一种治疗癌症的方法,其包括向患有癌症的受试者施用药学有效量的根据实施方案1-143中任一项所述的多肽或根据实施方案144-162中任一项所述的复合物或根据实施方案163所述的药物组合物。
实施方案177.根据实施方案176所述的方法,其中所述癌症选自基底细胞癌;胆道癌;膀胱癌;骨癌;脑和中枢神经系统癌症;乳腺癌;腹膜癌;宫颈癌;绒毛膜癌;结直肠癌;结缔组织癌;消化系统癌症;子宫内膜癌;食道癌;眼癌;头颈癌;胃癌;胃肠癌;胶质母细胞瘤;肝癌;肝肿瘤;上皮内瘤;肾脏癌或肾癌;喉癌;肝脏癌症;肺癌;小细胞肺癌;非小细胞肺癌;肺腺癌;肺鳞癌;黑色素瘤;骨髓瘤;神经母细胞瘤;口腔癌;卵巢癌;胰腺癌;前列腺癌;视网膜母细胞瘤;横纹肌肉瘤;直肠癌;呼吸系统癌症;唾液腺癌;肉瘤;皮肤癌;鳞状细胞癌;胃癌;睾丸癌;甲状腺癌;子宫或子宫内膜癌;泌尿系统癌症;外阴癌;淋巴瘤;霍奇金淋巴瘤;非霍奇金淋巴瘤;B细胞淋巴瘤;低分级/滤泡性非霍奇金淋巴瘤(NHL);小淋巴细胞(SL)NHL;中分级/滤泡性NHL;中分级弥漫性NHL;高分级免疫母细胞NHL;高分级淋巴母细胞NHL;高分级小非裂解细胞NHL;大肿块NHL;套细胞淋巴瘤;艾滋病相关淋巴瘤;华氏巨球蛋白血症;慢性淋巴细胞白血病(CLL);急性成淋巴细胞性白血病(ALL);毛细胞白血病;和慢性成髓细胞性白血病。
实施方案178.根据实施方案176或177所述的方法,其还包括施用另外的治疗剂。
实施方案179.根据实施方案178所述的方法,其中所述另外的治疗剂是抗癌剂。
实施方案180.根据实施方案179所述的方法,其中所述抗癌剂选自化疗剂、抗癌生物制剂、放射疗法、CAR-T疗法和溶瘤病毒。
实施方案181.根据实施方案179或实施方案180所述的方法,其中所述另外的治疗剂是抗癌生物制剂。
实施方案182.根据实施方案181所述的方法,其中所述抗癌生物制剂是抑制PD-1和/或PD-L1的药剂。
实施方案183.根据实施方案181所述的方法,其中所述抗癌生物制剂是抑制VISTA、gpNMB、B7H3、B7H4、HHLA2、CTLA4或TIGIT的药剂。
实施方案184.根据实施方案179-183中任一项所述的方法,其中所述抗癌剂是抗体。
实施方案185.根据实施方案181所述的方法,其中所述抗癌生物制剂是细胞因子。
实施方案186.根据实施方案179所述的方法,其中所述抗癌剂是CAR-T疗法。
实施方案187.根据实施方案179所述的方法,其中所述抗癌剂是溶瘤病毒。
实施方案188.根据实施方案176-187中任一项所述的方法,其还包括肿瘤切除术和/或放射疗法。
附图说明
图1A-图1H示出各种IL-2融合蛋白形式的示意图。图1A示出IL-2连接至异二聚体杵臼结构IgG1 Fc的N端。图1B示出IL-2连接至单结构域抗体的异二聚体IgG1 Fc的C端。图1C-1E示出IL-2连接至一个VHH(图1E)、两个相同的VHH(图1C)或两个不同的VHH(图1D)。图1F示出IL-2与常规抗体的同二聚体重链恒定区的C端连接。图1G示出IL-2与常规抗体的异二聚体重链恒定区的C端连接。图1H示出IL-2与异二聚体scFv抗体的C端融合。
图2A-图2C示出如通过流式细胞术测量的如图1A所示的IL-2融合蛋白与293F细胞的结合,所述IL-2融合蛋白包含与异二聚体Fc的N端融合的野生型IL-2(图2A)或修饰的IL-2(图2A-图2C),所述293F细胞瞬时转染了IL-2受体(CD25、CD122和CD132)的各种组合。“UT293F”指示未转染的293F细胞。
图3A-图3B示出如通过流式细胞术测量的如图1A所示的融合蛋白与293F细胞的结合,所述融合蛋白包含与异二聚体Fc的N端融合的野生型IL-2或修饰的IL-2,所述293F细胞瞬时转染了CD25和CD122。
图4A-图4B示出如通过流式细胞术测量的如图1A所示的融合蛋白与293F细胞的结合,所述融合蛋白包含与异二聚体Fc的N端融合的野生型IL-2或修饰的IL-2,所述293F细胞瞬时转染了CD122和CD132,或者CD25、CD122和CD132。
图5A-图5B示出如通过流式细胞术测量的如图1B所示的融合蛋白与静息和激活CD4+T细胞的结合,所述融合蛋白包含与连接异二聚体Fc的非靶向VHH的C端融合的野生型IL-2或修饰的IL-2。“同种型对照”指示不包含IL-2的对照蛋白。
图6A-图6B示出如通过流式细胞术测量的如图1B所示的融合蛋白与富集的调节性T细胞(Treg,图6A)、诱导的调节性T细胞(诱导Treg,图6B)和富集的应答CD4+T细胞(Tresp,图6C)的结合,所述融合蛋白包含与连接异二聚体Fc的非靶向VHH的C端融合的野生型IL-2或修饰的IL-2。
图7A-图7D示出如图1B所示的融合蛋白对静息CD4+和CD8+T细胞的活性,所述融合蛋白包含与连接异二聚体Fc的非靶向VHH的C端融合的野生型IL-2或修饰的IL-2。测量增殖(图7A和图7C)和CD71水平(图7B和图7D)。图7E-图7F示出如通过流式细胞术检测细胞内磷酸化STAT5水平测量的如图1B所示的与连接异二聚体Fc的非靶向VHH的C端融合的野生型IL-2或修饰的IL-2对静息CD4+和CD8+T细胞的活性。“同种型”指示不包含IL-2的对照蛋白。
图8A-图8B示出在用如图1B所示的融合蛋白处理7天后的增殖和CD25水平(作为富集的Treg激活的标记物),所述融合蛋白包含与连接异二聚体Fc的非靶向VHH的C端融合的野生型IL-2或修饰的IL-2。
图9A-图9D示出派姆单抗、其中IL-2-RAS融合至重链C端的派姆单抗类似物(如图1F所示)以及单独的IL-2-RAS(图9C和9D)对CD8+和CD4+T细胞的活性和结合。对CD8+(图9A)和CD4+(图9B)T细胞的活性是通过CellTraceTMViolet的流式细胞术检测来测量。通过流式细胞术测量与CD8+T细胞(图9C)和CD4+T细胞(图9D)的结合程度。
图10A-图10D示出诱导CD8+和CD4+T细胞增殖对IL-2的依赖性。在没有预先阻断(图10A和图10B)或用饱和浓度的派姆单抗预先阻断(图10C和图10D)的情况下,派姆单抗、非靶向IL-2-RAS、和其中IL-2-RAS融合至重链C端的派姆单抗类似物(如图1F所示)对CD8+(图10A和图10C)或CD4+(图10B和图10D)T细胞增殖的作用。
图11示出通过其中IL-2-RAS融合至重链C端的派姆单抗类似物(如图1F所示)、以及与非靶向VHH的C端融合的IL-2-RAS(如图1B所示)和与非靶向VHH的C端融合的野生型IL-2(如图1B所示)对CD4+T应答(Tresp)细胞增殖的恢复。Tresp增殖由CD3接合诱导(Tresp+珠),然后使用自体调节性T细胞(Treg)抑制。“Tresp+珠”线示出在没有Treg细胞的情况下在CD3接合情况下的基线Tresp细胞增殖。“无Ab”线示出在Treg细胞的存在下在CD3接合情况下的基线Tresp细胞增殖。
图12A-图12B示出由板结合的与非靶向VHH的C端融合的非靶向野生型IL-2(“IL-2WT”)或IL-2-RAS(如图1B所示)对T细胞的反式激活。通过流式细胞术检测细胞内磷酸化STAT5水平来测量T细胞激活。示出CD8+T细胞(图12A)和CD4+T细胞(图12B)应答。
图13A-图13I示出与靶向NKp46的异二聚体scFv抗体的C端融合的IL-2-RAS(如图1H所示)、单独的靶向NKp46的异二聚体scFv抗体、以及包含与连接异二聚体Fc的非靶向VHH的C端融合的野生型IL-2或IL-2-RAS的融合蛋白(如图1B所示)对NK细胞、CD8+T细胞、和CD4+T细胞的活性和结合。通过流式细胞术测量NK细胞(图13A)、CD8+T细胞(图13B)和CD4+T细胞(图13C)的增殖以及NK细胞(图13D)、CD8+T细胞(图13E)和CD4+T细胞(图13F)的pSTAT水平。还通过流式细胞术测量了所指示多肽与NK细胞(图13G)、CD8+T细胞(图13H)和CD4+T细胞(图13I)的结合。
图14A-图14H示出与抗LAG3异二聚体常规抗体(MAb)的C端融合的IL-2-RAS(如图1G所示)、与具有异二聚体Fc的抗LAG3 VHH的C端融合的IL-2-RAS(如图1B所示)、与非靶向VHH的C端融合的IL-2-RAS(如图1B所示)、与非靶向异二聚体Fc的C端融合的野生型IL-2(如图1B所示)、或者靶向LAG3的MAb或靶向LAG3的VHH-Fc分子(无IL-2)对CD8+或CD4+T细胞的活性和结合。通过流式细胞术测量CD8+T细胞(图14A)和CD4+T细胞(图14B)的增殖以及激活标记物CD25(图14C和图14D)和CD71(图14E和图14F)在CD8+T细胞(图14C和图14E)和CD4+T细胞(图14D和图14F)上的表达。图14G和14H示出与预激活的CD8+T细胞(图14G)和CD4+T细胞(图14H)的结合。
图15示出融合蛋白对HEK-Blue IL-2报告细胞的活性,所述融合蛋白包含与具有异二聚体Fc的VHH的C端融合的所指示的修饰的IL-2(如图1B所示),所述报告细胞不表达VHH靶抗原并因此仅依赖于修饰的IL-2与过表达的IL-2受体的结合以诱导报告基因。测量了在报告细胞中响应于IL-2受体介导的对pSTAT5信号传导的诱导而表达的分泌型胚胎碱性磷酸酶的活性。
图16A-图16B示出包含所指示的修饰的IL-2的多肽对不表达PD-1的HEK-Blue IL-2报告细胞(图16A)以及表达PD-1的IL-2报告细胞(图16B)的活性。如在图16A-图16B中所用,“RAS”意指IL-2突变T3A、P65R、H16A、D84S和C125S。
图17A-图17C示出在存在和不存在CD25阻断抗体的情况下包含所指示的修饰的IL-2的多肽对不表达PD-1的HEK-Blue IL-2报告细胞的活性。如在图17A-图17C中所用,“RAS”意指IL-2突变T3A、P65R、H16A、D84S和C125S。
图18A-图18B示出包含所指示的修饰的IL-2的多肽对不表达PD-1的HEK-Blue IL-2报告细胞(图18A)以及表达PD-1的IL-2报告细胞(图18B)的活性。如在图18A-图18B中所用,“RAS”意指IL-2突变T3A、P65R、H16A、D84S和C125S。如在图18B中所用,“INBRX-108”意指包含SEQ ID NO:28的氨基酸序列的修饰的IL-2。
图19A-图19E示出包含所指示的修饰的IL-2的多肽对如所指示的表达PD-1或不表达PD-1的IL-2报告细胞的活性。如在图19A-图19E中所用,“NT_突变体”意指多肽包含小图标题中所列的IL-2突变并且在不表达PD-1的细胞上测试。如在图19A-图19E中所用,“PD1_突变体”意指多肽包含小图标题中所列的IL-2突变并且在表达PD-1的细胞上测试。如在图19A-图19E中所用,“RAS”意指IL-2突变T3A、P65R、H16A、D84S和C125S。如在图19A-图19E中所用,“NT_INBRX-108”意指多肽包含含有SEQ ID NO:28的氨基酸序列的修饰的IL-2并且在不表达PD-1的细胞上测试。如在图19A-图19E中所用,“PD1_INBRX-108”意指多肽包含含有SEQ ID NO:28的氨基酸序列的修饰的IL-2并且在表达PD-1的细胞上测试。包括IL-2突变的多肽还描述于实施例19和表7中。
图20A-图20E示出包含所指示的修饰的IL-2的多肽对如所指示的表达PD-1或不表达PD-1的IL-2报告细胞的活性。如在图20A-图20E中所用,“NT_突变体”意指多肽包含小图标题中所列的IL-2突变并且在不表达PD-1的细胞上测试。如在图20A-图20E中所用,“PD1_突变体”意指多肽包含小图标题中所列的IL-2突变并且在表达PD-1的细胞上测试。如在图20A-图20E中所用,“RAS”意指IL-2突变T3A、P65R、H16A、D84S和C125S。如在图20A-图20E中所用,“NT_INBRX-108”意指多肽包含含有SEQ ID NO:28的氨基酸序列的修饰的IL-2并且在不表达PD-1的细胞上测试。如在图20A-图20E中所用,“PD1_INBRX-108”意指多肽包含含有SEQ ID NO:28的氨基酸序列的修饰的IL-2并且在表达PD-1的细胞上测试。包括IL-2突变的多肽还描述于实施例20和表8中。
图21A-图21D示出包含所指示的修饰的IL-2的多肽对如所指示的表达PD-1或不表达PD-1的IL-2报告细胞的活性。如在图21A-图21D中所用,“NT_突变体”意指多肽包含小图标题中所列的IL-2突变并且在不表达PD-1的细胞上测试。如在图21A-图21D中所用,“PD1_突变体”意指多肽包含小图标题中所列的IL-2突变并且在表达PD-1的细胞上测试。如在图21A-图21D中所用,“RAS”意指IL-2突变T3A、P65R、H16A、D84S和C125S。如在图21A-图21D中所用,“NT_INBRX-108”意指多肽包含含有SEQ ID NO:28的氨基酸序列的修饰的IL-2并且在不表达PD-1的细胞上测试。如在图21A-图21D中所用,“PD1_INBRX-108”意指多肽包含含有SEQ ID NO:28的氨基酸序列的修饰的IL-2并且在表达PD-1的细胞上测试。包括IL-2突变的多肽还描述于实施例21和表9中。
图22A-图22B示出包含所指示的修饰的IL-2的多肽对不表达PD-1的HEK-Blue IL-2报告细胞(图22A)以及表达PD-1的IL-2报告细胞(图22B)的活性。如在图22A-图22B中所用,“RAS”意指IL-2突变T3A、P65R、H16A、D84S和C125S。此外,所有所指示的修饰的IL-2突变包括T3A和C125S以及列出的突变。
图23A-图23B示出包含所指示的修饰的IL-2的多肽对不表达PD-1的HEK-Blue IL-2报告细胞(图23A)以及表达PD-1的IL-2报告细胞(图23B)的活性。如在图23A-图23B中所用,“RAS”意指IL-2突变T3A、P65R、H16A、D84S和C125S。
图24A-图24B示出包含含有所指示突变的经修饰IL-2的所指示多肽对不表达CD8a的HEK-Blue IL-2报告细胞(图24A)以及表达CD8a的IL-2报告细胞(图24B)的活性。如在图24A-图24B中所用,“RAS”意指IL-2突变T3A、P65R、H16A、D84S和C125S。如在图24A-图24B中所用,“RAY”意指IL-2突变T3A、P65R、H16A、D84Y和C125S。
图25A-图25C示出包含所指示的修饰的或野生型IL-2的所指示多肽对HEK-BlueIL-2报告细胞(图25A)、表达NKp46的IL-2报告细胞(图25B)以及表达CD8a的IL-2报告细胞(图25C)的活性。如在图25A-图25C中所用,“OprIxIL-2-WT tgcs”意指包含OprI结合结构域的多肽,所述多肽不与IL-2报告细胞上的靶标和包含T3G和C125S突变的IL-2结合。
图26A-图26E示出包含IL-2突变体的各种多肽的活性的分析。图26A示出各种IL-2突变体的非靶向活性。图26B-图26C是针对PD-1(图26B)或NKp46(图26C)的靶向EC50相比于非靶向EC50的图。图26D-图26E示出靶向PD-1(图26D)和NKp46(图26E)的窗口,所述窗口显示在避免非靶向IL-2活性的同时实现靶向活性的浓度范围。
图27A-图27H示出在用融合蛋白处理PBMC后的pSTAT5水平,所述融合蛋白包含与具有异二聚体Fc的γδTCR结合VHH的C端融合的修饰的IL-2,其中所述γδTCR结合结构域是单价的或二价的,如所指示的。图27A、图27C、图27E和图27G示出在用所指示的多肽处理后γδT细胞、NK细胞和αβT细胞上细胞内pSTAT5染色的中值荧光强度。图27B、图27D、图27F和图27H示出在用所指示的多肽处理后具有pSTAT5染色的γδT细胞、NK细胞和αβT细胞的百分比。
图28A-图28D示出在用融合蛋白处理PBMC后的γδT细胞增殖(图28A)、γδT细胞积累(图28B)、αβT细胞增殖(图28C)和αβT细胞积累(图28D),所述融合蛋白包含与具有异二聚体Fc的γδTCR结合VHH的C端融合的修饰的IL-2。
图29A-图29B示出在用野生型IL-2和包含修饰的IL-2的非靶向多肽处理PBMC后的pSTAT5水平。图29A示出CD56亮CD16-NK细胞上具有pSTAT5染色的细胞的百分比
具体实施方式
本文提供的实施方案涉及包含调节T细胞活性的修饰的IL-2的多肽及其在治疗癌症的各种方法中的用途。
定义和各种实施方案
本文使用的章节标题只是出于组织的目的,而不应解释为限制所描述的主题。
本文引用的所有参考文献,包括专利申请、专利出版物和Genbank登录号均通过引用并入本文,就好像每个单独的参考文献都被具体地和单独地指示为通过引用以其整体并入。
本文所述或参考的技术和程序通常是本领域技术人员很好理解和使用常规方法通常使用的,例如像在以下文献中所述的广泛使用的方法:Sambrook等人,MolecularCloning:A Laboratory Manual第3版(2001)Cold Spring Harbor Laboratory Press,冷泉港,纽约州CURRENT PROTOCOLS IN MOLECULAR BIOLOGY(F.M.Ausubel等人编,(2003));METHODS IN ENZYMOLOGY系列(Academic Press,Inc.):PCR 2:APRACTICAL APPROACH(M.J.MacPherson,B.D.Hames和G.R.Taylor编(1995));Harlow和Lane编(1988)ANTIBODIES,A LABORATORY MANUAL,and ANIMAL CELL CULTURE(R.I.Freshney编(1987));Oligonucleotide Synthesis(M.J.Gait编,1984);Methods in Molecular Biology,Humana Press;Cell Biology:A Laboratory Notebook(J.E.Cellis编,1998)AcademicPress;Animal Cell Culture(R.I.Freshney)编,1987;Introduction to Cell andTissue Culture(J.P.Mather和P.E.Roberts,1998)Plenum Press;Cell and TissueCulture Laboratory Procedures(A.Doyle,J.B.Griffiths和D.G.Newell编,1993-8)J.Wiley and Sons;Handbook of Experimental Immunology(D.M.Weir和C.C.Blackwell编);Gene Transfer Vectors for Mammalian Cells(J.M.Miller和M.P.Calos编,1987);PCR:The Polymerase Chain Reaction,(Mullis等人编,1994);Current Protocols inImmunology(J.E.Coligan等人编,1991);Short Protocols in Molecular Biology(Wileyand Sons,1999);Immunobiology(C.A.Janeway和P.Travers,1997);Antibodies(P.Finch,1997);Antibodies:A Practical Approach(D.Catty.编,IRL Press,1988-1989);Monoclonal Antibodies:APractical Approach(P.Shepherd和C.Dean编,OxfordUniversity Press,2000);Using Antibodies:A Laboratory Manual(E.Harlow和D.Lane(Cold Spring Harbor Laboratory Press,1999));The Antibodies(M.Zanetti和J.D.Capra编,Harwood Academic Publishers,1995);以及Cancer:Principles andPractice of Oncology(V.T.DeVita等人编,J.B.Lippincott Company,1993);以及其更新版本。
除非另外定义,否则结合本公开文本使用的科学和技术术语应具有由本领域普通技术人员通常所理解的含义。此外,除非另外通过上下文要求或明确指出,否则单数的术语应包括复数并且复数术语应包括单数。对于各种来源或参考文献之间的任何定义冲突,以本文提供的定义为准。
通常,免疫球蛋白重链中残基的编号是如Kabat等人,Sequences of Proteins ofImmunological Interest,第5版Public Health Service,National Institutes ofHealth,Bethesda,Md.(1991)中的EU索引的编号。“如Kabat中的EU索引”是指人IgG1 EU抗体的残基编号。
应理解,本文所述的本发明的实施方案包括“由实施方案组成”和/或“基本上由实施方案组成”。除非另有说明,否则如本文所用的单数形式“一个”、“一种”和“所述”包括复数个指示物。本文使用术语“或”并不意味着替代方案是相互排斥的。
在本申请中,除非本领域技术人员明确说明或理解,否则使用“或”意为“和/或”。在多个从属权利要求的上下文中,“或”的使用回指多于一个前述独立或从属权利要求。
短语“参考样品”、“参考细胞”或“参考组织”表示具有至少一种已知特征的样品,所述样品可用作与具有至少一种未知特征的样品的比较物。在一些实施方案中,参考样品可用作阳性或阴性指示物。与具有未知特征的样品中存在的蛋白质和/或mRNA的水平相比,参考样品可用于确定存在于例如健康组织中的蛋白质和/或mRNA的水平。在一些实施方案中,参考样品来自相同的受试者,但来自受试者的与被测试的部分不同的部分。在一些实施方案中,参考样品来自癌症周围或邻近处的组织区域。在一些实施方案中,参考样品不是来自被测试的受试者,而是来自已知患有或未患有所讨论的障碍(例如,特定癌症或T细胞相关障碍)的受试者的样品。在一些实施方案中,参考样品来自同一受试者,但来自受试者发生癌症之前的时间点。在一些实施方案中,参考样品来自于来自相同或不同受试者的良性癌症样品。当阴性参考样品用于比较时,阴性参考样品中所讨论的分子的表达水平或量将指示本领域技术人员在给定本公开文本的情况下认为不存在和/或存在低水平所述分子时的水平。当阳性参考样品用于比较时,阳性参考样品中所讨论的分子的表达水平或量将指示本领域技术人员在给定本公开文本的情况下认为存在一定水平的所述分子时的水平。
如本文所用的在受益于或响应于施用治疗剂的上下文中使用的术语“益处”、“临床益处”、“反应性”和“治疗反应性”可以通过评估各种终点来测量,所述终点例如在一定程度上对疾病进展的抑制,包括减慢和完全停止;疾病发作和/或症状的次数的减少;病灶大小的减小;疾病细胞浸润到邻近的外周器官和/或组织的抑制(即减少、减缓或完全终止);疾病传播的抑制(即减少、减缓或完全终止);在一定程度上对与障碍相关的一种或多种症状的缓解;治疗后无病表现的时间例如无进存活期的延长;增加的总存活期;更高的反应率;和/或降低的在治疗后给定时间点的死亡率。“无反应”或“反应失败”的受试者或癌症是未能满足上述“有反应”资格的受试者或癌症。
术语“核酸分子”、“核酸”和“多核苷酸”可以互换使用,并且是指核苷酸的聚合物。此类核苷酸聚合物可包含天然和/或非天然核苷酸,并且包括但不限于DNA、RNA和PNA。“核酸序列”是指核酸分子或多核苷酸中包含的核苷酸的线性序列。
术语“多肽”和“蛋白质”可互换使用以指代氨基酸残基的聚合物,并且不限于最小长度。氨基酸残基的此类聚合物可以含有天然或非天然氨基酸残基,并且包括但不限于氨基酸残基的肽、寡肽、二聚体、三聚体和多聚体。所述定义涵盖全长蛋白质以及其片段两者。所述术语还包括多肽的表达后修饰,例如糖基化、唾液酸化、乙酰化、磷酸化等。此外,出于本公开文本的目的,“多肽”是指包括对天然序列的修饰(如缺失、添加和取代,在本质上通常是保守的)的蛋白质,只要所述蛋白质保持期望的活性即可。这些修饰可能是故意的(如通过定点诱变),或者可能是偶然的(如通过产生蛋白质的宿主的突变或由于PCR扩增引起的错误)。“氨基酸序列”是指在多肽或蛋白质中包含的氨基酸的线性序列。
如本文所用,“IL-2”或“白细胞介素-2”是指由细胞中IL-2前体的加工产生的任何天然成熟IL-2。除非另有说明,否则所述术语包括来自任何脊椎动物来源的IL-2,所述脊椎动物来源包括哺乳动物,如灵长类动物(例如,人和食蟹猴或恒河猴)和啮齿动物(例如,小鼠和大鼠)。所述术语还包括天然存在的IL-2变体,如剪接变体或等位基因变体。非限制性示例性人IL-2氨基酸序列示于例如GenBank登录号NP_000577.2中。参见SEQ ID NO.1(成熟形式)。
如本文所用,“修饰的IL-2”是指由于在至少一个氨基酸位置处的取代而与野生型IL-2氨基酸序列不同的多肽。
术语“特异性结合”抗原或表位是本领域熟知的术语,并且确定这种特异性结合的方法也是本领域熟知的。如果相比于分子与替代细胞或物质反应或相缔合的情况,所述分子与特定细胞或物质更频繁更快速地以更长的持续时间和/或以更大的亲和力反应或相缔合,则所述分子被视为展现出“特异性结合”或“优先结合”。如果相比于抗原结合结构域与其他物质结合的情况,所述抗原结合结构域以更大的亲和力、亲合力更容易地和/或以更长的持续时间与抗原结合,则所述抗原结合结构域“特异性结合”或“优先结合”抗原。例如,特异性或优先结合表位的含有sdAb或VHH的多肽是如下的含有sdAb或VHH的多肽,其相比于结合相同靶抗原上的其他表位或其他靶抗原上的表位的情况以更大的亲和力、亲合力更容易地和/或以更长的持续时间结合该表位。通过阅读该定义还可以理解:例如,特异性或优先结合第一抗原的抗原结合结构域可以或可以不特异性或优先结合第二抗原。这样,“特异性结合”或“优先结合”并不一定需要(尽管可以包括)专一结合。通常,但并非必须,对结合的提及意指优先结合。“特异性”是指结合蛋白选择性结合抗原的能力。
如本文所用,关于IL-2活性的术语“调节”是指IL-2活性的变化。在一些实施方案中,“调节”是指IL-2活性的增加。
如本文所用,术语“表位”是指抗原结合分子(例如,含有抗原结合结构域的多肽)结合的在靶分子(例如,抗原,如蛋白质、核酸、碳水化合物或脂质)上的位点。表位通常包括诸如氨基酸、多肽或糖侧链等分子的化学活性表面分组,并且具有特定的三维结构特征以及特定的电荷特征。表位可以由所述靶分子的连续和/或并置的非连续残基(例如,氨基酸、核苷酸、糖、脂质部分)形成。由连续残基(例如,氨基酸、核苷酸、糖、脂质部分)形成的表位通常在暴露于变性溶剂时保留,而通过三级折叠形成的表位通常在用变性溶剂处理时丢失。表位可以包括但不限于至少3个、至少5个或8-10个残基(例如,氨基酸或核苷酸)。在一些实施方案中,表位长度为少于20个残基(例如,氨基酸或核苷酸)、少于15个残基或少于12个残基。如果两种抗体显示对一种抗原的竞争性结合,则它们可以结合所述抗原内的相同表位。在一些实施方案中,表位可以通过与抗原结合分子上的CDR残基的一定最小距离来鉴定。在一些实施方案中,表位可以通过上述距离来鉴定,并且进一步限于参与抗原结合分子的残基与抗原残基之间的键(例如,氢键)的那些残基。表位也可以通过各种扫描来鉴定,例如丙氨酸或精氨酸扫描可以指示抗原结合分子可以与之相互作用的一个或多个残基。除非明确指出,否则作为表位的一组残基不排除其他残基为特定抗原结合结构域或分子的表位的一部分。相反,这样一组的存在表示表位的最小系列(或物种组)。因此,在一些实施方案中,鉴定为表位的一组残基表示与抗原相关的最小表位,而不是抗原上表位的残基的排他列表。
“非线性表位”或“构象表位”包含抗原蛋白内的非连续多肽、氨基酸和/或糖,对所述表位具有特异性的抗原结合分子(例如,含有抗原结合结构域的多肽)与之结合。在一些实施方案中,残基中的至少一个将与表位的其他指出的残基不邻接;然而,残基中的一个或多个也可以与其他残基邻接。
“线性表位”包含抗原蛋白内的连续多肽、氨基酸和/或糖,对所述表位具有特异性的抗原结合分子(例如,含有抗原结合结构域的多肽)与之结合。应注意,在一些实施方案中,并非线性表位内的每一个残基都需要由抗原结合分子直接结合(或参与键合)。在一些实施方案中,线性表位可以来自用有效地由线性表位的序列组成的肽的免疫接种,或来自与蛋白质的其余部分相对分离的蛋白质的结构部分(使得抗原结合分子可以至少主要仅与该序列部分相互作用)。
术语“抗体”和“抗原结合分子”在最广泛的意义上可互换使用,并且涵盖包含抗原结合结构域的各种多肽,包括但不限于常规抗体(通常包含至少一条重链和至少一条轻链)、单结构域抗体(sdAb,仅包含一条链,通常与重链相似)、含有VHH的多肽(包含至少一个仅重链抗体可变结构域或VHH的多肽)、以及前述任一者的片段,只要它们展现出所需的抗原结合活性即可。在一些实施方案中,抗体包含二聚化结构域。此类二聚化结构域包括但不限于重链恒定结构域(包含CH1、铰链、CH2和CH3,其中CH1通常与轻链恒定结构域CL配对,而铰链介导二聚化)和Fc区(包含铰链、CH2和CH3,其中铰链介导二聚化)。术语抗体还包括但不限于嵌合抗体、人源化抗体、和各种物种(如骆驼科(包括美洲驼)、鲨鱼、小鼠、人、食蟹猴等)的抗体。
术语“单结构域抗体”和“sdAb”在本文中可互换使用,以指代具有单个单体结构域(通常为重链(或VHH))而没有轻链的抗体。
如本文所用,术语“VHH”或“VHH结构域”或“VHH抗原结合结构域”是指单结构域抗体如骆驼科抗体或鲨鱼抗体的抗原结合部分。在一些实施方案中,VHH包含三个CDR和四个框架区,指定为FR1、CDR1、FR2、CDR2、FR3、CDR3和FR4。在一些实施方案中,VHH可以在N端或C端被截短以使其仅包含部分FR1和/或FR4,或缺少那些框架区中的一个或两个,只要VHH基本上保持抗原结合和特异性即可。
术语“含有VHH的多肽”是指包含至少一个VHH结构域的多肽。在一些实施方案中,VHH多肽包含两个、三个或四个或更多个VHH结构域,其中每个VHH结构域可以是相同或不同的。在一些实施方案中,含有VHH的多肽包含Fc区。在一些此类实施方案中,VHH多肽可以形成二聚体。含有VHH的多肽的非限制性结构包括VHH1-Fc、VHH1-VHH2-Fc、和VHH1-VHH2-VHH3-Fc,其中VHH1、VHH2和VHH3可以是相同或不同的。在此类结构的一些实施方案中,一个VHH可以通过接头连接至另一个VHH,或者一个VHH可以通过接头连接至Fc。在一些此类实施方案中,接头包含1-20个氨基酸,优选1-20个主要由甘氨酸和任选的丝氨酸构成的氨基酸。在一些实施方案中,当含有VHH的多肽包含Fc时,它形成二聚体。因此,如果结构VHH1-VHH2-Fc形成二聚体,则认为它是四价的(即,二聚体具有四个VHH结构域)。类似地,如果结构VHH1-VHH2-VHH3-Fc形成二聚体,则认为它是六价的(即,二聚体具有六个VHH结构域)。
术语“单克隆抗体”是指基本上同质的抗体群体中的一种抗体(包括含有sdAb或VHH的多肽),即除了少量存在的可能天然存在的突变之外,构成所述群体的单个抗体是相同的。单克隆抗体针对单一抗原位点具有高度特异性。此外,与通常包括针对不同决定簇(表位)的不同抗体的多克隆抗体制剂相反,每种单克隆抗体针对抗原上的单一决定簇。因此,单克隆抗体样品可以与抗原上的相同表位结合。修饰语“单克隆的”指示抗体的特征是从基本上同质的抗体群体获得,并且不应解释为需要通过任何特定方法产生抗体。例如,单克隆抗体可以通过Kohler和Milstein,1975,Nature 256:495首次描述的杂交瘤方法制备,或者可以通过诸如美国专利号4,816,567等中所述的重组DNA方法制备。例如,还可以从使用McCafferty等人,1990,Nature 348:552-554中描述的技术产生的噬菌体文库中分离单克隆抗体。
术语“CDR”表示通过本领域技术人员的至少一种鉴定方式定义的互补决定区。在一些实施方案中,CDR可以根据Chothia编号方案、Kabat编号方案、Kabat和Chothia的组合、AbM定义和/或接触定义中的任一个来定义。VHH包含三个CDR,指定为CDR1、CDR2和CDR3。
如本文所用,术语“重链恒定区”是指包含至少三个重链恒定结构域CH1、铰链、CH2和CH3的区域。当然,除非另有说明,否则结构域内的非功能改变性缺失和改变都涵盖在术语“重链恒定区”的范围内。非限制性示例性重链恒定区包括γ、δ和α。非限制性示例性重链恒定区还包括ε和μ。每个重恒定区对应于一种抗体同种型。例如,含有γ恒定区的抗体为IgG抗体,含有δ恒定区的抗体为IgD抗体,以及含有α恒定区的抗体为IgA抗体。此外,包含μ恒定区的抗体为IgM抗体,以及包含ε恒定区的抗体为IgE抗体。某些同种型可以进一步细分为子类。例如,IgG抗体包括但不限于IgG1(包含γ1恒定区)、IgG2(包含γ2恒定区)、IgG3(包含γ3恒定区)和IgG4(包含γ4恒定区)抗体;IgA抗体包括但不限于IgA1(包含α1恒定区)和IgA2(包含α2恒定区)抗体;以及IgM抗体包括但不限于IgM1和IgM2。
如本文所用,“Fc区”是指包含CH2和CH3的重链恒定区的一部分。在一些实施方案中,Fc区包含铰链、CH2和CH3。在各种实施方案中,当Fc区包含铰链时,铰链介导两个含Fc多肽之间的二聚化。Fc区可以是本文讨论的任何抗体重链恒定区同种型的。在一些实施方案中,Fc区是IgG1、IgG2、IgG3或IgG4的。
如本文所用,“受体人框架”是包含源自人免疫球蛋白框架或人共有框架的重链可变结构域(VH)框架的氨基酸序列的框架,如本文所讨论的。源自人免疫球蛋白框架或人共有框架的受体人框架可以包含其相同的氨基酸序列,或者它可以含有氨基酸序列变化。在一些实施方案中,跨单个抗原结合结构域(如VHH)中的所有人框架,氨基酸变化的数量为少于10、或少于9、或少于8、或少于7、或少于6、或少于5、或少于4、或少于3。
“亲和力”是指分子(例如,含有抗体或VHH的多肽)的单个结合位点与其结合配偶体(例如,抗原)之间的非共价相互作用总和的强度。分子X对其配偶体Y的亲和力或表观亲和力通常可以分别由解离常数(KD)或KD-表观表示。可以通过本领域已知的常用方法(例如ELISA KD、KinExA、流式细胞术和/或表面等离子体共振装置)(包括本文所述的那些)测量亲和力。此类方法包括但不限于涉及或流式细胞术的方法。
如本文所用,术语“KD”是指抗原结合分子/抗原相互作用的平衡解离常数。当本文使用术语“KD”时,它包括KD和KD-表观。
在一些实施方案中,抗原结合分子的KD是使用表达抗原的细胞系通过流式细胞术并将在每个抗体浓度下测量的平均荧光拟合到非线性单位点结合方程(Prism Softwaregraphpad)来测量。在一些此类实施方案中,KD是KD-表观。
术语“生物活性”是指分子的任何一种或多种生物学特性(无论是在体内发现的天然存在的,还是通过重组方式提供或实现的)。生物学特性包括但不限于结合配体、诱导或增加细胞增殖(如T细胞增殖)、以及诱导或增加细胞因子的表达。
如本文所用,术语“IL-2活性”或IL-2的“生物活性”包括IL-2的任何生物学效应或至少一种生物学相关功能。在一些实施方案中,IL-2活性包括IL-2诱导T细胞增殖和/或激活自然杀伤(NK)细胞的能力。非限制性示例性IL-2活性包括增加pSTAT5表达、增加CD4+和/或CD8+T细胞的增殖、增加T细胞上的CD71表达、和降低Treg细胞对CD4+和CD8+T细胞激活和增殖的抑制活性。
“激动剂”或“激活性”抗体(如含有sdAb或VHH的多肽)是一种增加和/或激活靶抗原生物活性的抗体。在一些实施方案中,激动剂抗体与抗原结合,并且将所述抗原的生物活性提高至少约20%、40%、60%、80%、85%或更多。
“拮抗剂”、“阻断性”或“中和”抗体是使靶抗原的生物活性降低和/或失活的抗体。在一些实施方案中,中和抗体与抗原结合,并且将所述抗原的生物活性降低至少约20%、40%、60%、80%、85%、90%、95%、99%或更多。
“亲和力成熟的”含有VHH的多肽是指与不具有此类改变的含有VHH的亲本多肽相比,在一个或多个CDR中具有一个或多个改变的含有VHH的多肽,此类改变导致含有VHH的多肽对于抗原的亲和力提高。
如本文所用,“人源化VHH”是指其中一个或多个框架区已基本上被人框架区替代的VHH。在一些情况下,人免疫球蛋白的某些框架区(FR)残基被相应的非人残基替代。此外,人源化VHH可以包含在原始VHH和人框架序列中均未发现的、但被包括在内以进一步改善和优化VHH或含VHH多肽性能的残基。在一些实施方案中,含有人源化VHH的多肽包含人Fc区。应当理解,人源化序列可以通过其一级序列来鉴定,并且不一定表示产生抗体的过程。
“功能性Fc区”具有天然序列Fc区的“效应子功能”。示例性“效应子功能”包括Fc受体结合;Clq结合和补体依赖性细胞毒性(CDC);Fc受体结合;抗体依赖性细胞介导的细胞毒性(ADCC);吞噬作用;下调细胞表面受体(例如B细胞受体);和B细胞激活等。此类效应子功能通常需要将Fc区与结合结构域(例如,抗体可变结构域)组合,并且可以使用各种测定进行评估。
“天然序列Fc区”包含与在自然界中发现的Fc区的氨基酸序列相同的氨基酸序列。天然序列人Fc区包括天然序列人IgG1 Fc区(非A同种异型和A同种异型);天然序列人IgG2Fc区;天然序列人IgG3 Fc区;和天然序列人IgG4 Fc区以及其天然存在的变体。
“变体Fc区”包含由于至少一个氨基酸修饰而不同于天然序列Fc区氨基酸序列的氨基酸序列。在一些实施方案中,“变体Fc区”包含的氨基酸序列由于至少一个氨基酸修饰而不同于天然序列Fc区氨基酸序列,但仍保留天然序列Fc区的至少一种效应子功能。在一些实施方案中,与天然序列Fc区或与亲本多肽的Fc区相比,变体Fc区具有在天然序列Fc区或在亲本多肽的Fc区中的至少一个氨基酸取代,例如约一至约十个氨基酸取代,并且优选约一至约五个氨基酸取代。在一些实施方案中,本文的变体Fc区将与天然序列Fc区和/或与亲本多肽的Fc区具有至少约80%的序列同一性,与其至少约90%的序列同一性,与其至少约95%、至少约96%、至少约97%、至少约98%或至少约99%的序列同一性。
“Fc受体”或“FcR”描述了与抗体Fc区结合的受体。在一些实施方案中,FcγR是天然人FcR。在一些实施方案中,FcR是结合IgG抗体的受体(γ受体),并包括FcγRI、FcγRII和FcγRIII亚类的受体,包括这些受体的等位基因变体和选择性剪接形式。FcγRII受体包括FcγRIIA(“激活性受体”)和FcγRIIB(“抑制性受体”),它们具有相似的氨基酸序列,主要区别在于其细胞质结构域。激活性受体FcγRIIA在其细胞质结构域中包含免疫受体酪氨酸激活基序(ITAM)。抑制性受体FcγRIIB在其细胞质结构域中包含免疫受体酪氨酸抑制基序(ITIM)。(参见例如,Daeron,Annu.Rev.Immunol.15:203-234(1997))。例如,在以下文献中对FcR进行了综述:Ravetch和Kinet,Annu.Rev.Immunol9:457-92(1991);Capel等人,Immunomethods 4:25-34(1994);以及de Haas等人,J.Lab.Clin.Med.126:330-41(1995)。本文中的术语“FcR”涵盖其他FcR,包括将来要鉴定的那些。例如,术语“Fc受体”或“FcR”还包括新生儿受体FcRn,所述FcRn负责将母体IgG转移到胎儿(Guyer等人,J.Immunol.117:587(1976)和Kim等人,J.Immunol.24:249(1994))和调节免疫球蛋白的稳态。测量与FcRn结合的方法是已知的(参见例如Ghetie和Ward,Immunol.Today 18(12):592-598(1997);Ghetie等人,Nature Biotechnology,15(7):637-640(1997);Hinton等人,J.Biol.Chem.279(8):6213-6216(2004);WO 2004/92219(Hinton等人))。
如本文所用,术语“基本上相似”或“基本上相同”表示两个或更多个数值之间足够高的相似度,使得本领域技术人员认为这两个或更多个值之间的差异在由所述值测量的生物学特征的背景下具有很小或者没有生物学和/或统计学显著性。在一些实施方案中,两个或更多个基本上相似的值的差异不超过约5%、10%、15%、20%、25%或50%中的任一个。
多肽“变体”意指在比对序列和引入空位(如果需要)以实现最大序列同一性百分比并且不将任何保守取代视为序列同一性的一部分之后,与天然序列多肽具有至少约80%的氨基酸序列同一性的生物活性多肽。此类变体包括例如其中在多肽的N端或C端添加、或缺失一个或多个氨基酸残基的多肽。在一些实施方案中,变体将具有至少约80%的氨基酸序列同一性。在一些实施方案中,变体将具有至少约90%的氨基酸序列同一性。在一些实施方案中,变体将与天然序列多肽具有至少约95%的氨基酸序列同一性。
如本文所用,关于肽、多肽或抗体序列的“氨基酸序列同一性百分比(%)”和“同源性”定义为在比对序列和引入空位(如果需要)以实现最大序列同一性百分比并且不将任何保守取代视为序列同一性的一部分之后,候选序列中与特定肽或多肽序列中的氨基酸残基相同的氨基酸残基的百分比。用于确定氨基酸序列同一性百分比的比对可以以本领域熟知的多种方式来实现,例如,使用公众可获得的计算机软件,如BLAST、BLAST-2、ALIGN或MEGALIGNTM(DNASTAR)软件。本领域技术人员可以确定用于测量比对的适当参数,包括在所比较序列的全长上实现最大比对所需的任何算法。
氨基酸取代可以包括但不限于将多肽中的一种氨基酸用另一种氨基酸替代。示例性取代在表1中示出。可以将氨基酸取代引入目的抗体中,并筛选产物的所需活性,例如,保留/改善的抗原或受体结合,减少的抗原或受体结合,降低的免疫原性,或改善的ADCC或CDC。
表1
原始残基 | 示例性取代 |
Ala(A) | Val;Leu;Ile |
Arg(R) | Lys;Gln;Asn |
Asn(N) | Gln;His;Asp,Lys;Arg |
Asp(D) | Glu;Asn |
Cys(C) | Ser;Ala |
Gln(Q) | Asn;Glu |
Glu(E) | Asp;Gln |
Gly(G) | Ala |
His(H) | Asn;Gln;Lys;Arg |
Ile(I) | Leu;Val;Met;Ala;Phe;正亮氨酸 |
Leu(L) | 正亮氨酸;Ile;Val;Met;Ala;Phe |
Lys(K) | Arg;Gln;Asn |
Met(M) | Leu;Phe;Ile |
Phe(F) | Trp;Leu;Val;Ile;Ala;Tyr |
Pro(P) | Ala |
Ser(S) | Thr |
Thr(T) | Val;Ser |
Trp(W) | Tyr;Phe |
Tyr(Y) | Trp;Phe;Thr;Ser |
Val(V) | Ile;Leu;Met;Phe;Ala;正亮氨酸 |
可根据常见的侧链特性将氨基酸分组:
(1)疏水性:正亮氨酸、Met、Ala、Val、Leu、Ile;
(2)中性亲水性:Cys、Ser、Thr、Asn、Gln;
(3)酸性:Asp、Glu;
(4)碱性:His、Lys、Arg;
(5)影响链取向的残基:Gly、Pro;
(6)芳香族:Trp、Tyr、Phe。
非保守取代将需要将这些类别之一的成员交换为另一类别。
术语“载体”用于描述可以被工程化为含有一种或多种克隆的多核苷酸的可以在宿主细胞中繁殖的多核苷酸。载体可包括一种或多种以下元件:复制起点、调节目的多肽表达的一种或多种调节序列(如启动子和/或增强子)、和/或一种或多种选择性标记基因(如抗生素抗性基因和可用于比色测定的基因,例如β-半乳糖苷酶)。术语“表达载体”是指用于在宿主细胞中表达目的多肽的载体。
“宿主细胞”是指可以是或已经是载体或分离的多核苷酸的受体的细胞。宿主细胞可以是原核细胞或真核细胞。示例性真核细胞包括哺乳动物细胞,如灵长类动物或非灵长类动物细胞;真菌细胞,如酵母;植物细胞;以及昆虫细胞。非限制性示例性哺乳动物细胞包括但不限于NSO细胞、PER.细胞(Crucell)以及293F和CHO细胞,以及它们的衍生物,如293-6E、CHO-DG44、CHO-K1、CHO-S、和CHO-DS细胞。宿主细胞包括单个宿主细胞的后代,并且由于天然的、偶然的或故意的突变,所述后代可能不一定与原始亲本细胞完全相同(在形态学或基因组DNA互补序列方面)。宿主细胞包括用本文提供的一种或多种多核苷酸在体内转染的细胞。
如本文所用,术语“分离的”是指已经与通常在自然界中发现或产生的至少一些组分分离的分子。例如,当多肽与产生它的细胞的至少一些组分分离时,称其为“分离的”。当多肽在表达后由细胞分泌时,将含有所述多肽的上清液与产生它的细胞物理分离,认为是“分离”所述多肽。类似地,当多核苷酸不是通常在自然界中发现的较大的多核苷酸(诸如例如,在DNA多核苷酸的情况下的基因组DNA或线粒体DNA)的一部分时,或例如在RNA多核苷酸的情况下与产生它的细胞的至少一些组分分离时,多核苷酸被称为“分离的”。因此,在宿主细胞内的载体中包含的DNA多核苷酸可称为“分离的”。
术语“个体”和“受试者”在本文中可互换使用以指代动物,例如哺乳动物。在一些实施方案中,提供了治疗哺乳动物的方法,所述哺乳动物包括但不限于人、啮齿动物、猿猴、猫科动物、犬科动物、马科动物、牛科动物、猪、绵羊、山羊、哺乳动物实验室动物、哺乳动物家畜、哺乳动物运动动物和哺乳动物宠物。在一些例子中,“个体”或“受试者”是指需要治疗疾病或障碍的个体或受试者。在一些实施方案中,接受治疗的受试者可以是指明如下事实的患者:受试者已被鉴定为患有与治疗相关的障碍,或有患上所述障碍的足够风险。
如本文所用,“疾病”或“障碍”是指需要和/或期望治疗的病症。
除非另有说明,否则术语“肿瘤细胞”、“癌细胞”、“癌症”、“肿瘤”和/或“瘤”在本文中可互换使用,并且是指展现出会干扰身体器官和系统的正常功能发挥的不受控制的生长和/或异常增加的细胞存活和/或细胞凋亡的抑制的一种细胞(或多种细胞)。此定义包括良性和恶性癌症、息肉、增生以及休眠的肿瘤或微转移。
术语“癌症”和“肿瘤”涵盖实体癌和血液/淋巴癌,并且还涵盖恶性、恶变前和良性生长,如发育不良。此定义还包括具有不受免疫系统阻碍(例如免疫逃避和免疫逃避机制)的异常增殖的细胞(例如病毒感染的细胞)。示例性癌症包括但不限于:基底细胞癌;胆道癌;膀胱癌;骨癌;脑和中枢神经系统癌症;乳腺癌;腹膜癌;宫颈癌;绒毛膜癌;结直肠癌;结缔组织癌;消化系统癌症;子宫内膜癌;食道癌;眼癌;头颈癌;胃癌(包括胃肠癌);胶质母细胞瘤;肝癌;肝肿瘤;上皮内瘤;肾脏癌或肾癌;喉癌;白血病;肝脏癌症;肺癌(例如小细胞肺癌、非小细胞肺癌、肺腺癌、和肺鳞癌);黑色素瘤;骨髓瘤;神经母细胞瘤;口腔癌(唇、舌、口、和咽);卵巢癌;胰腺癌;前列腺癌;视网膜母细胞瘤;横纹肌肉瘤;直肠癌;呼吸系统癌症;唾液腺癌;肉瘤;皮肤癌;鳞状细胞癌;胃癌;睾丸癌;甲状腺癌;子宫或子宫内膜癌;泌尿系统癌症;外阴癌;淋巴瘤,包括霍奇金和非霍奇金淋巴瘤、以及B细胞淋巴瘤(包括低分级/滤泡性非霍奇金淋巴瘤(NHL);小淋巴细胞(SL)NHL;中分级/滤泡性NHL;中分级弥漫性NHL;高分级免疫母细胞NHL;高分级淋巴母细胞NHL;高分级小非裂解细胞NHL;大肿块NHL;套细胞淋巴瘤;艾滋病相关淋巴瘤;以及华氏巨球蛋白血症;慢性淋巴细胞白血病(CLL);急性成淋巴细胞性白血病(ALL);毛细胞白血病;慢性成髓细胞性白血病;以及其他癌和肉瘤;以及移植后淋巴增殖性疾病(PTLD),以及与斑痣性错构瘤病相关的异常血管增生,水肿(如与脑肿瘤相关的),以及梅格斯综合征。
如本文所用,术语“非肿瘤细胞”是指正常细胞或组织。示例性非肿瘤细胞包括但不限于:T细胞,B细胞,自然杀伤(NK)细胞,自然杀伤T(NKT)细胞,树突细胞,单核细胞,巨噬细胞,上皮细胞,成纤维细胞,肝细胞,肾间质细胞,成纤维细胞样滑膜细胞,成骨细胞,和位于乳房、骨骼肌、胰腺、胃、卵巢、小肠、胎盘、子宫、睾丸、肾、肺、心脏、脑、肝、前列腺、结肠、淋巴器官、骨骼中的细胞,和骨源性间充质干细胞。如本文所用,术语“位于外周的细胞或组织”是指不位于肿瘤细胞附近和/或在肿瘤微环境内的非肿瘤细胞。
如本文所用,术语“肿瘤微环境内的细胞或组织”是指围绕和/或滋养肿瘤细胞的细胞、分子、细胞外基质和/或血管。肿瘤微环境内的示例性细胞或组织包括但不限于:肿瘤脉管系统;肿瘤浸润性淋巴细胞;成纤维细胞网状细胞;内皮祖细胞(EPC);癌症相关成纤维细胞;周细胞;其他基质细胞;细胞外基质(ECM)的组分;树突细胞;抗原呈递细胞;T细胞;调节性T细胞(Treg细胞);巨噬细胞;嗜中性粒细胞;髓源性抑制细胞(MDSC)和位于肿瘤附近的其他免疫细胞。鉴定肿瘤细胞和/或位于肿瘤微环境内的细胞/组织的方法是本领域熟知的,如下文所述。
在一些实施方案中,“增加”或“减少”分别是指统计学上显著的增加或减少。技术人员将清楚,“调节”还可以涉及与相同条件但不存在测试药剂的情况相比,实现靶标或抗原对其配体、结合配偶体、用于缔合为同多聚体或异多聚体形式的配偶体、或底物中的一种或多种的亲和力、亲合力、特异性和/或选择性的改变(可以是增加或减少);实现靶标或抗原对存在靶标或抗原的介质或环境中的一种或多种条件(如pH、离子强度、存在辅因子等)的敏感性的改变(可以是增加或减少);和/或细胞增殖或细胞因子产生。这可以以任何合适的方式和/或使用本身已知的或本文描述的任何合适的测定来确定,这取决于所涉及的靶标。
如本文所用,“免疫应答”意在涵盖足以抑制或预防疾病(例如,癌症或癌症转移)的发作或改善所述疾病的症状的细胞免疫应答和/或体液免疫应答。“免疫应答”可以涵盖先天免疫系统和适应性免疫系统的方面。
如本文所用,“治疗”是用于获得有益的或期望的临床结果的途径。如本文所用,“治疗”涵盖针对包括人在内的哺乳动物中的疾病的治疗剂的任何施用或应用。出于本公开文本的目的,有益或期望的临床结果包括但不限于以下中的任何一个或多个:减轻一种或多种症状,降低疾病程度,预防或延迟疾病的传播(例如转移,例如转移到肺或淋巴结),预防或延迟疾病的复发,延迟或减缓疾病的进展,改善疾病状态,抑制疾病或疾病进展,抑制或减缓疾病或疾病进展,停滞疾病发展和缓解(无论是部分还是全部)。“治疗”还涵盖降低增殖性疾病的病理后果。本文提供的方法考虑了这些治疗方面中的任何一个或多个。与上述一致,术语治疗不需要百分之百地去除所述障碍的所有方面。
“改善”是指与不施用治疗剂相比,一种或多种症状的减轻或改进。“改善”还包括缩短或减少症状的持续时间。
术语“抗癌剂”在本文中以其最广泛的意义使用,是指用于治疗一种或多种癌症的药剂。此类药剂的示例性类别包括但不限于化学治疗剂、抗癌生物制剂(如细胞因子、受体细胞外结构域-Fc融合物、和抗体)、放射疗法、CAR-T疗法、治疗性寡核苷酸(如反义寡核苷酸和siRNA)和溶瘤病毒。
术语“生物样品”意指来自活物或曾经的活物的物质的量。此类物质包括但不限于血液(例如全血)、血浆、血清、尿液、羊水、滑液、内皮细胞、白细胞、单核细胞、其他细胞、器官、组织、骨髓、淋巴结和脾脏。
术语“对照”或“参考”是指已知不含有分析物(“阴性对照”)或含有分析物(“阳性对照”)的组合物。阳性对照可包含已知浓度的分析物。
术语“抑制”(“inhibition”或“inhibit”)是指任何表型特征的减少或停止,或该特征的发生率、程度或可能性的减少或停止。“降低”或“抑制”是指与参考相比,活性、功能和/或量的减少、降低或阻滞。在一些实施方案中,“降低”或“抑制”意指导致总体减少10%或更多的能力。在一些实施方案中,“降低”或“抑制”意指导致总体减少50%或更多的能力。在一些实施方案中,“降低”或“抑制”意指引起总体减少75%、85%、90%、95%或更多的能力。在一些实施方案中,在相同的时间段内,相对于对照,上述量在一段时间内被抑制或减少。
如本文所用,“延迟疾病的发展”意指推迟、阻碍、减缓、延缓、稳定、抑制和/或延期疾病(例如癌症)的发展。此延迟可以具有不同的时间长度,这取决于病史和/或所治疗的个体。对于本领域技术人员清楚的是,足够或显著的延迟实际上可以涵盖预防,因为个体不会患上疾病。例如,可能延迟晚期癌症,如转移的发展。
如本文所用,“预防”包括提供关于受试者的疾病的发生或复发的预防,所述受试者可能易患所述疾病但尚未被诊断患有所述疾病。除非另有说明,否则术语“降低”、“抑制”或“预防”并不表示或要求在所有时间内完全预防,而只是在所测量的时间段内如此。
物质/分子、激动剂或拮抗剂的“治疗有效量”可根据诸如个体的疾病状态、年龄、性别和体重,以及物质/分子、激动剂或拮抗剂在个体中引发所需应答的能力等因素而变化。治疗有效量也是治疗有益效果超过物质/分子、激动剂或拮抗剂的任何毒性或有害作用的量。治疗有效量可以按一次或多次施用来递送。“治疗有效量”是指在必要的剂量和持续必要的时间段的情况下有效实现所需治疗和/或预防结果的量。
术语“药物配制品”和“药物组合物”是指呈使得一种或多种活性成分的生物活性有效的形式、并且不含对所述配制品所施用的受试者具有不可接受的毒性的其他组分的制剂。此类配制品可以是无菌的。
“药学上可接受的载体”是指用于与治疗剂一起使用的无毒固体、半固体或液体填充剂、稀释剂、包囊材料、配制助剂或本领域常规的载体,所述载体和治疗剂共同构成用于向受试者施用的“药物组合物”。药学上可接受的载体在使用的剂量和浓度下对接受者无毒,并且与配制品的其他成分相容。药学上可接受的载体适用于所用配制品。
与一种或多种其他治疗剂“组合”施用包括同时(并行)和以任何顺序依序施用。
术语“并行”在本文中用于指两种或更多种治疗剂的施用,其中至少部分施用在时间上重叠或者其中一种治疗剂的施用相对于另一种治疗剂的施用在很短的时间段内发生,或者其中两种药剂的治疗作用重叠持续至少一段时间。
术语“依序”在本文中用于指两种或更多种治疗剂的施用在时间上不重叠,或者其中药剂的治疗作用不重叠。
如本文所用,术语“与……结合”是指除了一种治疗模式之外还施用另一种治疗模式。因此,“与……结合”是指在向个体施用一种治疗模式之前、期间或之后施用另一种治疗模式。
术语“包装插页”用于指代通常包括在治疗产品的商业包装中的说明书,所述说明书含有关于使用此类治疗产品的适应证、用法、剂量、施用、组合疗法、禁忌症和/或警告的信息。
“制品”是包含至少一种试剂(例如用于治疗疾病或障碍(例如癌症)的药物)或用于特异性地检测本文所述的生物标记物的探针的任何制造物(例如包装或容器)或试剂盒。在一些实施方案中,所述制造物或试剂盒作为用于实施本文所述的方法的单元进行促销、分发或销售。
术语“标记”和“可检测标记”意指例如与抗体或抗原附接的部分,以使特异性结合对的成员之间的反应(例如,结合)可检测。所述特异性结合对的经标记的成员被称为“被可检测地标记”。因此,术语“经标记的结合蛋白”是指掺入了用于鉴定所述结合蛋白的标记的蛋白质。在一些实施方案中,所述标记是可产生能通过视觉或仪器手段检测的信号的可检测标记,例如,掺入经放射性标记的氨基酸或将生物素基部分附接到多肽,所述生物素基部分可以通过加标记的抗生物素蛋白检测(例如,链霉抗生物素蛋白含有荧光标记物或酶活性,可通过光学方法或比色法检测)。用于多肽的标记的例子包括但不限于以下:放射性同位素或放射性核素(例如,3H、14C、35S、90Y、99Tc、111In、125I、131I、177Lu、166Ho或153Sm);色原、荧光标记(例如,FITC、罗丹明、镧系荧光粉)、酶标记(例如,辣根过氧化物酶、萤光素酶、碱性磷酸酶);化学发光标记;生物素基团;由第二报道分子识别的预定多肽表位(例如,亮氨酸拉链对序列、第二抗体的结合位点、金属结合结构域、表位标签);和诸如钆螯合物等的磁性剂。通常用于免疫测定的标记的代表性例子包括产生光的部分,例如吖啶化合物;和产生荧光的部分,例如荧光素。在这方面,所述部分本身可能没有被可检测地标记,但在与又另一部分反应时可能变得可检测。
示例性含有修饰的IL-2的多肽
本文提供了包含修饰的IL-2的多肽。在一些实施方案中,修饰的IL-2包含至少一个氨基酸取代,与野生型IL-2相比,所述至少一个氨基酸取代降低修饰的IL-2对IL-2受体的亲和力。在各种实施方案中,本文提供的包含修饰的IL-2的多肽是IL-2R的激动剂。在一些实施方案中,修饰的IL-2是修饰的人IL-2,并且IL-2R是人IL-2R。在一些实施方案中,与人野生型IL-2对于IL-2R的亲和力相比,所述修饰的IL-2以低至少2倍、3倍、4倍、5倍、6倍、7倍、8倍、9倍、至少10倍、至少20倍、至少30倍、至少50倍或至少100倍的亲和力结合人IL-2R。
在各种实施方案中,包含修饰的IL-2的多肽包含结合T细胞或自然杀伤(NK)细胞抗原的至少一个抗原结合结构域。在一些实施方案中,包含本文提供的修饰的IL-2的多肽包含一个、两个、三个、四个、五个、六个、七个或八个抗原结合结构域,其中至少一个或全部结合T细胞或自然杀伤细胞抗原。在一些实施方案中,包含本文提供的修饰的IL-2的多肽包含一个、两个、三个或四个抗原结合结构域,其中至少一个或全部结合T细胞或自然杀伤细胞抗原。在一些实施方案中,在不存在抗原结合结构域的情况下,含有修饰的IL-2的多肽不结合或激活IL-2R。在一些实施方案中,仅当含有修饰的IL-2的多肽包含与IL-2R所处的相同细胞上的抗原结合的抗原结合结构域时,所述多肽才结合和/或激活细胞上的IL-2R。
在各种实施方案中,修饰的IL-2在选自L19、Q22、R38、E61、N88、R120、T123、Q126、S127、I129和S130的至少一个氨基酸位置处包含至少一个取代。在一些实施方案中,修饰的IL-2在选自T3、P65、H16、D84、M23、E95和C125的至少一个氨基酸位置处包含至少一个取代。在一些实施方案中,修饰的IL-2在至少一个选自L19、Q22、R38、E61、N88、R120、T123、Q126、S127、I129和S130的氨基酸位置处以及在氨基酸位置T3、P65、H16、D84和C125处包含取代。在一些此类实施方案中,所述修饰的IL-2还在氨基酸位置M23和/或E95处包含取代。
在一些实施方案中,在氨基酸位置L19处的取代选自L19A、L19N、L19P、L19Q、L19Y、L19S、L19T和L19V。在一些实施方案中,在氨基酸位置Q22处的取代选自Q22A、Q22D、Q22G、Q22H、Q22K、Q22N、Q22R、Q22S、Q22T、Q22V和Q22Y。在一些实施方案中,在氨基酸位置R38处的取代是R38A或R38G。在一些实施方案中,在氨基酸位置E61处的取代选自E61A、E61P、E61G、E61H、E61Q、E61N、E61R、E61S、E61T、E61K和E61Y。在一些实施方案中,在氨基酸位置N88处的取代选自N88A、N88S和N88T。在一些实施方案中,在氨基酸位置R120处的取代选自R120A、R120D、R120G、R120H、R120E、R120F、R120K、R120N、R120P、R120Q、R120S、R120V和R120Y。在一些实施方案中,在氨基酸位置T123处的取代选自T123D、T123E、T123H、T123K、T123N、T123R和T123Q。在一些实施方案中,在氨基酸位置Q126处的取代选自Q126A、Q126N和Q126Y。在一些实施方案中,在氨基酸位置S127处的取代选自S127E、S127D、S127N、S127H、S127P、S127Q和S127R。在一些实施方案中,在氨基酸位置I129处的取代选自I129A、I129H、I129R和I129S。在一些实施方案中,在氨基酸位置S130处的取代选自S130D、S130P、S130E、S130K、S130N、S130R、S130H和S130Q。
在一些实施方案中,在氨基酸位置P65处的取代选自P65R、P65E、P65K、P65H、P65Y、P65Q、P65D和P65N。在一些实施方案中,在氨基酸位置H16处的取代选自H16A、H16N、H16T和H16V。在一些实施方案中,在氨基酸位置D84处的取代选自D84S、D84N、D84G、D84A、D84T、D84V和D84Y。在一些实施方案中,在氨基酸位置M23处的取代选自M23A、M23R、M23Q、M23N、M23L、M23K、M23G、M23E、M23D、M23S、M23T和M23V。在一些实施方案中,在氨基酸位置E95处的取代选自E95Q、E95Y、E95G、E95T、E95V、E95P、E95H和E95N。
在一些实施方案中,在氨基酸位置T3处的取代选自T3A和T3G。在一些实施方案中,在氨基酸位置C125处的取代选自C125A和C125S。
在一些实施方案中,修饰的IL-2还包含在氨基酸位置F42处的取代。在一些此类实施方案中,在F42处的取代选自F42K、F42A、F42R、F42G、F42S和F42T。
在一些实施方案中,修饰的IL-2在选自Y45和L72的至少一个氨基酸位置处还包含至少一个取代。在一些此类实施方案中,所述修饰的IL-2包含至少一个选自Y45R、Y45K和L72G的取代。
在一些实施方案中,修饰的IL-2包含取代T3A、P65R、H16A、D84Y和C125S。在一些实施方案中,所述修饰的IL-2包含取代T3A、P65R、H16A、D84Y和C125S,并且在至少一个选自L19、Q22、R38、E61、N88、R120、T123、Q126、S127、I129和S130的位置处包含一个或多个取代。在一些实施方案中,所述修饰的IL-2包含取代T3A、P65R、H16A、D84S和C125S,并且在至少一个选自L19、Q22、R38、E61、N88、R120、T123、Q126、S127、I129和S130的位置处包含一个或多个取代。在一些实施方案中,所述修饰的IL-2包含取代T3A、P65R、H16A、D84Y、C125S和E61R。在一些实施方案中,所述修饰的IL-2包含取代T3A、P65R、H16A、D84Y、C125S和E61R并且包含至少一个选自L19N、M23T、E95Q和S127D的取代。在一些实施方案中,所述修饰的IL-2包含取代
a)T3A、H16A、E61R、P65R、D84Y和C125S,
b)T3A、H16A、M23T、E61R、P65R、D84Y、E95Q和C125S,
c)T3A、H16A、L19N、E61R、P65R、D84Y和C125S,
d)T3A、H16A、L19N、M23T、E61R、P65R、D84Y、E95Q和C125S,
e)T3A、H16A、E61R、P65R、D84Y、C125S和S127D,
f)T3A、H16A、M23T、E61R、P65R、D84Y、E95Q、C125S和S127D,
g)T3A、H16A、L19N、E61R、P65R、D84Y、C125S和S127D或
h)T3A、H16A、L19N、M23T、E61R、P65R、D84Y、E95Q、C125S和S127D。
在本文所述的任何实施方案中,修饰的IL-2可以是修饰的人IL-2。在各种实施方案中,取代的氨基酸位置对应于SEQ ID NO:1中的氨基酸位置。
在一些实施方案中,所述修饰的IL-2包含与SEQ ID NO:84至少90%、91%、92%、93%、94%、95%、96%、97%、98%或99%相同并且包括与选自在某些序列的列表的描述列中所列的SEQ ID NO:105-277的氨基酸序列中的取代对应的氨基酸取代的氨基酸序列。对应的取代意指比对两个序列时相同的氨基酸。例如,SEQ ID NO:106包含取代T3A、E61R、P65R和C125S。如果比对SEQ ID NO:84和SEQ ID NO:106,SEQ ID NO:106中的位置E61与SEQID NO:84中的序列位置E51对应。SEQ ID NO:106的T3在SEQ ID NO:84中无对应位置,因为无对应氨基酸。因此,在与SEQ ID NO:106的位置对应的位置包含SEQ ID NO:106的取代的SEQ ID NO:84包含与E61R、P65R和C125S对应的突变(在SEQ ID NO:84中分别为E51R、P55R和C115S)。在一些实施方案中,所述修饰的IL-2包含与SEQ ID NO:84至少90%、91%、92%、93%、94%、95%、96%、97%、98%或99%相同并且在至少一个与选自SEQ ID NO:1的L19、Q22、R38、E61、N88、R120、T123、Q126、S127、I129和S130的位置对应的位置处包括取代的氨基酸序列。
在一些实施方案中,所述修饰的IL-2包含与选自SEQ ID NO:105-290的氨基酸序列至少90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或100%相同并且包括某些序列的列表中关于相应氨基酸序列的描述中所指示的取代的氨基酸序列。在一些实施方案中,所述修饰的IL-2包含与选自SEQ ID NO:105-290的氨基酸序列至少90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或100%相同并且在至少一个选自L19、Q22、R38、E61、N88、R120、T123、Q126、S127、I129和S130的位置处包括取代的氨基酸序列。在一些实施方案中,所述修饰的IL-2包含选自SEQ ID NO:105-290的氨基酸序列。在一些实施方案中,所述修饰的IL-2包含选自SEQ ID NO:270-277的氨基酸序列。
在一些实施方案中,含有修饰的IL-2的多肽包含结合T细胞或自然杀伤细胞抗原的至少一个抗原结合结构域和Fc区。在一些实施方案中,本文提供的含有修饰的IL-2的多肽包含一个、两个、三个或四个抗原结合结构域和Fc区。在一些实施方案中,Fc区在生理条件下介导含有修饰的IL-2的多肽的二聚化,从而形成使抗原结合位点数量加倍的二聚体。例如,包含三个抗原结合结构域和Fc区的含有修饰的IL-2的多肽作为单体是三价的,但在生理条件下,Fc区可介导二聚化,使得含有修饰的IL-2的多肽在此类条件下以六价二聚体存在。
在各种实施方案中,包含修饰的IL-2的多肽包含选自SEQ ID NO:105-290的序列。在各种实施方案中,包含修饰的IL-2的多肽包含选自SEQ ID NO:270-277的序列。在一些实施方案中,所述多肽还包含抗原结合结构域。在一些实施方案中,所述抗原结合结构域是人源化的。
在一些实施方案中,至少一个抗原结合结构域是自然或天然同源结合配偶体、Anticalin(工程化脂质运载蛋白)、Darpin、Fynomer、Centyrin(工程化纤连蛋白III结构域)、胱氨酸结结构域、Affilin、亲和体(Affibody)或工程化CH3结构域。在一些实施方案中,所述自然同源结合配偶体包含肿瘤相关抗原(TAA)的天然同源结合配偶体的配体或细胞外结构域或其结合片段,或其展现出与所述TAA的结合活性的变体。
在一些实施方案中,包含修饰的IL-2和至少一个抗原结合结构域的多肽增强抗肿瘤T细胞应答或自然杀伤细胞应答,同时规避Treg、外周T细胞和内皮细胞。在一些此类实施方案中,所述至少一个抗原结合结构域将修饰的IL-2靶向激活的T细胞。在一些实施方案中,仅当IL-2R与由所述至少一个抗原结合结构域结合的抗原在同一细胞上时,修饰的IL-2才结合并调节IL-2R。在一些实施方案中,当IL-2R在与表达由所述至少一个抗原结合结构域结合的抗原的细胞不同的细胞上时,修饰的IL-2不结合或激活IL-2R。
在各种实施方案中,抗原结合结构域结合选自PD-1、CTLA-4、LAG3、TIM3、4-1BB、OX40、GITR、CD8a、CD8b、CD4、NKp30、NKG2A、TIGIT、TGFβR1、TGFβR2、Fas、NKG2D、NKp46、PD-L1、CD107a、ICOS、TNFR2、CD16a和γδTCR的蛋白质。在一些实施方案中,包含修饰的IL-2的多肽包含以下抗体的抗原结合结构域:纳武单抗(BMS;PD-1);派姆单抗(Merck;PD-1);AMP-514(Amplimmune;PD-1);TSR-042(Tesaro/AnaptysBio,ANB-011;PD-1);STI-A1110(Sorrento Therapeutics;PD-1)、伊匹单抗(BMS;CTLA-4);曲美目单抗(AstraZeneca,CTLA-4);乌瑞鲁单抗(BMS,4-1BB);乌托鲁单抗(Pfizer,4-1BB);阿特珠单抗(Roche,PD-L1),度伐鲁单抗(AstraZeneca,PD-L1);莫那利珠单抗(NKG2A,Innate Pharma和AstraZeneca);BMS-986016(Bristo-Meyers Squibb,LAG-3)。
在一些实施方案中,所述多肽包含特异性结合PD-1的至少一个抗原结合结构域。在一些实施方案中,所述多肽包含特异性结合LAG3的至少一个抗原结合结构域。在一些实施方案中,所述多肽包含特异性结合NKp46的至少一个抗原结合结构域。在一些实施方案中,所述多肽包含特异性结合NKG2D的至少一个抗原结合结构域。在一些实施方案中,所述多肽包含特异性结合CD8a的至少一个抗原结合结构域。
在一些实施方案中,抗原结合结构域可以是人源化的。包含人源化抗原结合结构域的多肽(如含有VHH的多肽)可用作治疗分子,因为人源化抗原结合结构域和人源化抗体降低或消除人对非人抗体的免疫应答,人对非人抗体的免疫应答可导致对抗体治疗剂的免疫应答以及降低的治疗剂的有效性。通常,人源化抗原结合结构域或人源化抗体包含一个或多个可变结构域,其中CDR(或其部分)源自非人抗体,并且FR(或其部分)源自人抗体序列。人源化抗原结合结构域或人源化抗体任选地还将包含人恒定区的至少一部分。在一些实施方案中,人源化抗原结合结构域或人源化抗体中的一些FR残基被来自非人抗体(例如,衍生出CDR残基的抗体)的相应残基取代,例如以恢复或改善抗体特异性或亲和力。
人源化抗体及其制备方法综述于例如Almagro和Fransson(2008)Front.Biosci.13:1619-1633中,并且进一步描述于例如以下文献中:Riechmann等人,(1988)Nature332:323-329;Queen等人,(1989)Proc.Natl Acad.Sci.USA 86:10029-10033;美国专利号5,821,337、7,527,791、6,982,321和7,087,409;Kashmiri等人,(2005)Methods 36:25-34;Padlan,(1991)Mol.Immunol.28:489-498(描述了“表面重修”);Dall'Acqua等人,(2005)Methods 36:43-60(描述了“FR改组”);以及Osbourn等人,(2005)Methods 36:61-68和Klimka等人,(2000)Br.J.Cancer,83:252-260(描述了用于FR改组的“导向选择”方法)。
可以用于人源化的人框架区包括但不限于:使用“最佳拟合”法选择的框架区(参见例如,Sims等人(1993)J.Immunol.151:2296);衍生自具有特定亚组的重链可变区的人抗体的共有序列的框架区(参见例如,Carter等人(1992)Proc.Natl.Acad.Sci.USA,89:4285;和Presta等人(1993)J.Immunol,151:2623);人成熟(体细胞突变)框架区或人种系框架区(参见例如,Almagro和Fransson(2008)Front.Biosci.13:1619-1633);和衍生自筛选FR文库的框架区(参见例如,Baca等人,(1997)J.Biol.Chem.272:10678-10684和Rosok等人,(1996)J.Biol.Chem.271:22611-22618)。通常,将VHH的FR区替代为人FR区以制备人源化VHH。在一些实施方案中,替代人FR的某些FR残基以改善人源化VHH的一种或多种特性。具有此类替代残基的VHH结构域在本文中仍称为“人源化”的。
在各种实施方案中,在含有修饰的IL-2的多肽中包含的Fc区是人Fc区,或源自人Fc区。
在一些实施方案中,在含有修饰的IL-2的多肽中包含的Fc区源自人Fc区,并且在对应于IgG1 E233、L234和L235的下铰链中包含三个氨基酸缺失,在本文称为“Fc xELL”。FcxELL多肽不与FcγR接合,并因此被称为“效应子沉默”或“效应子无效”,然而在一些实施方案中,xELL Fc区结合FcRn并因此具有与FcRn介导的再循环相关的延长半衰期和胞吞转运。
在一些实施方案中,在含有修饰的IL-2的多肽中包含的Fc区源自人Fc区,并且包含突变M252Y和M428V,在本文称为“Fc-YV”。在一些实施方案中,在含有修饰的IL-2的多肽中包含的Fc区源自人Fc区,并且包含突变M252Y和M428L,在本文称为“Fc-YL”。在一些实施方案中,此类突变在内体的酸性pH(接近6.5)下增强与FcRn的结合,同时在中性pH(约7.2)下失去可检测的结合,从而允许增强的FcRn介导的再循环和延长的半衰期。
在一些实施方案中,在本文的含有修饰的IL-2的多肽中包含的Fc区源自人Fc区,并且包含被设计用于异二聚化的突变,所述突变在本文称为“杵状结构”和“臼状结构”。在一些实施方案中,“杵状”Fc区包含突变T366W。在一些实施方案中,“臼状”Fc区包含突变T366S、L368A和Y407V。在一些实施方案中,用于异二聚化的Fc区包含另外的突变,如异二聚体Fc对的第一成员上的突变S354C,其与异二聚体Fc对的第二成员上的相应突变Y349C形成不对称二硫键。在一些实施方案中,异二聚体Fc对的一个成员包含修饰H435R或H435K以防止蛋白A结合同时维持FcRn结合。在一些实施方案中,异二聚体Fc对的一个成员包含修饰H435R或H435K,而异二聚体Fc对的第二成员在H435处未修饰。在各种实施方案中,臼状Fc区包含修饰H435R或H435K(当修饰是H435R时,在一些情况下称为“臼状R”),而杵状Fc区不包含这些。在一些情况下,臼状R突变相比于可能存在的同二聚体臼状Fc区改善了异二聚体的纯化。
可用于含有修饰的IL-2的多肽的非限制性示例性Fc区包括包含SEQ ID NO:47-83、292和293的氨基酸序列的Fc区。
在一些实施方案中,包含至少一个抗原结合结构域和Fc区的含有修饰的IL-2的多肽包含选自SEQ ID NO:105-290的氨基酸序列以及与该氨基酸序列的C端融合的Fc区。在一些实施方案中,包含至少一个抗原结合结构域和Fc区的含有修饰的IL-2的多肽包含选自SEQ ID NO:270-277的氨基酸序列以及与该氨基酸序列的C端融合的Fc区。在一些实施方案中,包含至少一个抗原结合结构域和Fc区的含有修饰的IL-2的多肽包含选自SEQ ID NO:105-290的氨基酸序列以及与该氨基酸序列的N端融合的Fc区。在一些实施方案中,包含至少一个抗原结合结构域和Fc区的含有修饰的IL-2的多肽包含选自SEQ ID NO:270-277的氨基酸序列以及与该氨基酸序列的N端融合的Fc区。在一些实施方案中,包含至少一个抗原结合结构域和Fc区的含有修饰的IL-2的多肽包含选自SEQ ID NO:105-290的氨基酸序列以及选自SEQ ID NO:47-83、292和293的氨基酸序列。在一些实施方案中,包含至少一个抗原结合结构域和Fc区的含有修饰的IL-2的多肽包含选自SEQ ID NO:105-290的氨基酸序列以及选自SEQ ID NO:48、64、292和293的氨基酸序列。在一些实施方案中,包含至少一个抗原结合结构域和Fc区的含有修饰的IL-2的多肽包含选自SEQ ID NO:270-277的氨基酸序列以及选自SEQ ID NO:48、64、292和293的氨基酸序列。在一些实施方案中,所述多肽包含选自SEQID NO:105-290的氨基酸序列和结合在T细胞或自然杀伤细胞上表达的抗原的抗原结合结构域。在一些实施方案中,所述多肽包含选自SEQ ID NO:270-277的氨基酸序列和结合在T细胞或自然杀伤细胞上表达的抗原的抗原结合结构域。
含有修饰的IL-2的多肽的示例性活性
在各种实施方案中,本文提供的含有修饰的IL-2的多肽是IL-2R活性的激动剂。在一些实施方案中,可以使用本文实施例中提供的方法,如使用293F细胞或类似细胞来测定激动剂活性。在一些实施方案中,本文提供的含有修饰的IL-2的多肽在靶向T细胞时是IL-2R活性的激动剂,但在没有靶向的情况下显示几乎没有激动剂活性。在一些实施方案中,本文提供的含有修饰的IL-2的多肽在靶向NK细胞和/或T细胞时是IL-2R活性的激动剂,但在没有靶向的情况下显示几乎没有激动剂活性。在一些实施方案中,靶向T细胞或NK细胞的含有修饰的IL-2的多肽包含至少一个抗原结合结构域,其特异性结合T细胞或NK细胞上表达的抗原。
在一些实施方案中,本文提供的含有修饰的IL-2的多肽在体外和/或体内增加CD4+和/或CD8+T细胞的增殖。在一些实施方案中,所述多肽在Treg细胞的存在下增加CD4+和/或CD8+T细胞增殖。在一些此类实施方案中,CD4+和/或CD8+T细胞是激活的CD4+和/或CD8+T细胞。在一些实施方案中,本文提供的含有修饰的IL-2的多肽在体外增加激活的CD4+和/或CD8+T细胞增殖。在一些实施方案中,含有修饰的IL-2的多肽,相对于不存在所述多肽时的CD4+和/或CD8+T细胞增殖而言,使激活的CD4+和/或CD8+T细胞增殖增加至少1.5倍、至少2倍、至少3倍或至少5倍。在一些实施方案中,相对于不存在所述多肽时观察到的增殖而言,所述多肽使激活的CD4+和/或CD8+T细胞的增殖增加至少1.5倍、至少2倍、至少3倍或至少5倍,并且基本上不增加静息CD4+和/或CD8+T细胞的增殖。
在一些实施方案中,本文提供的含有修饰的IL-2的多肽在体外和/或体内增加NK细胞的增殖。在一些此类实施方案中,NK细胞是激活的NK细胞。在一些实施方案中,本文提供的含有修饰的IL-2的多肽在体外增加激活的NK细胞增殖。在一些实施方案中,含有修饰的IL-2的多肽,相对于不存在所述多肽时的NK细胞增殖而言,使激活的NK细胞增殖增加至少1.5倍、至少2倍、至少3倍或至少5倍。在一些实施方案中,相对于不存在所述多肽时观察到的增殖而言,所述多肽使激活的NK细胞的增殖增加至少1.5倍、至少2倍、至少3倍或至少5倍,并且基本上不增加静息NK细胞的增殖。
激活的CD4+和/或CD8+T细胞增殖的增加可以通过本领域的任何方法,例如本文实施例中提供的方法来确定。非限制性示例性测定如下。CD4+和/或CD8+T细胞可以从一个或多个健康人供体中分离。将T细胞用CellTrace Violet(CTV)染色并用抗CD3抗体激活,与包含修饰的IL-2的多肽接触,然后通过FACS进行分析。CTV染色缺失指示增殖。在一些实施方案中,CD4+和/或CD8+T细胞增殖的增加被确定为来自一组实验或来自汇集的T细胞的平均值,如通过测量从不同健康人供体分离的CD4+和/或CD8+T细胞的增殖。在一些实施方案中,CD4+和/或CD8+T细胞增殖的增加被确定为来自使用来自至少五个或至少十个不同健康供体的T细胞或来自至少五个或至少十个不同健康供体的T细胞库的T细胞进行的实验的平均值。在一些实施方案中,即使在Treg细胞的存在下,本文提供的含有修饰的IL-2的多肽也增加CD4+和/或CD8+T细胞的增殖。
在一些实施方案中,本文提供的含有修饰的IL-2的多肽在体外和/或体内增加CD4+和/或CD8+T细胞上的CD71表达。CD71表达指示T细胞激活。在一些实施方案中,本文提供的含有修饰的IL-2的多肽在体外增加CD4+和/或CD8+T细胞上的CD71表达。在一些实施方案中,含有修饰的IL-2的多肽,相对于不存在所述多肽时的CD71表达而言,使CD4+和/或CD8+T细胞上的CD71表达增加至少1.5倍、至少2倍、至少3倍、或至少5倍。在一些实施方案中,相对于不存在所述多肽时观察到的CD71表达而言,所述多肽使激活的CD4+和/或CD8+T细胞上的CD71表达增加至少1.5倍、至少2倍、至少3倍或至少5倍,并且基本上不增加静息CD4+和/或CD8+T细胞上的CD71表达。在一些实施方案中,所述多肽在Treg细胞的存在下增加CD4+和/或CD8+T细胞上的CD71表达。
CD4+和/或CD8+T细胞上的CD71表达的增加可以通过本领域的任何方法,例如本文实施例中提供的方法来确定。非限制性示例性测定如下。可以将CD4+和/或CD8+T细胞从一个或多个健康人供体中分离,并用抗CD3抗体刺激,与含有修饰的IL-2的多肽接触,然后通过FACS分析CD71表达。在一些实施方案中,CD4+和/或CD8+T细胞上的CD71表达的增加被确定为来自一组实验或来自汇集的T细胞的平均值,如通过测量从不同健康人供体分离的CD4+和/或CD8+T细胞上的CD71表达。在一些实施方案中,CD4+和/或CD8+T细胞上的CD71表达的增加被确定为来自使用来自至少五个或至少十个不同健康供体的T细胞或来自至少五个或至少十个不同健康供体的T细胞库的T细胞进行的实验的平均值。在一些实施方案中,即使在Treg细胞的存在下,本文提供的含有修饰的IL-2的多肽也增加CD4+和/或CD8+T细胞上的CD71表达。
在一些实施方案中,本文提供的含有修饰的IL-2的多肽在体外和/或体内增加CD4+和/或CD8+T细胞中的pSTAT5表达。pSTAT5表达指示T细胞激活。在一些实施方案中,本文提供的含有修饰的IL-2的多肽在体外增加CD4+和/或CD8+T细胞中的pSTAT5表达。在一些实施方案中,含有修饰的IL-2的多肽,相对于不存在所述多肽时的pSTAT5表达而言,使CD4+和/或CD8+T细胞上的pSTAT5表达增加至少1.5倍、至少2倍、至少3倍、或至少5倍。在一些实施方案中,所述多肽在Treg细胞的存在下增加CD4+和/或CD8+T细胞上的pSTAT5表达。CD4+和/或CD8+T细胞中的pSTAT5表达的增加可以通过本领域的任何方法,例如本文实施例中提供的方法来确定。在一些实施方案中,即使在Treg细胞的存在下,本文提供的含有修饰的IL-2的多肽也增加CD4+和/或CD8+T细胞中的pSTAT5表达。
在一些实施方案中,本文提供的含有修饰的IL-2的多肽在体外和/或体内增加NK细胞中的pSTAT5表达。pSTAT5表达表明NK细胞激活。在一些实施方案中,本文提供的含有修饰的IL-2的多肽在体外增加NK细胞中的pSTAT5表达。在一些实施方案中,含有修饰的IL-2的多肽,相对于不存在所述多肽时的pSTAT5表达而言,使NK细胞上的pSTAT5表达增加至少1.5倍、至少2倍、至少3倍、或至少5倍。在一些实施方案中,所述多肽在Treg细胞的存在下增加NK细胞中的pSTAT5表达。NK细胞中的pSTAT5表达的增加可以通过本领域的任何方法,例如本文实施例中提供的方法来确定。
在一些实施方案中,本文提供的含有修饰的IL-2的多肽降低或减弱调节性T细胞(Treg)的抑制活性。在一些实施方案中,含有修饰的IL-2的多肽使Treg对CD4+和/或CD8+T细胞的抑制活性降低至少10%、至少20%、至少30%或至少50%。Treg对常规CD4+和/或CD8+T细胞的抑制活性的降低可以通过本领域的任何方法,例如本文实施例中提供的方法来确定。非限制性示例性测定如下。将Treg和CD4+T细胞在从健康人供体PBMC中分离后,用荧光增殖细胞染料进行差异标记。将CD4+T细胞用抗CD3抗体刺激,而将Treg细胞在本文提供的含有修饰的IL-2多肽的存在下孵育。将两种T细胞群共培养3天,并且通过流式细胞术监测CD4+T细胞的增殖和激活。在一些实施方案中,例如与在Treg细胞的存在下但不存在本文提供的含有修饰的IL-2的多肽的情况下的CD4+和/或CD8+T细胞激活和增殖相比,本文提供的含有修饰的IL-2的多肽在Treg细胞的存在下增加了CD4+和/或CD8+T细胞激活和增殖。
多肽表达和生产
提供了包含编码含有修饰的IL-2的结合多肽的多核苷酸的核酸分子。因此,在各种实施方案中,提供了编码包含修饰的IL-2的多肽的核酸分子。在一些实施方案中,所述核酸分子编码修饰的IL-2和至少一个抗原结合结构域。在各种实施方案中,所述核酸分子编码修饰的IL-2和Fc区以及任选的至少一个抗原结合结构域。在一些实施方案中,Fc区包含设计用于异二聚化的突变,如“杵状结构”或“臼状结构”突变。在一些实施方案中,提供了编码含有修饰的IL-2的多肽的核酸分子,所述多肽包含修饰的IL-2、至少一个抗原结合结构域和Fc区,其中所述Fc区与所述至少一个抗原结合结构域的C端融合,并且所述修饰的IL-2与所述Fc区的C端融合。在任何前述实施方案中,所述核酸分子还可以编码引导含有修饰的IL-2的多肽分泌的前导序列,所述前导序列通常被切割以使其不存在于分泌的多肽中。前导序列可以是天然重链(或VHH)前导序列,或者可以是另一种异源前导序列。
可以使用本领域常规的重组DNA技术构建核酸分子。在一些实施方案中,核酸分子是适合在选择的宿主细胞中表达的表达载体。
提供了包含编码本文所述的含有修饰的IL-2的多肽的核酸的载体。此类载体包括但不限于DNA载体、噬菌体载体、病毒载体、逆转录病毒载体等。在一些实施方案中,选择优化用于在所需细胞类型如293F、CHO、或CHO衍生细胞、或NSO细胞中表达多肽的载体。示例性的此类载体描述于例如Running Deer等人,Biotechnol.Prog.20:880-889(2004)中。
在一些实施方案中,含有修饰的IL-2的多肽可以在原核细胞如细菌细胞中;或在真核细胞如真菌细胞(如酵母)、植物细胞、昆虫细胞和哺乳动物细胞中表达。这种表达可以例如根据本领域已知的程序进行。可用于表达多肽的示例性真核细胞包括但不限于COS细胞,包括COS 7细胞;293细胞,包括293F细胞;CHO细胞,包括CHO-S、DG44.Lec13 CHO细胞和FUT8 CHO细胞;PER.细胞(Crucell);以及NSO细胞。在一些实施方案中,可以在酵母中表达含有修饰的IL-2的多肽。参见例如美国公开号US 2006/0270045A1。在一些实施方案中,基于其对所述多肽进行所需翻译后修饰的能力来选择特定的真核宿主细胞。例如,在一些实施方案中,CHO细胞产生的多肽的唾液酸化水平高于293F细胞中产生的相同多肽的唾液酸化水平。
可通过任何方法将一种或多种核酸(如载体)引入所需宿主细胞,所述方法包括但不限于磷酸钙转染、DEAE-葡聚糖介导的转染、阳离子脂质介导的转染、电穿孔、转导、感染等。非限制性示例性方法描述于例如Sambrook等人,Molecular Cloning,ALaboratoryManual,第3版Cold Spring Harbor Laboratory Press(2001)。根据任何合适的方法,可以在所需宿主细胞中瞬时地或稳定地转染核酸。
还提供了包含本文所述的任何核酸或载体的宿主细胞。在一些实施方案中,提供了表达本文所述的含有修饰的IL-2的多肽的宿主细胞。在宿主细胞中表达的含有修饰的IL-2的多肽可以通过任何合适的方法进行纯化。此类方法包括但不限于使用亲和基质或疏水相互作用色谱。合适的亲和配体包括ROR1 ECD和结合Fc区的药剂。例如,蛋白A、蛋白G、蛋白A/G或抗体亲和柱可用于结合Fc区并纯化包含Fc区的含有修饰的IL-2的多肽。疏水相互作用色谱,例如丁基或苯基柱,也可适用于纯化一些多肽,如抗体。离子交换色谱(例如阴离子交换色谱和/或阳离子交换色谱)也可适用于纯化一些多肽,如抗体。混合模式色谱(例如反相/阴离子交换、反相/阳离子交换、亲水相互作用/阴离子交换、亲水相互作用/阳离子交换等)也可适用于纯化某些多肽,如抗体。许多纯化多肽的方法是本领域已知的。
在一些实施方案中,含有修饰的IL-2的多肽在无细胞系统中产生。非限制性示例性无细胞系统描述于例如以下文献中:Sitaraman等人,Methods Mol.Biol.498:229-44(2009);Spirin,Trends Biotechnol.22:538-45(2004);Endo等人,Biotechnol.Adv.21:695-713(2003)。
在一些实施方案中,提供了通过上述方法制备的含有修饰的IL-2的多肽。在一些实施方案中,在宿主细胞中制备含有修饰的IL-2的多肽。在一些实施方案中,在无细胞系统中制备含有修饰的IL-2的多肽。在一些实施方案中,纯化含有修饰的IL-2的多肽。在一些实施方案中,提供了包含含有修饰的IL-2的多肽的细胞培养基。
在一些实施方案中,提供了包含通过上述方法制备的抗体的组合物。在一些实施方案中,所述组合物包含在宿主细胞中制备的含有修饰的IL-2的多肽。在一些实施方案中,所述组合物包含在无细胞系统中制备的含有修饰的IL-2的多肽。在一些实施方案中,所述组合物包含纯化的含有修饰的IL-2的多肽。
使用含有修饰的IL-2的多肽治疗疾病的示例性方法
在一些实施方案中,提供了治疗个体疾病的方法,其包括施用含有修饰的IL-2的多肽。此类疾病包括将受益于CD4+和/或CD8+T细胞增殖和激活的增加的任何疾病。在一些实施方案中,提供了治疗个体的癌症的方法。所述方法包括向所述个体施用有效量的本文提供的含有修饰的IL-2的多肽。此类治疗方法可用于人或动物。在一些实施方案中,提供了治疗人的方法。可以用本文提供的含有修饰的IL-2的多肽治疗的非限制性示例性癌症包括基底细胞癌;胆道癌;膀胱癌;骨癌;脑和中枢神经系统癌症;乳腺癌;腹膜癌;宫颈癌;绒毛膜癌;结直肠癌;结缔组织癌;消化系统癌症;子宫内膜癌;食道癌;眼癌;头颈癌;胃癌;胃肠癌;胶质母细胞瘤;肝癌;肝肿瘤;上皮内瘤;肾脏癌或肾癌;喉癌;肝脏癌症;肺癌;小细胞肺癌;非小细胞肺癌;肺腺癌;肺鳞癌;黑色素瘤;骨髓瘤;神经母细胞瘤;口腔癌;卵巢癌;胰腺癌;前列腺癌;视网膜母细胞瘤;横纹肌肉瘤;直肠癌;呼吸系统癌症;唾液腺癌;肉瘤;皮肤癌;鳞状细胞癌;胃癌;睾丸癌;甲状腺癌;子宫或子宫内膜癌;泌尿系统癌症;和外阴癌;淋巴瘤;霍奇金淋巴瘤;非霍奇金淋巴瘤;B细胞淋巴瘤;低分级/滤泡性非霍奇金淋巴瘤(NHL);小淋巴细胞(SL)NHL;中分级/滤泡性NHL;中分级弥漫性NHL;高分级免疫母细胞NHL;高分级淋巴母细胞NHL;高分级小非裂解细胞NHL;大肿块NHL;套细胞淋巴瘤;艾滋病相关淋巴瘤;华氏巨球蛋白血症;慢性淋巴细胞白血病(CLL);急性成淋巴细胞性白血病(ALL);毛细胞白血病;和慢性成髓细胞性白血病。
可以根据需要向受试者施用含有修饰的IL-2的多肽。施用频率的确定可以由本领域技术人员(如主治医生)基于对以下因素的考量来进行:所治疗的病症、所治疗受试者的年龄、所治疗病症的严重程度、所治疗受试者的一般健康状态等。在一些实施方案中,将有效剂量的含有修饰的IL-2的多肽施用于受试者一次或多次。在一些实施方案中,每天、每半周、每周、每两周、每月一次等向受试者施用有效剂量的含有修饰的IL-2的多肽。将有效剂量的含有修饰的IL-2的多肽施用于受试者至少一次。在一些实施方案中,可多次施用有效剂量的含有修饰的IL-2的多肽,包括在至少一个月、至少六个月或至少一年的历程中多次施用。
在一些实施方案中,以有效治疗(包括预防)癌症和/或增加T细胞增殖的量施用包含含有修饰的IL-2的多肽的药物组合物。治疗有效量通常取决于所治疗受试者的体重、其身体或健康状况、要治疗的病症的广泛性或所治疗受试者的年龄。通常,可以以每剂量约0.05mg/kg体重至约100mg/kg体重范围内的量施用多肽。在一些实施方案中,可以以每剂量约10μg/kg体重至约100mg/kg体重范围内的量施用多肽。在一些实施方案中,可以以每剂量约50μg/kg体重至约5mg/kg体重范围内的量施用多肽。在一些实施方案中,可以以每剂量约100μg/kg体重至约10mg/kg体重范围内的量施用多肽。在一些实施方案中,可以以每剂量约100μg/kg体重至约20mg/kg体重范围内的量施用多肽。在一些实施方案中,可以以每剂量约0.5mg/kg体重至约20mg/kg体重范围内的量施用多肽。在一些实施方案中,可以以每剂量约0.5mg/kg体重至约10mg/kg体重范围内的量施用多肽。在一些实施方案中,可以以每剂量约0.05mg/kg体重至约20mg/kg体重范围内的量施用多肽。在一些实施方案中,可以以每剂量约0.05mg/kg体重至约10mg/kg体重范围内的量施用多肽。在一些实施方案中,可以以约5mg/kg体重或更低,例如少于4、少于3、少于2、或少于1mg/kg的抗体的范围内的量施用多肽。
在一些实施方案中,可以通过各种途径在体内施用含有修饰的IL-2的多肽,所述途径包括但不限于静脉内、动脉内、肠胃外、腹膜内或皮下。可以根据预期的应用选择适当的配制品和施用途径。
在一些实施方案中,使用含有修饰的IL-2的多肽的治疗性处理是通过增加T细胞增殖和/或激活来实现的。在一些实施方案中,增加T细胞增殖和/或激活抑制癌症的生长。
药物组合物
在一些实施方案中,包含含有修饰的IL-2的多肽的组合物以具有各种药学上可接受的载体的配制品形式提供(参见例如Gennaro,Remington:The Science and Practiceof Pharmacy with Facts and Comparisons:Drugfacts Plus,第20版(2003);Ansel等人,Pharmaceutical Dosage Forms and Drug Delivery Systems,第7版,LippencottWilliams and Wilkins(2004);Kibbe等人,Handbook of Pharmaceutical Excipients,第3版,Pharmaceutical Press(2000))。可以使用各种药学上可接受的载体,包括媒介物、佐剂和稀释剂。此外,还可以使用各种药学上可接受的辅助物质,如pH调节剂和缓冲剂、张力调节剂、稳定剂、湿润剂等。非限制性示例性载体包括盐水、缓冲盐水、右旋糖、水、甘油、乙醇及其组合。
在一些实施方案中,药物组合物包含以下浓度的含有修饰的IL-2的多肽:至少10mg/mL、20mg/mL、30mg/mL、40mg/mL、50mg/mL、60mg/mL、70mg/mL、80mg/mL、90mg/mL、100mg/mL、125mg/mL、150mg/mL、175mg/mL、200mg/mL、225mg/mL、或250mg/mL。
组合疗法
可以将含有修饰的IL-2的多肽单独施用或与其他治疗模式如其他抗癌剂组合施用。可以将它们在其他治疗模式之前、基本上同时或之后(即,并行或依序)提供。在一些实施方案中,本文所述的治疗方法还可以包括施用:放射疗法、化学疗法、疫苗接种、靶向肿瘤疗法、CAR-T疗法、溶瘤病毒疗法、癌症免疫疗法、细胞因子疗法、手术切除术、染色质修饰、消融、冷冻疗法、针对肿瘤靶标的反义药剂、针对肿瘤靶标的siRNA剂、针对肿瘤靶标的微小RNA剂或抗癌/抗肿瘤剂、或生物制剂(如抗体、细胞因子或受体细胞外结构域-Fc融合物)。
在一些实施方案中,将本文提供的含有修饰的IL-2的多肽与第二治疗剂例如PD-1抗体并行给予。PD-1抗体的例子包括纳武单抗(BMS);派姆单抗(Merck);AMP-514(Amplimmune);TSR-042(Tesaro/AnaptysBio,ANB-011);STI-A1110(SorrentoTherapeutics);和其他针对程序性死亡蛋白-1(PD-1)的药剂。
在一些实施方案中,将本文提供的含有修饰的IL-2的多肽与第二治疗剂例如PD-L1疗法并行给予。PD-L1疗法的例子包括匹地利珠单抗(CureTech,CT-011);度伐鲁单抗(Medimmune/AstraZeneca);阿特珠单抗(Genentech/Roche);阿维鲁单抗(Pfizer);AMP-224(Amplimmune);BMS-936559(Bristol-Myers Squibb);STI-A1010(SorrentoTherapeutics);和其他针对程序性死亡蛋白-1配体(PD-L1)的药剂。
在一些实施方案中,将本文提供的含有修饰的IL-2多肽与CAR-T(嵌合抗原受体T细胞)疗法、溶瘤病毒疗法、细胞因子疗法和/或靶向其他检查点分子如VISTA、gpNMB、B7H3、B7H4、HHLA2、CD73、CTLA4、TIGIT等的药剂并行给予。
诊断和治疗的非限制性示例性方法
在一些实施方案中,本文描述的方法可用于评价受试者和/或来自受试者(例如癌症患者)的样本。在一些实施方案中,评价是诊断、预后和/或对治疗的反应中的一者或多者。
在一些实施方案中,本文所述的方法包括评价蛋白质的存在、不存在或水平。在一些实施方案中,本文所述的方法包括评价核酸的存在、不存在或表达水平。本文所述的组合物可用于这些测量。例如,在一些实施方案中,本文所述的方法包括使肿瘤样本或从肿瘤培养的细胞与如本文所述的治疗剂接触。
在一些实施方案中,评价可以指导治疗(包括用本文所述的多肽的治疗)。在一些实施方案中,评价可以指导切除术后辅助疗法的使用或停止。辅助疗法,也称为辅助护理,是在初级、主要或初始治疗之外给予的治疗。作为非限制性例子,辅助疗法可以是通常在手术后给予的其他治疗,其中所有可检测的疾病均已去除,但由于隐匿性疾病仍存在复发的统计学风险。在一些实施方案中,所述多肽用作治疗癌症的辅助疗法。在一些实施方案中,抗体用作治疗癌症的唯一辅助疗法。在一些实施方案中,本文所述的抗体不作为治疗癌症的辅助疗法。例如,如果患者不太可能对本文所述的抗体有反应或将具有最小反应,则可能为了生活质量和避免无效化学疗法引起的不必要毒性而不会施用治疗。在此类情况下,可以使用缓和照顾。
在一些实施方案中,在切除术之前将所述多肽作为新辅助疗法施用。在一些实施方案中,新辅助疗法是指在任何手术之前使肿瘤缩小和/或降级的疗法。在一些实施方案中,新辅助疗法是指在手术前施用于癌症患者的化学疗法。在一些实施方案中,新辅助疗法是指在手术前施用于癌症患者的多肽。通常考虑进行新辅助化学疗法的癌症类型包括例如乳腺癌、结直肠癌、卵巢癌、宫颈癌、膀胱癌和肺癌。在一些实施方案中,抗体用作治疗癌症的新辅助疗法。在一些实施方案中,在切除术之前使用。
在一些实施方案中,本文描述的方法中考虑的肿瘤微环境是以下中的一种或多种:肿瘤脉管系统;肿瘤浸润性淋巴细胞;成纤维细胞网状细胞;内皮祖细胞(EPC);癌症相关成纤维细胞;周细胞;其他基质细胞;细胞外基质(ECM)的组分;树突细胞;抗原呈递细胞;T细胞;调节性T细胞;巨噬细胞;嗜中性粒细胞;和位于肿瘤附近的其他免疫细胞。
试剂盒
还提供了制品和试剂盒,其包括如本文所述的任何含有修饰的IL-2的多肽以及合适的包装。在一些实施方案中,本发明包括试剂盒,其具有(i)含有修饰的IL-2的多肽,和(ii)使用所述试剂盒向个体施用含有修饰的IL-2的多肽的说明书。
用于本文所述组合物的合适包装是本领域中已知的,并且包括例如小瓶(例如密封的小瓶)、器皿、安瓿、瓶子、罐子、软包装(例如密封的Mylar或塑料袋)等。可以进一步将这些制品灭菌和/或密封。还提供了包含本文所述的组合物的单位剂型。这些单位剂型可以以单个或多个单位剂量储存在合适的包装中,并且也可以进一步灭菌和密封。本发明的试剂盒中提供的说明书通常是标签或包装说明书(例如,试剂盒中包括的纸页)上的书面说明书,但机器可读的说明书(例如,磁性或光学存储盘上携带的说明书)也是可接受的。与抗体的使用有关的说明书通常包括关于用于预期治疗或工业用途的剂量、给药时间表、和施用途径的信息。所述试剂盒还可包括选择合适的个体或治疗的描述。
所述容器可以是单位剂量、散装包装(例如,多剂量包装)或亚单位剂量。例如,还可以提供包含足够剂量的本文公开的分子的试剂盒以在延长的时间段内为个体提供有效治疗,所述延长的时间段为如约一周、2周、3周、4周、6周、8周、3个月、4个月、5个月、6个月、7个月、8个月、9个月或更长时间中的任一者。试剂盒还可以包括多个单位剂量的分子和使用说明书,并且其包装量足以在药房(例如,医院药房和复合药房)中存储和使用。在一些实施方案中,试剂盒包括干燥(例如冻干的)组合物,所述干燥组合物可以重构、重悬浮或再水合以形成总体上稳定的多肽水性悬浮液。
实施例
以下所讨论的实施例仅旨在举例说明本发明,并且因此不应视为以任何方式限制本发明。实施例并不旨在表示以下实验是进行的全部或仅有的实验。已经努力确保关于所使用的数字(例如,量、温度等)的准确性,但是应考虑到一些实验误差和偏差。除非另有指示,否则份数是重量份,分子量是重均分子量,温度是按摄氏度计,并且压力是大气压或接近大气压。
实施例1:IL-2的P65R突变基本上消除了CD25结合
IL-2突变体被设计为通过空间阻塞破坏CD25界面(P65R和P65E),并测试与瞬时转染了IL-2受体的一种或多种组分(CD25、CD122和/或CD132)的293F细胞的结合)。将突变体与IL-2-F42K进行比较,IL-2-F42K是一种据报道具有降低的对CD25的亲和力的突变体。将渐增浓度的包含与“杵状”Fc的N端融合并与“臼状”Fc(SEQ ID NO:44)复合的野生型人IL-2(SEQ ID NO:32)、IL-2-F42K(SEQ ID NO:33)、IL-2-P65R(SEQ ID NO:35)或IL-2-P65E(SEQID NO:34)的融合蛋白添加至转染的293F细胞中,并在4℃下孵育45分钟。
基本上如下通过流式细胞术分析结合。将细胞在200μL FACS缓冲液(PBS、2%FBS、0.05%叠氮化钠)中洗涤一次,然后将细胞沉淀重悬浮在100μl表面标记物染色溶液(在FACS缓冲液中以1:300稀释度含有A647缀合的抗人Fcg二抗)中。在最后一次洗涤之前,将细胞在4℃下孵育45分钟,并在流式细胞仪上进行分析。通过FSC/SSC尺寸排除法排除细胞碎片,并基于其阳性碘化丙啶信号排除死细胞。使用FSC-A/FSC-H双峰和聚集体排除法选择单个细胞。瞬时转染的细胞也表达细胞质EGFP,并对FL1阳性的细胞进行分析。抗人二抗的渐增MFI水平指示IL-2结合。FlowJo软件用于分析细胞群。然后导出每个标记物的原始平均荧光强度(“MFI”),并使用Excel和GraphPad PRISM进行分析。对值进行绘图,并拟合滴定曲线以使用非线性回归单点-总曲线拟合来评估剂量-反应关系。
如图2A-图2C所示,相对于包含野生型IL-2的融合蛋白,包含IL-2-P65E变体的融合蛋白对IL-2R的亲和力略微降低。包含IL-2F42K的融合蛋白展现出比包含IL-2-P65E的融合蛋白更低的亲和力,而包含IL-2-P65R的融合蛋白对异三聚体IL-2R展现出最低的亲和力(图2A)。此外,包含IL-2-P65R的融合蛋白未展现出与CD25/CD132的可检测结合,并且仅与CD25/CD122弱结合(图2C),而包含IL-2-F42K的融合蛋白保留了一些对CD25/CD132的亲和力(图2B)并且以比包含IL-2-P65R的融合蛋白更大的亲和力结合CD25/CD122(图2B和图2C)。因此,在P65R突变的IL-2显著降低了与含有CD25的IL-2受体的结合。
实施例2:降低对CD122的亲和力的IL-2修饰
如实施例1中所述,P65R IL-2突变被设计为通过空间阻塞破坏CD25界面。此外,IL-2突变被设计为通过消除某些接触残基相互作用(例如D84S、E95Q、M23A、H16A和E15S)来降低对CD122界面的亲和力。单突变体或双突变体与异二聚体Fc(二硫化物稳定的杵状结构进入包含“臼状”Fc SEQ ID NO:44的臼状结构中)的“杵状”半部分的N端融合,以用于单价IL-2结合IL-2R。通过用CD25和CD122瞬时转染293F细胞来评估相对结合亲和力(与CD132共转染显示类似的结果,但额外的结合亲合力降低了观察到的亲和力的差异)。基本上如实施例1中所述,将结合的IL-2-Fc融合蛋白用荧光抗人二抗检测,并通过流式细胞术分析。
如图3A-图3B所示,所有包含掺入F42K的以及在CD122界面中掺入突变的双IL-2突变体的融合蛋白(SEQ ID NO:36-39)相对于包含单突变体IL-2-F42K的融合蛋白(SEQ IDNO:33)显示出降低的对于CD25/CD122的结合亲和力,但IL-2-F42K-E15S(SEQ ID NO:85)除外。
实施例3:IL-2-RAS(P65R、H16A和D84S)具有降低的对在IL-2R的三聚体和二聚体形式的背景中的CD122的亲和力
将实施例2中描述的降低CD122亲和力的突变与P65R突变组合以构建IL-2双突变体和三突变体。IL-2突变体与异二聚体Fc的“杵状”半部分的N端融合,并与包含SEQ ID NO:44的“臼状”Fc配对,以用于单价IL-2结合IL-2受体(IL-2R)。基本上如实施例1中所述,评估所得融合蛋白对用IL-2R亚基瞬时转染的293F细胞的相对结合亲和力。
相对于包含野生型IL-2的融合蛋白(SEQ ID NO:32),包含IL-2-P65R-H16A的融合蛋白(SEQ ID NO:41)和包含IL-2-P65R-D84S的融合蛋白(SEQ ID NO:42)具有降低的对CD122/CD132(异二聚体IL-2R)(图4A)和异三聚体IL-2R(图4B)的亲和力,而包含三突变体的融合蛋白IL-2P65R-H16A-D84S(“IL-2-RAS”,SEQ ID NO:43)的亲和力甚至更弱(图4A-图4B)。在最大结合和EC50方面观察到的对这些IL-2突变体的结合变化表明这些突变降低了结合速率(EC50右移)和解离速率(降低的最大结合)。
实施例4.IL-2-RAS具有降低的对静息T细胞和预激活T细胞的亲和力
为了分离T细胞,将非T细胞群在室温下用针对CD14、CD16、CD19、CD20、CD36、CD56、CD123、TCRγ/δ(BioLegend)的生物素化抗谱系标记物抗体标记20分钟。然后通过在室温下与磁性链霉亲和素颗粒(500μl珠浆液加500μl细胞悬浮液/100x106,在磁体上孵育2x8分钟)一起孵育20分钟来耗尽非T细胞群。未结合的细胞上清液含有分离的T细胞。
将一些分离的T细胞(5.5x 106,3mL)通过在预先包被有1μg/ml抗CD3 OKT3抗体(BD Biosciences)的6孔板中孵育2天来激活,然后用PBS/2% FBS洗涤,并在RPMI+10%FBS中以2x106/mL静置1天。静息或预激活T细胞直接用于结合测定。通过流式细胞术测量非靶向VHH-Fc同种型对照以及包含和连接异二聚体Fc的非靶向VHH的C端融合的IL-2-RAS或野生型IL-2的融合蛋白与静息或预激活T细胞的结合,基本上如实施例1所述,不同之处在于使用以下二抗:AF647抗人Fc(1:1000)、PI(1:2000)、BV785-CD4(1:300)、APC/Fire-CD8(1:500)和PE/Cy7-CD25(1:100)。
与包含非靶向VHH结构域和野生型IL-2的融合蛋白(包含SEQ ID NO:45)相比,非靶向IL-2-RAS融合蛋白(包含SEQ ID NO:46)以降低的亲和力结合静息(图5A)和预激活(图5B)T细胞。不包含IL-2的同种型对照不结合静息或预激活T细胞,如图5A和图5B所示。
实施例5:IL-2-RAS具有降低的对Treg的亲和力
调节性T细胞(“Treg”)具有CD25以及CD122和CD132的高内源性表达,并且对野生型IL-2具有高反应性。测量了包含和非靶向VHH的异二聚体Fc(二硫化物稳定的杵臼结构)的“杵状”半部分的C端融合的野生型IL-2(包含SEQ ID NO:45)或IL-2-RAS三突变体(包含SEQ ID NO:46)的融合蛋白与Treg的结合。
按照制造商的说明,使用EasySep人CD4+CD127低CD25+调节性T细胞分离试剂盒(Stemcell)从新鲜的健康供体PBMC中富集和分离Treg和CD4+T应答细胞(Tresp)。通过在补充有rhTGF-B1、全反式视黄酸、CD3/CD28 T细胞激活剂和IL-2的ImmunoCult-XF T细胞扩增培养基中培养7天,从幼稚CD4+T细胞产生Treg。
为了区分两种细胞群,将富集的Treg和CD4+应答T细胞分别用增殖染料CellTraceViolet(CTV)和CFSE标记,在37℃下持续10分钟。洗涤后,将Treg和CD4+T细胞在补充有10%FBS和1X抗生素/抗真菌剂的RPMI中重悬浮至1.5x106个细胞/ml。将Treg以50μl体积接种,在96孔圆底板中产生75,000个Treg/孔。如实施例1中所述,通过流式细胞术将Treg在37℃下在10nM IL-2-RAS的存在下孵育过夜。
如图6所示,与包含野生型IL-2的融合蛋白相比,包含IL-2-RAS的融合蛋白没有显示出与从PBMC(图6A)、诱导的Treg(图6B)或CD4+T应答细胞(图6C)富集的Treg的可观察到的结合。
实施例6:IL-2-RAS具有降低的对静息T细胞的活性
基本上如实施例4中所述,通过磁珠分离来分离T细胞,用CellTrace Violet(CTV)标记,并用包含与连接异二聚体Fc的非靶向VHH的C端融合的野生型IL-2(包含SEQ ID NO:45)或IL-2-RAS(包含SEQ ID NO:46)的融合蛋白处理。通过流式细胞术测量CD4、CD8、CD71和CTV的水平。增殖的T细胞具有降低的CTV水平。
如图7A和图7C所示,诱导静息CD4+和CD8+T细胞增殖所需的包含IL-2-RAS的融合蛋白的浓度是实现相同的增殖诱导所需的包含野生型IL-2的融合蛋白的浓度或包含IL-2v-类似物的融合蛋白的浓度的超过100倍。
如图7B和图7D所示,诱导CD8+和CD4+T细胞上的CD71表达(为T细胞激活的标记物)所需的包含IL-2-RAS的融合蛋白的浓度是实现相同的激活诱导所需的包含野生型IL-2或IL-2v-类似物的融合蛋白的浓度的至少100倍。
T细胞激活也可以通过磷酸化STAT5水平来测量,所述水平在激活的T细胞中会增加。将T细胞通过磁珠分离来分离,并用包含与含异二聚体Fc的非靶向VHH的C端融合的野生型IL-2的融合蛋白(包含SEQ ID NO:45)或包含与含异二聚体Fc的非靶向VHH的C端融合的IL-2-RAS的融合蛋白(包含SEQ ID NO:46)处理15分钟。将细胞用BD Cytofix/CytopermTM(BD Biosciences)固定,在90%冰冷甲醇中透化,并使用流式细胞术使用抗pSTAT5-PE抗体(1:70)来测量CD4+和CD8+T细胞上的磷酸化STAT5(“pSTAT5”)的水平。将细胞用以下抗体共染色:抗CD3-FITC(1:200)、CD56-BV421(1:100)、CD4-BV785(1:200)、CD8-APC-Fire(1:300)。
如图7E和图7F所示,即使在测试的最高浓度下,非靶向IL-2-RAS融合蛋白在静息CD4+和CD8+T细胞中实现了最少的STAT5磷酸化,而非靶向IL-2-野生型融合蛋白在比测试的最高浓度低多于1000倍的浓度下诱导STAT5磷酸化。
实施例7:IL-2突变体具有降低的对Treg的活性
使用EasySepTM人CD4+CD127低CD25+调节性T细胞分离试剂盒(Stemcell)从PBMC中分离Treg。将Treg用CellTrace Violet标记,并在100μl RPMI/10% FBS中以0.15x106个细胞/孔(96孔,U形底)铺板。将细胞与100μl融合蛋白逐步调整液(以100nM起始、按1:4逐步调整)组合。将细胞孵育7天。在第7天,基本上如实施例1中所述,通过流式细胞术(Novocyte)测量增殖和激活标记物CD25,不同之处在于使用以下抗体:BV785-CD4(1:300)、APC/Fire-CD8(1:500)PE/Cy7-CD25(1:100)、PI(1:2000)。
如图8A和图8B所示,包含与连接异二聚体Fc的非靶向VHH的C端融合的野生型IL-2的融合蛋白(包含SEQ ID NO:45),但不是包含替代野生型IL-2的IL-2-RAS的融合蛋白(包含SEQ ID NO:46),诱导Treg增殖和激活标记物CD25的表达。
实施例8:将表达PD-1的激活T细胞通过靶向PD-1的IL-2-RAS进行刺激
使用派姆单抗(抗PD-1常规抗体)和包含派姆单抗类似物和连接重链C端的IL-2-RAS的融合蛋白测试结合和刺激表达PD-1的T细胞的能力(参见图1F)。
基本上如实施例4中所述,将来自健康供体的富集的T细胞激活。将6孔板在4℃下用1μg/ml OKT3抗体包被过夜。第二天,将板洗涤两次以去除未结合的OKT3抗体。使用CTL培养基将富集的T细胞解冻,并在完全RPMI中重悬浮至5.5x 106个细胞/mL,并以每孔3mL接种到包被板中。两天后,将激活的T细胞收集并洗涤一次,之后在不含OKT3抗体的培养基中铺板24小时以静置。将细胞用增殖染料CellTraceTMViolet(CTV)标记。对T细胞进行计数,然后重悬浮至2x106个细胞/mL。在96孔圆底板中,每孔接种100μL重悬浮细胞。添加派姆单抗或派姆单抗类似物-IL-2-RAS融合蛋白,以最终浓度100nM起始并且按1:5逐步调整。在第三天,将T细胞在室温下用活力标记物PI和以下荧光标记的抗体染色20min:CD4-BV785、CD8-APC/Fire、CD25-PE/Cy7、CD71-FITC、和CD69-APC。基本上如实施例7中所述,在Novocyte流式细胞仪上读取板,以测量增殖,并且基本上如实施例1中所述测量结合,并且将数据输出到Excel中以便进一步分析。
如图9所示,派姆单抗类似物-IL-2-RAS融合蛋白刺激CD8+T细胞增殖(图9A)和CD4+T细胞增殖(图9B),而单独的派姆单抗并未如此。无意受任何特定理论的束缚,所观察到的增殖的双相性质可表明低浓度下的活性是由于PD-1靶向活性,而在较高浓度下增加的活性是由于非靶向活性。如图9C和图9D所示,派姆单抗和派姆单抗类似物-IL-2-RAS二者以相似的亲和力结合激活的CD8+和CD4+T细胞,不同之处在于对于包含IL-2-RAS的融合蛋白在高于10nM的稀释范围上端观察到额外的结合,这可能是由IL-2-RAS与IL-2R的结合所介导的。
实施例9:在激活的T细胞上预先阻断PD-1可阻止靶向PD-1的IL-2-RAS的信号传导
基本上如实施例4中所述,通过磁珠分离从健康供体中分离和富集T细胞,并在包被有OKT3抗体的板上孵育以激活它们。将细胞用CTV标记。将预激活的T细胞与派姆单抗(为抗PD-1抗体)一起孵育以阻断PD-1结合位点,或用非靶向抗体作为对照。然后将细胞与包含和派姆单抗类似物融合的IL-2-RAS的融合蛋白、或包含和非靶向抗体融合的IL-2-RAS的融合蛋白(作为对照)一起孵育3天。基本上如实施例7中所述,通过流式细胞术测量CD4+和CD8+T细胞增殖来评价IL-2信号传导的程度。
如图10A-图10D所示,野生型IL-2诱导CD8+和CD4+T细胞二者的稳固增殖,而用派姆单抗或包含IL-2-RAS和非靶向抗体的融合蛋白处理的CD4+T细胞和CD8+T细胞展现出不受预先阻断PD-1影响的低水平增殖。相比之下,用包含IL-2-RAS和派姆单抗类似物的融合蛋白处理的CD4+T细胞(图10B和图10D)和CD8+T细胞(图10A和图10C)二者均展现出显著的PD-1依赖性增殖(图10A和图10B),所述增殖通过与抗PD-1抗体预孵育而被阻断(图10C和图10D)。因此,仅当PD-1在T细胞上表达和可及时,包含IL-2-RAS和抗PD-1抗体的融合蛋白才会激活T细胞。
实施例10:靶向PD-1的IL-2-RAS克服Treg抑制
如实施例5中所述分离CD4+T应答细胞和Treg。将CD4+应答细胞用CTV标记,与分离的Treg以2:1的比率混合,并用抗CD3珠(每2个T细胞1个珠)激活。将得到的混合物用如下处理7天:系列稀释的如图1B所示的与非靶向VHH的C端融合的野生型IL-2、如图1B所示的包含与非靶向VHH的C端融合的IL-2-RAS的融合蛋白,或者包含与抗PD-1抗体融合的IL-2-RAS的融合蛋白(派姆单抗类似物-IL-2-RAS)。基本上如实施例7中所述,通过流式细胞术来测量增殖。
如图11所示,T应答细胞被Treg抑制,但尽管存在Treg,非靶向野生型IL-2以及包含IL-2-RAS和抗PD-1抗体的融合蛋白(派姆单抗类似物-IL-2-RAS)也诱导CD4+T应答细胞增殖。用包含IL-2-RAS和非靶向抗体的融合蛋白处理细胞并没有在相似程度上挽救增殖。非靶向IL-2-RAS只能在比靶向PD-1的IL-2-RAS融合蛋白高得多的浓度下对抗Treg对T应答细胞的抑制作用。因此,靶向PD-1的IL-2-RAS克服了Treg的抑制作用,并且这种活性依赖于与T细胞上表达的PD-1的结合。
实施例11:靶向PD-1的IL-2-RAS不以反式发出信号
根据制造商推荐的包被程序,以200μg PD-1抗原/4x 108个珠包被珠。简而言之,将珠在缓冲液1(0.1M磷酸钠缓冲液,pH 7.4-8.0)中洗涤一次,然后在含有PD-1抗原的缓冲液1中在试管旋转器中室温孵育18小时。然后将珠用缓冲液2(PBS,0.1% BSA,2mM EDTA pH7.4)洗涤4次。通过将珠在缓冲液3(0.2M Tris,0.1% BSA,pH 8.5)中在37℃下孵育4小时,使游离甲苯磺酰基基团失活。然后将珠在缓冲液2中洗涤一次并重悬浮至400x106个珠/mL的浓度。
将包被的珠与包含和抗PD-1抗体融合的野生型IL-2或IL-2-RAS的融合蛋白一起孵育并洗涤。然后将珠与分离的静息T细胞一起孵育。通过流式细胞术测量pSTAT5水平来评价IL-2信号传导。
与珠结合的包含野生型IL-2的融合蛋白稳固激活CD8+T细胞和CD4+T细胞,而与珠结合的包含IL-2-RAS的融合蛋白直至测试的最高浓度对CD4+或CD8+T细胞没有活性。因此,IL-2-RAS的T细胞靶向是IL-2信号传导所需要的,并且靶向IL-2-RAS的信号传导不会以反式发生。
实施例12:IL-2-RAS不以反式发出信号
将非靶向野生型IL-2和非靶向IL-2-RAS的稀释系列(以1000nM起始并按1:4稀释)包被在测定板上,孵育过夜,并洗涤。添加T细胞并在37℃下孵育30分钟。基本上如实施例6中所述,通过检测磷酸化STAT5水平来测量CD8+和CD4+T细胞的激活。
如图12A和图12B所示,如通过pSTAT5诱导测量的,CD8+和CD4+T细胞被野生型IL-2反式激活;然而,非靶向IL-2-RAS无法反式激活。无意受任何特定理论的束缚,IL-2-RAS对IL-2受体的亲和力降低可阻止IL-2R的有效结合和聚集而不能诱导下游信号传导。因此,只有靶向IL-2-RAS融合蛋白驱动pSTAT5信号传导。
实施例13:靶向NKp46的IL-2-RAS特异性驱动NK细胞增殖
测定了包含与靶向NKp46的异二聚体scFv抗体的C端融合的IL-2-RAS的融合蛋白(如图1H所示)、包含与连接异二聚体Fc的非靶向VHH的C端融合的野生型IL-2或IL-2-RAS的融合蛋白(如图1B所示)、以及单独的靶向NKp46的异二聚体scFv抗体对NK细胞、CD4+T细胞和CD8+T细胞的作用。
将来自健康供体的新鲜PBMC用CellTraceTMViolet标记并以200,000个细胞/孔铺板在96孔圆底板中。将融合蛋白和NKp46 scFv-Fc对照的稀释物添加到铺板的细胞中,并在37℃下孵育7天。在第7天,基本上如实施例7中所述测量细胞增殖,不同之处在于使用以下抗体:抗CD3-BV785(1:200)、抗CD56-APC(1:100)、抗CD4-PE(1:200)、抗CD8-APC-Fire(1:300)和PI(1:2000)。
此外,将来自健康供体的新鲜PBMC用相同的融合蛋白或NKp46 scFv-Fc对照处理,并在37℃下孵育15分钟。将CD8+T细胞、CD4+T细胞和NK细胞(CD3-、CD56+)中的pSTAT5水平通过检测磷酸化STAT5水平来测量,基本上如实施例6中所述。
基本如实施例1中所述,测量融合蛋白和NKp46 scFV-Fc对照与来自健康供体的新鲜PBMC的结合,不同之处在于使用以下抗体:抗CD3-FITC(1:100)、抗CD56-BV421(1:100)、抗CD4-BV785(1:200)、抗CD8-APC-Fire(1:300)、抗人IgG-Alexa Fluor 647(1:500)、和PI(1:2000)。
如图13A-13I所示,靶向NKp46的IL-2-RAS有效激活NK细胞增殖和激活,同时不影响CD4+或CD8+T细胞。相比之下,非靶向野生型IL-2驱动所有测试的淋巴细胞(NK、CD4+和CD8+T细胞)的增殖和激活。NKp46 scFV-Fc(不含IL-2-RAS)的结合不会驱动NK增殖或pSTAT5诱导。因此,靶向NKp46的IL-2-RAS驱动NK细胞上IL-2的顺式信号传导,但不会反式激活CD4+或CD8+T细胞。
实施例14:靶向LAG3的IL-2-RAS刺激预激活的LAG3+T细胞
测定以下对CD4+T细胞和CD8+T细胞的作用:包含与抗LAG3异二聚体常规抗体(MAb)的C端融合的IL-2-RAS的融合蛋白(如图1G所示),与具有异二聚体Fc的抗LAG3 VHH融合的IL-2-RAS的融合蛋白(如图1B所示),与非靶向VHH融合的IL-2-RAS的融合蛋白(如图1B所示),或包含与非靶向异二聚体Fc的C端融合的野生型IL-2的融合蛋白(如图1B所示),或靶向LAG3的Mab(对照),或靶向LAG3的VHH-Fc(对照)。
用1μg/mL所包被的抗CD3(OKT3)和10μg/mL可溶性抗CD28刺激来自健康供体的富集T细胞48小时,然后静置24小时。将预激活的细胞用CellTraceTMViolet标记并以200,000个细胞/孔接种。添加融合蛋白和对照蛋白的稀释物并孵育3天。基本上如实施例7中那样测量激活标记物CD25和CD71的增殖和表达,但使用这些另外的抗体:抗CD25-FITC(1:100)和抗CD71-PE/Cy7。
经刺激的CD8+T细胞将LAG3上调至CD8+T细胞的45%,而CD4+T细胞将LAG3上调至CD4+T细胞的22%。相比之下,非刺激T细胞在CD8+或CD4+T细胞上的LAG3表达阳性率接近0%。
如图14A-图14D所示,抗-LAG3 Mab-IL-2-RAS和抗-LAG3 VHH-IL-2-RAS二者均增加了CD8+和CD4+增殖(图14A和图14B)以及如通过CD25(图14C和图14D)和CD71(图14E和图14F)表达水平所指示的激活。非靶向野生型IL-2是CD8+和CD4+T细胞增殖和激活的强诱导物,并以更高的亲和力和饱和度结合经刺激的T细胞。
实施例15:IL-2的组合突变体进一步降低非靶向活性
使用HEK-Blue IL-2报告细胞(InvivoGen)测量非靶向IL-2突变体的相对活性。用与非靶向VHH的C端融合的IL-2突变体的稀释物处理报告细胞并孵育20小时,之后使用比色酶底物(QUANTI-BlueTM(Invivogen))将IL-2诱导的报告细胞的碱性磷酸酶的分泌量化。
如图15所示,IL-2突变体示出一系列活性。上述实验显示,IL-2-RAS(P65R、H16A和D84S)与野生型IL-2相比具有显著降低的与IL-2R的结合(参见图4-图6),并且与野生型IL-2相比具有降低的活性(参见图7A-图7E)。与IL-2-RAS相比,具有另外的M23A突变的IL-2-RAS和具有另外的E95Q突变的IL-2-RAS二者均显示出降低的活性,并且IL-2-RAS与M23A和E95Q二者的组合均甚至具有进一步减弱的活性。在使用表达PD-1的报告细胞的实验中,这些亲和力降低的IL-2突变体都显示出可比的PD-1靶向活性(数据未显示),表明与PD-1顺式高亲和力结合可以补偿IL-2突变体对IL-2R的降低的亲和力。虽然HEK-Blue IL-2报告系统可用于相对活性测量,但与原代淋巴细胞相比,报告系统中观察到的IL-2突变体的EC50显著左移,这可能是由于与原代细胞上较低的IL-2R水平相比在报告细胞中IL-2R组分的过度表达造成的。
实施例16:包含修饰的IL-2的多肽的活性
将HEK-Blue IL-2报告细胞(InvivoGen)或表达PD-1的修饰的IL-2报告细胞克隆用于测量包含与PD-1结合VHH的C端融合的修饰的IL-2的多肽的相对活性。IL-2修饰和每个修饰的IL-2的SEQ ID NO示出在表2和表3中。还测试了包含仅包含T3G和C125S突变的IL-2或野生型IL-2的对照多肽。使用不表达PD-1的报告细胞测量非靶向IL-2活性。如实施例15中所述,将报告细胞用多肽的稀释物处理并孵育20小时,之后进行Quanti-Blue分析。使用Prism 8中的四参数非线性曲线拟合([激动剂]与反应-可变斜率)计算缺少PD-1的细胞上的测试多肽的EC50并在以下表2示出,并且剂量反应曲线在图16A中示出。
表2:缺少PD-1的细胞上包含修饰的IL-2的多肽的EC50
如表2和图16A所示,测试的包含修饰的IL-2的多肽示出一定范围的活性。相比于IL-2-RAS-T3A-C125S,具有另外的F42R、Δ42、K43E和/或Y45R、I114F、E61R或R38A修饰的IL-2-RAS-T3A-C125S示出降低的活性。如图25A-图25C所示,报告细胞响应于野生型IL-2和包含T3G和C125S突变的IL-2。
在表达PD-1的IL-2报告细胞中测试了相同多肽的靶向PD-1的IL-2活性。使用Prism 8中的四参数非线性曲线拟合([激动剂]与反应-可变斜率)计算表达PD-1的细胞上的EC50并在以下表3示出,并且剂量反应曲线在图16B中示出。
表3:表达PD-1的细胞上包含修饰的IL-2的多肽的EC50
如表3和图16B所示,包含具有另外的F42R、Δ42、K43E和/或Y45R、I114F、E61R或R38A修饰的IL-2-RAS-T3A-C125S的多肽的靶向PD-1的IL-2活性示出在IL-2-RAS-T3A-C125S的活性的2至5倍内的活性。
实施例17:阻断CD25对包含修饰的IL-2的多肽的活性的作用
将不表达PD-1的HEK-Blue IL-2报告细胞(InvivoGen)用于测量在阻断IL-2与CD25的结合的CD25抗体的存在或不存在下包含与PD-1结合VHH的C端融合的修饰的IL-2的多肽的相对活性。IL-2修饰和修饰的IL-2的SEQ ID NO示出在表4中。如实施例15中所述,将报告细胞用多肽的稀释物处理并孵育20小时,之后进行Quanti-Blue分析。剂量反应曲线示出在图17A-图17C中,并且CD25阻断对IL-2活性的作用列举在以下表4中。
表4:阻断CD25对缺少PD-1的细胞的作用
如表4和图17A-图17C所示,包含IL-2-RAS-T3A-C125S或包含具有另外的K43E或I114F修饰的IL-2-RAS-T3A-C125S的多肽在CD25阻断抗体的存在下未保留全部IL-2活性,表明CD25对它们的活性是必要的。包含具有另外的F42R、Δ42、E61R或R38A修饰或具有另外的K43E和Y45R修饰的IL-2-RAS-T3A-C125S的多肽在CD25阻断抗体的存在下保留了全部活性,表明CD25对它们的活性不是必要的。
实施例18:包含修饰的IL-2的多肽的活性
将实施例16中所述的HEK-Blue IL-2报告细胞用于测量包含与PD-1结合VHH的C端融合的修饰的IL-2的多肽的相对活性。IL-2修饰和每个修饰的IL-2的SEQ ID NO示出在表5中。使用不表达PD-1的报告细胞测量非靶向IL-2活性。如实施例15中所述,将报告细胞用多肽的稀释物处理并孵育20小时,之后进行Quanti-Blue分析。使用Prism 8中的四参数非线性曲线拟合([激动剂]与反应-可变斜率)计算缺少PD-1的细胞上的测试多肽的EC50并在以下表5示出,并且剂量反应曲线在图18A中示出。
表5:缺少PD-1的细胞上包含修饰的IL-2的多肽的EC50
如表5和图18A所示,测试的包含修饰的IL-2的多肽示出一定范围的活性。相比于IL-2-RAS-T3A-C125S,具有另外的N88S、E95Q和/或M23A修饰的IL-2-RAS-T3A-C125S示出降低的活性。L19A修饰的添加导致大大降低的IL-2活性。
在表达PD-1的IL-2报告细胞中测试了相同多肽的靶向PD-1的IL-2活性。使用Prism 8中的四参数非线性曲线拟合([激动剂]与反应-可变斜率)计算表达PD-1的细胞上的EC50并在以下表6示出,并且剂量反应曲线在图18B中示出。
表6:表达PD-1的细胞上包含修饰的IL-2的多肽的EC50
如表6和图18B所示,包含具有一个或多个另外的N88S、M23A或M23A和E95Q修饰的IL-2-RAS-T3A-C125S的多肽的靶向PD-1的IL-2活性示出在IL-2-RAS-T3A-C125S的活性的2倍内的活性。尽管在PD-1的存在下,L19A修饰的添加导致大大降低的IL-2活性。
实施例19:包含修饰的IL-2的多肽的活性
将实施例16中所述的HEK-Blue IL-2报告细胞用于测量包含与PD-1结合VHH的C端融合的修饰的IL-2的多肽的相对活性。如实施例15中所述,将报告细胞用多肽的稀释物处理并孵育20小时,之后进行Quanti-Blue分析。修饰的IL-2的身份和SEQ ID NO以及测试多肽的EC50示出在以下表7中,并且剂量反应曲线示出在图19A-图19E中。
表7:包含修饰的IL-2的多肽的EC50
如表7和图19A-图19E所示,包含修饰的IL-2的测试多肽示出一定范围的活性。虽然所有包含具有另外的修饰的IL-2-RAS-T3A-C125S的多肽相比于包含IL-2-RAS-T3A-C125S的多肽展现出显著降低的非靶向活性,包含具有另外的L19A和E61R修饰的以及具有另外的M23A、E61R和E95Q修饰的IL-2-RAS-T3A-C125S的多肽相比于包含IL-2-RAS-T3A-C125S的多肽展现出可比的靶向PD-1的活性。实施例18示出,在E61R突变不存在时,L19A突变降低包含IL-2-RAS-T3A-C125S的多肽的非靶向和靶向活性;然而,这些结果显示,E61R突变的添加恢复靶向PD-1的活性。因此,组合单独突变的作用难以预测。
实施例20:包含修饰的IL-2的多肽的活性
将实施例16中所述的HEK-Blue IL-2报告细胞用于测量包含与PD-1结合VHH的C端融合的修饰的IL-2的多肽的相对活性。如实施例15中所述,将报告细胞用多肽的稀释物处理并孵育20小时,之后进行Quanti-Blue分析。修饰的IL-2的身份和SEQ ID NO以及测试多肽的EC50示出在以下表8中,并且剂量反应曲线示出在图20A-图20E中。
表8:包含修饰的IL-2的多肽的EC50
如表8和图20A-图20E所示,包含修饰的IL-2的测试多肽示出一定范围的活性。所有包含具有另外的修饰的IL-2-RAS-T3A-C125S的多肽相比于包含IL-2-RAS-T3A-C125S的多肽展现出降低的非靶向活性,并且一些未展现出非靶向活性。包含具有另外的L19A和R38A修饰的和具有另外的M23A、R38A和E95Q修饰的IL-2-RAS-T3A-C125S的多肽相比于包含IL-2-RAS-T3A-C125S的多肽展现出可比的靶向PD-1的活性。
实施例21:包含修饰的IL-2的多肽的活性
将实施例16中所述的HEK-Blue IL-2报告细胞用于测量包含与PD-1结合VHH的C端融合的修饰的IL-2的多肽的相对活性。如实施例15中所述,将报告细胞用多肽的稀释物处理并孵育20小时,之后进行Quanti-Blue分析。修饰的IL-2的身份和SEQ ID NO以及测试多肽的EC50示出在以下表9中,并且剂量反应曲线示出在图21A-图21D中。
表9:包含修饰的IL-2的多肽的EC50
如表9和图21A-图21D所示,包含具有另外的L19修饰的IL-2-RAS-T3A-C125S的多肽相比于包含IL-2-RAS-T3A-C125S的多肽展现出可比的靶向PD-1的活性,而相比于包含IL-2-RAS-T3A-C125S的多肽,测试多肽的非靶向活性在轻微降低到显著降低之间变化。
实施例22:包含修饰的IL-2的多肽的活性
将实施例16中所述的HEK-Blue IL-2报告细胞用于测量包含与PD-1结合VHH的C端融合的修饰的IL-2的多肽的相对活性。将多肽用旨在破坏IL-2-CD25界面的IL-2突变进行修饰,并将其与包含IL-2-RAS-T3A-C125S的对照多肽进行比较。如实施例15中所述,将报告细胞用多肽的稀释物处理并孵育20小时,之后进行Quanti-Blue分析。修饰的IL-2的身份和SEQ ID NO以及测试多肽的EC50示出在以下表10中,并且剂量反应曲线示出在图22A(缺少PD-1的细胞)中以及图22B(表达PD-1的细胞)中。
表10:包含修饰的IL-2的多肽的EC50
如表10和图22A所示,包含IL-2-T3A-R38A-C125S的多肽未展现出非靶向活性,并且剩余的测试多肽相比于包含IL-2-RAS-T3A-C125S的多肽展现出显著增加的非靶向活性。如图22B所示,与包含IL-2-RAS-T3A-C125S的多肽相比,包含IL-2-T3A-R38A-C125S的多肽展现出一些显著降低的靶向PD-1的活性。剩余的测试多肽相比于包含IL-2-RAS-T3A-C125S的多肽展现出可比的靶向PD-1的活性。
实施例23:包含修饰的IL-2的多肽的活性
将实施例16中所述的IL-2报告细胞用于测量包含与PD-1结合VHH的C端融合的修饰的IL-2的多肽的相对活性。如实施例15中所述,将报告细胞用多肽的稀释物处理并孵育20小时,之后进行Quanti-Blue分析。修饰的IL-2的身份和SEQ ID NO以及测试多肽的EC50示出在以下表11中,并且剂量反应曲线示出在图23A(缺少PD-1的细胞)中以及图23B(表达PD-1的细胞)中。
表11:包含修饰的IL-2的多肽的EC50
如表11和图23A所示,相比于包含IL-2-RAS-T3A-C125S的多肽,包含具有另外的修饰的IL-2-RAS-T3A-C125S的测试多肽展现出显著降低的非靶向活性。如图23B所示,与包含IL-2-RAS-T3A-C125S的多肽相比,包含具有另外的修饰的IL-2-RAS-T3A-C125S的测试多肽展现出在从轻微降低到显著降低范围内的靶向PD-1的活性。包含具有另外的L19N和R38A或E61R突变的IL-2-RAS-T3A-C125S的多肽展现出包含具有另外的修饰的IL-2-RAS-T3A-C125S的测试多肽的最高的靶向PD-1的活性。
实施例24:包含修饰的IL-2的多肽与CD25结合
使用生物膜层干涉法(ForteBio)测试包含与PD-1结合VHH的C端融合的修饰的IL-2的多肽和对照多肽与CD25的结合。固定带组氨酸标签的CD25,并添加300nM的列在下表中的多肽。得到的结合结果在下表12中示出。
表12:测试多肽与CD25结合
尽管包含旨在破坏CD25-IL-2界面的突变,包含IL-2-RAS-T3A-C125S的多肽结合CD25。与包含仅包含RAS-T3A-C125S突变的IL-2的多肽相比,包含含有E61R和P65R突变的IL-2的多肽展现出显著降低的CD25结合或无CD25结合。
实施例25:包含修饰的IL-2的多肽的活性
如实施例16所述,使用HEK-Blue IL-2报告细胞(InvivoGen)或表达PD-1的修饰的细胞克隆测量包含与PD-1结合VHH的C端融合的修饰的IL-2的多肽的相对活性。IL-2修饰和修饰的IL-2的SEQ ID NO示出在表13中。
使用HEK-Blue IL-2报告细胞(InvivoGen)或表达NKp46的修饰的细胞克隆测量包含与NKp46结合VHH的C端融合的修饰的IL-2的多肽的相对活性。IL-2修饰和修饰的IL-2的SEQ ID NO示出在表13中。
使用HEK-Blue IL-2报告细胞(InvivoGen)或表达CD8a的修饰的细胞克隆测量包含与CD8a结合VHH的C端融合的修饰的IL-2的多肽的相对活性。IL-2修饰和修饰的IL-2的SEQ ID NO示出在表14中。
使用缺少PD-1表达、缺少NKp46表达和缺少CD8a表达的细胞测量非靶向活性。
结果示出在以下表13和表14中,并且对应于表14的剂量反应曲线示出在图24A(缺少CD8a的细胞)和图24B(表达CD8a的细胞)中。将最大值50.000nM用于非靶向EC50条目,包括用于由于活性差和对非线性回归计算拟合差而无法计算的非靶向EC50。使用包含PD-1结合VHH的多肽和表达PD-1的报告细胞计算靶向PD-1的EC50。使用包含NKp46结合VHH的多肽和表达NKp46的报告细胞计算靶向NKp46的EC50。使用包含CD8a结合VHH的多肽和表达CD8a的报告细胞计算靶向CD8a的EC50。“窗口”是非靶向EC50除以靶向EC50并且代表靶向IL-2活性的浓度差。空条目指示在对应实验中未测试多肽。
表13:包含修饰的IL-2的多肽的EC50
表14:包含修饰的IL-2的多肽的EC50
实施例26:包含修饰的IL-2的多肽的非靶向活性与靶向活性
通过对上文所述IL-2报告物测定中测定的非靶向和靶向EC50绘图来分析和比较本文所述多肽的非靶向和靶向IL-2报告物活性。图26A示出包括在分析中的IL-2突变体的非靶向活性。此图示出IL-2突变体对三聚体IL-2受体的亲和力的降低。图26B和图26C示出分别针对PD-1和NKp46的靶向EC50与非靶向EC50的图。这些对比示出,当通过高亲和力VHH靶向PD-1或NKp46时,亲和力降低的IL-2突变体增强的信号传导能力。图26D和图26E分别示出靶向PD-1和NKp46的窗口,如实施例25所述计算。这些图示出在避免非靶向IL-2活性的同时实现靶向活性的浓度范围。
实施例27:包含修饰的IL-2的多肽的活性
通过借助流式细胞术测量PBMC的pSTAT5水平来测定包含与γδTCR结合VHH的C端融合的修饰的IL-2的多肽的相对活性。所述多肽包含所选择的形成单价或二价γδTCR结合多肽的Fc区。所述多肽的结构在下表中指示出。
表15:靶向γδTCR的包含修饰的IL-2的多肽
通过lymphoprep密度梯度离心从健康供体白细胞中分离PBMC。在室温下用以下荧光缀合抗体标记细胞并持续20分钟:非竞争性抗γδTCR-FITC、抗CD3-BV785和抗CD56-BV421在洗涤后,在96孔板中每孔接种200,000个PBMC。通过上表列出的融合蛋白的逐步调整液(以100nM的初始浓度起始并按1:5在板上逐步调整)处理细胞,一式两份。将板在37℃/5% CO2下孵育20分钟。将细胞用BD Cytofix/CytopermTM(BD Biosciences)固定,在90%冰冷甲醇中透化,并使用流式细胞术使用磷酸特异性抗pSTAT5-PE抗体(1:70)来测量γδT细胞上的磷酸化STAT5(“pSTAT5”)的水平。
如图27A-图27H所示,用各种二价或单价靶向γδTCR的修饰的IL-2多肽处理导致pSTAT5+γδT细胞的百分比和特定地在γδT细胞上的pSTAT5中值荧光强度的剂量依赖性增加。相比之下,在低于100nM时,NK或αβT细胞上的pSTAT5激活很少。
实施例28:包含修饰的IL-2的多肽的活性
通过测量γδT细胞和αβT细胞增殖和积累来测定包含与γδTCR结合VHH或非靶向VHH的C端融合的修饰的IL-2的多肽的相对活性。所述多肽包含所选择的形成单价或二价多肽的Fc区。所述多肽的结构在下表中指示出。
表16:靶向和非靶向γδTCR的包含修饰的IL-2的多肽
IL-2促进T细胞群的激活和增殖。为评估靶向γδTCR的修饰的IL-2对T细胞增殖的作用,使用lymphoprep密度梯度介质将PBMC从健康供体白细胞中分离。在37℃下将细胞用CellTrace Violet增殖染料标记10分钟。在洗涤后,将细胞在RPMI+10% FBS中重悬浮并向96孔板中每孔添加300,000个细胞。通过上表列出的融合蛋白的逐步调整液(以100nM的初始浓度起始并按1:5在板上逐步调整)处理细胞,一式两份。将板在37℃/5% CO2下孵育7天。在4℃下将细胞用以下荧光缀合抗体标记30分钟:CD3-BV785、γδTCR-FITC以及活力染料碘化丙啶。将细胞洗涤并通过流式细胞术分析。
如图28A-图28D所示,用靶向γδTCR的修饰的IL-2处理导致γδT细胞增殖和积累的剂量依赖性增加(图28A和图28B)。用靶向γδTCR的修饰的IL-2处理还使得γδT细胞在总CD3+群体中的百分比提高,在T细胞中的百分比随之降低。此作用是特异性针对γδT细胞的,因为αβT细胞群未响应于用靶向γδTCR的修饰的IL-2处理而增殖或积累(图28C和图28D)。在测试的剂量下,与修饰的IL-2融合的非靶向VHH未促进γδT细胞或αβT细胞的增殖,证明靶向性修饰的IL-2多肽的靶向特异性。
实施例29:包含修饰的IL-2的多肽的活性
通过借助流式细胞术测量PBMC的pSTAT5水平来测定包含修饰的IL-2的多肽的相对活性。所述多肽的结构在下表中指示出。
表17:包含修饰的IL-2的多肽
通过细胞内流式细胞术测量pSTAT5水平,将其作为IL-2受体接合和信号传导的近似读出。将人PBMC以每孔1,000,000个细胞铺板于96孔板的完全生长培养基(RPMI,10%FBS,1%抗生素-抗真菌剂)中。然后将测试多肽稀释并制作5倍系列稀释物。将系列稀释物添加至细胞中并在37℃下孵育15分钟。然后将细胞在4℃下在100μL的Cytofix固定缓冲液(BD)中固定30分钟。然后将细胞在200μL FACS缓冲液中洗涤一次并在4℃下在Perm缓冲液III(BD Phosflow)中透化30分钟。将透化的细胞在透化缓冲液(eBioscience)中共洗涤三次,之后在4℃下在含有荧光标记的针对CD4(OKT4,1:100)、CD3(SP34-2,1:50)、CD16(3G8,1:1000)、pSTAT5(SRBCZX,1:70)、CD56(NCAM16.2,1:500)和CD8(RPA-T8,1:4000)的抗体的透化缓冲液中孵育过夜。第二天,将细胞用150μL FACS缓冲液洗涤并使用ACEABiosciences Novocyte-Quanteon流式细胞术分析。通过用于检测NK细胞(CD3-CD56亮CD16-)上的pSTAT5的荧光标记抗体的频率和中值荧光强度水平的提高将IL-2信号传导量化。对数据绘图并使用GraphPad Prism分析软件分析。
如图29A-图29B所示,野生型IL-2以剂量依赖性方式激活细胞,其中野生型重组IL-2的EC50为大约0.06nM。相比于野生型IL-2,包含含有T3A、H16A、E61R、P65R、D84Y和C125S突变的IL-2变体的多肽示出显著减弱的活性。
在不脱离本公开文本的精神或本质特征的情况下,本发明可以以其他特定形式实施。因此,前述实施方案在所有方面都被认为是说明性的,而不是对本公开文本的限制。本公开文本的范围因此由所附权利要求而不是由前述描述指示,并且因此在权利要求的等效含义和范围内的所有变化都旨在包含在本文中。
某些序列的列表
在包含框或下划线的序列中,单独字母周围的框表示相对于相应野生型或亲本序列的氨基酸取代;字母组周围的框表示接头序列。带下划线的字母是接头序列。不含方框或下划线的序列还可以含有氨基酸取代和/或接头序列。
序列表
<110> 印希比股份有限公司
<120> 包含修饰的IL-2多肽的多肽及其用途
<130> 01202-0040-00PCT
<150> US 63/047,681
<151> 2020-07-02
<160> 301
<170> PatentIn 3.5版
<210> 1
<211> 133
<212> PRT
<213> 智人(Homo sapiens)
<220>
<221> 位点
<222> (1)..(133)
<223> 野生型人 IL-2
<400> 1
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 2
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2v
<400> 2
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Ala Lys Phe Ala Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Gly Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ala Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 3
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-P65R
<400> 3
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 4
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-H16A
<400> 4
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 5
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-D84S
<400> 5
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 6
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-E15S
<400> 6
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Ser His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 7
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-M23A
<400> 7
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 8
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-E95Q
<400> 8
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 9
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-P65E
<400> 9
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Glu Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 10
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-F42K
<400> 10
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Lys Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 11
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-H16A-F42K
<400> 11
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Lys Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 12
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-D84S-F42K
<400> 12
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Lys Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 13
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-E15S-F42K
<400> 13
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Ser His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Lys Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 14
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-M23A-F42K
<400> 14
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Lys Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 15
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-E95Q-F42K
<400> 15
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Lys Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 16
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-P65R-H16A
<400> 16
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 17
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-P65R-D84S
<400> 17
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 18
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-P65R-E15S
<400> 18
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Ser His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 19
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-P65R-M23A
<400> 19
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 20
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-P65R-E95Q
<400> 20
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 21
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-P65R-H16A-D84S(IL-2-RAS)
<400> 21
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 22
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-C125S
<400> 22
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 23
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-P65R-C125S
<400> 23
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 24
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-C125S
<400> 24
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 25
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-D84S-C125S
<400> 25
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 26
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-P65R-C125S
<400> 26
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 27
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-P65R-D84S-C125S
<400> 27
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 28
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-P65R-D84S-C125S
<400> 28
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 29
<211> 124
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-no9-H16A-P65R-C125S
<400> 29
Thr Gln Leu Gln Leu Glu Ala Leu Leu Leu Asp Leu Gln Met Ile Leu
1 5 10 15
Asn Gly Ile Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr
20 25 30
Phe Lys Phe Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln
35 40 45
Cys Leu Glu Glu Glu Leu Lys Arg Leu Glu Glu Val Leu Asn Leu Ala
50 55 60
Gln Ser Lys Asn Phe His Leu Arg Pro Arg Asp Leu Ile Ser Asn Ile
65 70 75 80
Asn Val Ile Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys
85 90 95
Glu Tyr Ala Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp
100 105 110
Ile Thr Phe Ser Gln Ser Ile Ile Ser Thr Leu Thr
115 120
<210> 30
<211> 124
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-no9-P65R-D84S-C125S
<400> 30
Thr Gln Leu Gln Leu Glu His Leu Leu Leu Asp Leu Gln Met Ile Leu
1 5 10 15
Asn Gly Ile Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr
20 25 30
Phe Lys Phe Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln
35 40 45
Cys Leu Glu Glu Glu Leu Lys Arg Leu Glu Glu Val Leu Asn Leu Ala
50 55 60
Gln Ser Lys Asn Phe His Leu Arg Pro Arg Ser Leu Ile Ser Asn Ile
65 70 75 80
Asn Val Ile Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys
85 90 95
Glu Tyr Ala Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp
100 105 110
Ile Thr Phe Ser Gln Ser Ile Ile Ser Thr Leu Thr
115 120
<210> 31
<211> 124
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-no9-H16A-P65R-D84S-C125S
<400> 31
Thr Gln Leu Gln Leu Glu Ala Leu Leu Leu Asp Leu Gln Met Ile Leu
1 5 10 15
Asn Gly Ile Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr
20 25 30
Phe Lys Phe Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln
35 40 45
Cys Leu Glu Glu Glu Leu Lys Arg Leu Glu Glu Val Leu Asn Leu Ala
50 55 60
Gln Ser Lys Asn Phe His Leu Arg Pro Arg Ser Leu Ile Ser Asn Ile
65 70 75 80
Asn Val Ile Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys
85 90 95
Glu Tyr Ala Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp
100 105 110
Ile Thr Phe Ser Gln Ser Ile Ile Ser Thr Leu Thr
115 120
<210> 32
<211> 362
<212> PRT
<213> 人工序列
<220>
<223> 合成的: 野生型 IL-2-xELL 杵状 Fc
<400> 32
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr Pro Gly Gly Gly Gly Asp Lys Thr His Thr Cys
130 135 140
Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
145 150 155 160
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
165 170 175
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
180 185 190
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
195 200 205
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
210 215 220
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
225 230 235 240
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
245 250 255
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu
260 265 270
Leu Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr
275 280 285
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
290 295 300
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
305 310 315 320
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
325 330 335
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
340 345 350
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
355 360
<210> 33
<211> 362
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-F42K-xELL 杵状 Fc
<400> 33
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Lys Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr Pro Gly Gly Gly Gly Asp Lys Thr His Thr Cys
130 135 140
Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
145 150 155 160
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
165 170 175
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
180 185 190
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
195 200 205
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
210 215 220
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
225 230 235 240
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
245 250 255
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu
260 265 270
Leu Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr
275 280 285
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
290 295 300
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
305 310 315 320
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
325 330 335
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
340 345 350
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
355 360
<210> 34
<211> 362
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-P65E-xELL 杵状 Fc
<400> 34
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Glu Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr Pro Gly Gly Gly Gly Asp Lys Thr His Thr Cys
130 135 140
Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
145 150 155 160
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
165 170 175
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
180 185 190
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
195 200 205
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
210 215 220
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
225 230 235 240
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
245 250 255
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu
260 265 270
Leu Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr
275 280 285
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
290 295 300
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
305 310 315 320
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
325 330 335
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
340 345 350
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
355 360
<210> 35
<211> 362
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-P65R-xELL 杵状 Fc
<400> 35
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr Pro Gly Gly Gly Gly Asp Lys Thr His Thr Cys
130 135 140
Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
145 150 155 160
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
165 170 175
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
180 185 190
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
195 200 205
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
210 215 220
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
225 230 235 240
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
245 250 255
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu
260 265 270
Leu Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr
275 280 285
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
290 295 300
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
305 310 315 320
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
325 330 335
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
340 345 350
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
355 360
<210> 36
<211> 362
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-F42K-D84S-xELL 杵状 Fc
<400> 36
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Lys Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr Pro Gly Gly Gly Gly Asp Lys Thr His Thr Cys
130 135 140
Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
145 150 155 160
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
165 170 175
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
180 185 190
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
195 200 205
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
210 215 220
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
225 230 235 240
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
245 250 255
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu
260 265 270
Leu Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr
275 280 285
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
290 295 300
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
305 310 315 320
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
325 330 335
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
340 345 350
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
355 360
<210> 37
<211> 362
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-F42K-E95Q-xELL 杵状 Fc
<400> 37
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Lys Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr Pro Gly Gly Gly Gly Asp Lys Thr His Thr Cys
130 135 140
Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
145 150 155 160
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
165 170 175
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
180 185 190
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
195 200 205
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
210 215 220
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
225 230 235 240
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
245 250 255
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu
260 265 270
Leu Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr
275 280 285
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
290 295 300
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
305 310 315 320
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
325 330 335
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
340 345 350
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
355 360
<210> 38
<211> 362
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-F42K-M23A-xELL 杵状 Fc
<400> 38
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Lys Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr Pro Gly Gly Gly Gly Asp Lys Thr His Thr Cys
130 135 140
Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
145 150 155 160
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
165 170 175
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
180 185 190
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
195 200 205
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
210 215 220
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
225 230 235 240
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
245 250 255
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu
260 265 270
Leu Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr
275 280 285
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
290 295 300
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
305 310 315 320
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
325 330 335
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
340 345 350
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
355 360
<210> 39
<211> 362
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-H16A-F42K- xELL 杵状 Fc
<400> 39
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Lys Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr Pro Gly Gly Gly Gly Asp Lys Thr His Thr Cys
130 135 140
Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
145 150 155 160
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
165 170 175
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
180 185 190
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
195 200 205
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
210 215 220
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
225 230 235 240
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
245 250 255
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu
260 265 270
Leu Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr
275 280 285
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
290 295 300
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
305 310 315 320
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
325 330 335
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
340 345 350
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
355 360
<210> 40
<211> 362
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-H16A-xELL 杵状 Fc
<400> 40
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr Pro Gly Gly Gly Gly Asp Lys Thr His Thr Cys
130 135 140
Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
145 150 155 160
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
165 170 175
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
180 185 190
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
195 200 205
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
210 215 220
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
225 230 235 240
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
245 250 255
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu
260 265 270
Leu Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr
275 280 285
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
290 295 300
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
305 310 315 320
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
325 330 335
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
340 345 350
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
355 360
<210> 41
<211> 362
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-P65R-H16A-xELL 杵状 Fc
<400> 41
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr Pro Gly Gly Gly Gly Asp Lys Thr His Thr Cys
130 135 140
Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
145 150 155 160
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
165 170 175
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
180 185 190
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
195 200 205
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
210 215 220
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
225 230 235 240
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
245 250 255
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu
260 265 270
Leu Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr
275 280 285
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
290 295 300
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
305 310 315 320
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
325 330 335
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
340 345 350
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
355 360
<210> 42
<211> 362
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-P65R-D84S-xELL 杵状 Fc
<400> 42
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr Pro Gly Gly Gly Gly Asp Lys Thr His Thr Cys
130 135 140
Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
145 150 155 160
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
165 170 175
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
180 185 190
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
195 200 205
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
210 215 220
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
225 230 235 240
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
245 250 255
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu
260 265 270
Leu Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr
275 280 285
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
290 295 300
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
305 310 315 320
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
325 330 335
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
340 345 350
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
355 360
<210> 43
<211> 362
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-RAS-xELL 杵状 Fc
<400> 43
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr Pro Gly Gly Gly Gly Asp Lys Thr His Thr Cys
130 135 140
Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
145 150 155 160
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
165 170 175
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
180 185 190
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
195 200 205
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
210 215 220
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
225 230 235 240
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
245 250 255
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu
260 265 270
Leu Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr
275 280 285
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
290 295 300
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
305 310 315 320
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
325 330 335
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
340 345 350
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
355 360
<210> 44
<211> 230
<212> PRT
<213> 人工序列
<220>
<223> 合成的: 接头EVN xELL 臼状 Fc
<400> 44
Lys Pro Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro
1 5 10 15
Ala Pro Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
20 25 30
Thr Leu Met Arg Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
35 40 45
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
50 55 60
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
65 70 75 80
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
85 90 95
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
100 105 110
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
115 120 125
Pro Gln Val Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn
130 135 140
Gln Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile
145 150 155 160
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
165 170 175
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys
180 185 190
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
195 200 205
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
210 215 220
Ser Leu Ser Pro Gly Lys
225 230
<210> 45
<211> 361
<212> PRT
<213> 人工序列
<220>
<223> 合成的: xELL 杵状 Fc-IL-2-T3G-C125S
<400> 45
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
20 25 30
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
35 40 45
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
50 55 60
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65 70 75 80
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
85 90 95
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
100 105 110
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
115 120 125
Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys
130 135 140
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
180 185 190
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
195 200 205
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly
210 215 220
Ser Gly Gly Ser Ala Pro Gly Ser Ser Ser Thr Lys Lys Thr Gln Leu
225 230 235 240
Gln Leu Glu His Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile
245 250 255
Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe
260 265 270
Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu
275 280 285
Glu Glu Leu Lys Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys
290 295 300
Asn Phe His Leu Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile
305 310 315 320
Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala
325 330 335
Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe
340 345 350
Ser Gln Ser Ile Ile Ser Thr Leu Thr
355 360
<210> 46
<211> 361
<212> PRT
<213> 人工序列
<220>
<223> 合成的: xELL 杵状 Fc-IL-2-RAS-T3G-C125S
<400> 46
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
20 25 30
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
35 40 45
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
50 55 60
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65 70 75 80
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
85 90 95
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
100 105 110
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
115 120 125
Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys
130 135 140
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
180 185 190
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
195 200 205
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly
210 215 220
Ser Gly Gly Ser Ala Pro Gly Ser Ser Ser Thr Lys Lys Thr Gln Leu
225 230 235 240
Gln Leu Glu Ala Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile
245 250 255
Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe
260 265 270
Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu
275 280 285
Glu Glu Leu Lys Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys
290 295 300
Asn Phe His Leu Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile
305 310 315 320
Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala
325 330 335
Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe
340 345 350
Ser Gln Ser Ile Ile Ser Thr Leu Thr
355 360
<210> 47
<211> 226
<212> PRT
<213> 智人(Homo sapiens)
<220>
<221> 位点
<222> (1)..(226)
<223> Fc区 1(人野生型 IgG1)
<400> 47
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly
225
<210> 48
<211> 223
<212> PRT
<213> 智人(Homo sapiens)
<220>
<221> 位点
<222> (1)..(223)
<223> Fc区 2(人IgG1 xELL 杵状结构)
<400> 48
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
20 25 30
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
35 40 45
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
50 55 60
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65 70 75 80
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
85 90 95
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
100 105 110
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
115 120 125
Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys
130 135 140
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
180 185 190
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
195 200 205
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
210 215 220
<210> 49
<211> 223
<212> PRT
<213> 智人(Homo sapiens)
<220>
<221> 位点
<222> (1)..(223)
<223> Fc区 3(人IgG1 EVN xELL 臼状 I253R)
<400> 49
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Arg Ser Arg
20 25 30
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
35 40 45
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
50 55 60
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65 70 75 80
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
85 90 95
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
100 105 110
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Cys Thr Leu
115 120 125
Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Ser Cys
130 135 140
Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175
Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val Asp Lys Ser
180 185 190
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
195 200 205
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
210 215 220
<210> 50
<211> 226
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区
<400> 50
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly
225
<210> 51
<211> 223
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 xELL
<400> 51
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
20 25 30
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
35 40 45
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
50 55 60
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65 70 75 80
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
85 90 95
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
100 105 110
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
115 120 125
Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys
130 135 140
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
180 185 190
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
195 200 205
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
210 215 220
<210> 52
<211> 222
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 xELL H435R
<400> 52
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
20 25 30
Thr Pro Glu Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
35 40 45
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
50 55 60
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
65 70 75 80
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
85 90 95
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile
100 105 110
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
115 120 125
Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
130 135 140
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
145 150 155 160
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
165 170 175
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
180 185 190
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
195 200 205
His Asn Arg Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
210 215 220
<210> 53
<211> 223
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 xELL M252Y和M428V (YV)
<400> 53
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Ser Arg
20 25 30
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
35 40 45
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
50 55 60
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65 70 75 80
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
85 90 95
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
100 105 110
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
115 120 125
Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys
130 135 140
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
180 185 190
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Val His Glu Ala
195 200 205
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
210 215 220
<210> 54
<211> 223
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 xELL M252Y和M428L (YL)
<400> 54
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Ser Arg
20 25 30
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
35 40 45
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
50 55 60
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65 70 75 80
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
85 90 95
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
100 105 110
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
115 120 125
Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys
130 135 140
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
180 185 190
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Leu His Glu Ala
195 200 205
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
210 215 220
<210> 55
<211> 223
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 xELL M252Y, M428L, H435R (YLR)
<400> 55
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Ser Arg
20 25 30
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
35 40 45
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
50 55 60
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65 70 75 80
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
85 90 95
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
100 105 110
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
115 120 125
Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys
130 135 140
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
180 185 190
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Leu His Glu Ala
195 200 205
Leu His Asn Arg Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
210 215 220
<210> 56
<211> 223
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 xELL M252Y, M428V, H435R (YVR)
<400> 56
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Ser Arg
20 25 30
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
35 40 45
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
50 55 60
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65 70 75 80
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
85 90 95
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
100 105 110
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
115 120 125
Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys
130 135 140
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
180 185 190
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Val His Glu Ala
195 200 205
Leu His Asn Arg Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
210 215 220
<210> 57
<211> 223
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 xELL S354C T366W 杵状结构
<400> 57
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
20 25 30
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
35 40 45
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
50 55 60
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65 70 75 80
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
85 90 95
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
100 105 110
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
115 120 125
Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys
130 135 140
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
180 185 190
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
195 200 205
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
210 215 220
<210> 58
<211> 223
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 xELL H435R S354C T366W 杵状结构
<400> 58
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
20 25 30
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
35 40 45
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
50 55 60
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65 70 75 80
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
85 90 95
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
100 105 110
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
115 120 125
Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys
130 135 140
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
180 185 190
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
195 200 205
Leu His Asn Arg Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
210 215 220
<210> 59
<211> 223
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 xELL M252Y和M428V (YV) S354C T366W 杵状结构
<400> 59
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Ser Arg
20 25 30
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
35 40 45
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
50 55 60
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65 70 75 80
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
85 90 95
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
100 105 110
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
115 120 125
Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys
130 135 140
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
180 185 190
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Val His Glu Ala
195 200 205
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
210 215 220
<210> 60
<211> 223
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 xELL M252Y和M428L (YL) S354C T366W 杵状结构
<400> 60
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Ser Arg
20 25 30
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
35 40 45
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
50 55 60
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65 70 75 80
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
85 90 95
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
100 105 110
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
115 120 125
Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys
130 135 140
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
180 185 190
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Leu His Glu Ala
195 200 205
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
210 215 220
<210> 61
<211> 223
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 xELL M252Y, M428L, H435R (YLR) S354C T366W
杵状结构
<400> 61
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Ser Arg
20 25 30
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
35 40 45
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
50 55 60
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65 70 75 80
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
85 90 95
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
100 105 110
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
115 120 125
Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys
130 135 140
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
180 185 190
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Leu His Glu Ala
195 200 205
Leu His Asn Arg Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
210 215 220
<210> 62
<211> 223
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 xELL M252Y, M428V, H435R (YVR) S354C T366W
杵状结构
<400> 62
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Ser Arg
20 25 30
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
35 40 45
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
50 55 60
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65 70 75 80
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
85 90 95
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
100 105 110
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
115 120 125
Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys
130 135 140
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
180 185 190
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Val His Glu Ala
195 200 205
Leu His Asn Arg Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
210 215 220
<210> 63
<211> 223
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 xELL T366S, L368A, Y407V 臼状结构
<400> 63
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
20 25 30
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
35 40 45
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
50 55 60
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65 70 75 80
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
85 90 95
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
100 105 110
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Cys Thr Leu
115 120 125
Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Ser Cys
130 135 140
Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175
Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val Asp Lys Ser
180 185 190
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
195 200 205
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
210 215 220
<210> 64
<211> 223
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 xELL H435R, T366S, L368A, Y407V 臼状结构
<400> 64
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
20 25 30
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
35 40 45
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
50 55 60
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65 70 75 80
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
85 90 95
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
100 105 110
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Cys Thr Leu
115 120 125
Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Ser Cys
130 135 140
Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175
Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val Asp Lys Ser
180 185 190
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
195 200 205
Leu His Asn Arg Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
210 215 220
<210> 65
<211> 223
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 xELL M252Y和M428V(YV)T366S, L368A,
Y407V 臼状结构
<400> 65
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Ser Arg
20 25 30
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
35 40 45
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
50 55 60
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65 70 75 80
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
85 90 95
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
100 105 110
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Cys Thr Leu
115 120 125
Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Ser Cys
130 135 140
Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175
Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val Asp Lys Ser
180 185 190
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Val His Glu Ala
195 200 205
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
210 215 220
<210> 66
<211> 223
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 xELL M252Y和 M428L(YL)T366S, L368A,
Y407V 臼状结构
<400> 66
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Ser Arg
20 25 30
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
35 40 45
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
50 55 60
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65 70 75 80
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
85 90 95
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
100 105 110
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Cys Thr Leu
115 120 125
Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Ser Cys
130 135 140
Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175
Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val Asp Lys Ser
180 185 190
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Leu His Glu Ala
195 200 205
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
210 215 220
<210> 67
<211> 223
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 xELL M252Y, M428L, H435R (YLR) T366S, L368A,
Y407V 臼状结构
<400> 67
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Ser Arg
20 25 30
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
35 40 45
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
50 55 60
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65 70 75 80
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
85 90 95
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
100 105 110
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Cys Thr Leu
115 120 125
Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Ser Cys
130 135 140
Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175
Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val Asp Lys Ser
180 185 190
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Leu His Glu Ala
195 200 205
Leu His Asn Arg Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
210 215 220
<210> 68
<211> 223
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 xELL M252Y, M428V, H435R(YVR)T366S, L368A,
Y407V 臼状结构
<400> 68
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Ser Arg
20 25 30
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
35 40 45
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
50 55 60
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65 70 75 80
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
85 90 95
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
100 105 110
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Cys Thr Leu
115 120 125
Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Ser Cys
130 135 140
Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175
Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val Asp Lys Ser
180 185 190
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Val His Glu Ala
195 200 205
Leu His Asn Arg Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
210 215 220
<210> 69
<211> 226
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 H435R
<400> 69
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn Arg Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly
225
<210> 70
<211> 226
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 M252Y和M428V(YV)
<400> 70
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Val
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly
225
<210> 71
<211> 226
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 M252Y和M428L(YL)
<400> 71
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Leu
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly
225
<210> 72
<211> 226
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 M252Y, M428L, H435R (YLR)
<400> 72
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Leu
195 200 205
His Glu Ala Leu His Asn Arg Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly
225
<210> 73
<211> 226
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 M252Y, M428V, H435R (YVR)
<400> 73
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
130 135 140
Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Val
195 200 205
His Glu Ala Leu His Asn Arg Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly
225
<210> 74
<211> 226
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 S354C T366W 杵状结构
<400> 74
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
130 135 140
Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly
225
<210> 75
<211> 226
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 H435R S354C T366W 杵状结构
<400> 75
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
130 135 140
Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn Arg Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly
225
<210> 76
<211> 226
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 M252Y和M428L (YL) S354C T366W 杵状结构
<400> 76
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
130 135 140
Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Leu
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly
225
<210> 77
<211> 226
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 M252Y, M428L, H435R (YLR) S354C T366W 杵状结构
<400> 77
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
130 135 140
Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Leu
195 200 205
His Glu Ala Leu His Asn Arg Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly
225
<210> 78
<211> 226
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 M252Y, M428V, H435R (YVR) S354C T366W 杵状结构
<400> 78
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
130 135 140
Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Val
195 200 205
His Glu Ala Leu His Asn Arg Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly
225
<210> 79
<211> 226
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 T366S, L368A, Y407V 臼状结构
<400> 79
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
130 135 140
Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly
225
<210> 80
<211> 226
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 H435R, T366S, L368A, Y407V 臼状结构
<400> 80
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
130 135 140
Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205
His Glu Ala Leu His Asn Arg Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly
225
<210> 81
<211> 226
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 M252Y 和 M428V (YV) T366S, L368A, Y407V
臼状结构
<400> 81
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
130 135 140
Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Val
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly
225
<210> 82
<211> 226
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 M252Y和M428L (YL) T366S, L368A, Y407V
臼状结构
<400> 82
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
130 135 140
Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Leu
195 200 205
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly
225
<210> 83
<211> 226
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 M252Y, M428L, H435R (YLR) T366S, L368A,
Y407V 臼状结构
<400> 83
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr
20 25 30
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125
Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
130 135 140
Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val
180 185 190
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Leu
195 200 205
His Glu Ala Leu His Asn Arg Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220
Pro Gly
225
<210> 84
<211> 119
<212> PRT
<213> 智人(Homo sapiens)
<220>
<221> 位点
<222> (1)..(119)
<223> 截短的野生型人 IL-2
<400> 84
Gln Leu Gln Leu Glu His Leu Leu Leu Asp Leu Gln Met Ile Leu Asn
1 5 10 15
Gly Ile Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr Phe
20 25 30
Lys Phe Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln Cys
35 40 45
Leu Glu Glu Glu Leu Lys Pro Leu Glu Glu Val Leu Asn Leu Ala Gln
50 55 60
Ser Lys Asn Phe His Leu Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn
65 70 75 80
Val Ile Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys Glu
85 90 95
Tyr Ala Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp Ile
100 105 110
Thr Phe Cys Gln Ser Ile Ile
115
<210> 85
<211> 362
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-F42K-E15S-xELL 杵状 Fc
<400> 85
Ala Pro Thr Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Ser His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Lys Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Cys Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr Pro Gly Gly Gly Gly Asp Lys Thr His Thr Cys
130 135 140
Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
145 150 155 160
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
165 170 175
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
180 185 190
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
195 200 205
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
210 215 220
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
225 230 235 240
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
245 250 255
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu
260 265 270
Leu Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr
275 280 285
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
290 295 300
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
305 310 315 320
Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
325 330 335
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
340 345 350
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
355 360
<210> 86
<211> 361
<212> PRT
<213> 人工序列
<220>
<223> 合成的: xELL-杵状 Fc-IL-2-T3A, C125S
<400> 86
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
20 25 30
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
35 40 45
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
50 55 60
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65 70 75 80
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
85 90 95
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
100 105 110
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
115 120 125
Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys
130 135 140
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
180 185 190
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
195 200 205
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly
210 215 220
Ser Gly Gly Ser Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu
225 230 235 240
Gln Leu Glu His Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile
245 250 255
Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe
260 265 270
Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu
275 280 285
Glu Glu Leu Lys Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys
290 295 300
Asn Phe His Leu Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile
305 310 315 320
Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala
325 330 335
Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe
340 345 350
Ser Gln Ser Ile Ile Ser Thr Leu Thr
355 360
<210> 87
<211> 361
<212> PRT
<213> 人工序列
<220>
<223> 合成的: xELL-杵状 Fc-IL-2-RAS-T3A, C125S
<400> 87
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
20 25 30
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
35 40 45
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
50 55 60
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65 70 75 80
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
85 90 95
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
100 105 110
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
115 120 125
Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys
130 135 140
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
180 185 190
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
195 200 205
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly
210 215 220
Ser Gly Gly Ser Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu
225 230 235 240
Gln Leu Glu Ala Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile
245 250 255
Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe
260 265 270
Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu
275 280 285
Glu Glu Leu Lys Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys
290 295 300
Asn Phe His Leu Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile
305 310 315 320
Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala
325 330 335
Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe
340 345 350
Ser Gln Ser Ile Ile Ser Thr Leu Thr
355 360
<210> 88
<211> 584
<212> PRT
<213> 人工序列
<220>
<223> 合成的: 派姆单抗类似物 杵状 Fc-IL-2-RAS-T3A, C125S
<400> 88
Gln Val Gln Leu Val Gln Ser Gly Val Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Tyr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe
50 55 60
Lys Asn Arg Val Thr Leu Thr Thr Asp Ser Ser Thr Thr Thr Ala Tyr
65 70 75 80
Met Glu Leu Lys Ser Leu Gln Phe Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Arg Asp Tyr Arg Phe Asp Met Gly Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125
Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
130 135 140
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
145 150 155 160
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170 175
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190
Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
195 200 205
Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp
210 215 220
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
260 265 270
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Asp Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Asp Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn Arg Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Ser
435 440 445
Gly Gly Ser Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln
450 455 460
Leu Glu Ala Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn
465 470 475 480
Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr
485 490 495
Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu
500 505 510
Glu Leu Lys Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn
515 520 525
Phe His Leu Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val
530 535 540
Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp
545 550 555 560
Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser
565 570 575
Gln Ser Ile Ile Ser Thr Leu Thr
580
<210> 89
<211> 447
<212> PRT
<213> 人工序列
<220>
<223> 合成的:派姆单抗类似物 臼状 Fc
<400> 89
Gln Val Gln Leu Val Gln Ser Gly Val Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Tyr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe
50 55 60
Lys Asn Arg Val Thr Leu Thr Thr Asp Ser Ser Thr Thr Thr Ala Tyr
65 70 75 80
Met Glu Leu Lys Ser Leu Gln Phe Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Arg Asp Tyr Arg Phe Asp Met Gly Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125
Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
130 135 140
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
145 150 155 160
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170 175
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190
Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
195 200 205
Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp
210 215 220
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
260 265 270
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Cys Thr Leu Pro
340 345 350
Pro Ser Arg Asp Lys Leu Thr Lys Asn Gln Val Ser Leu Ser Cys Ala
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Lys Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Lys Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440 445
<210> 90
<211> 218
<212> PRT
<213> 人工序列
<220>
<223> 合成的: 派姆单抗轻链类似物
<400> 90
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Lys Gly Val Ser Thr Ser
20 25 30
Gly Tyr Ser Tyr Leu His Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro
35 40 45
Arg Leu Leu Ile Tyr Leu Ala Ser Tyr Leu Glu Ser Gly Val Pro Ala
50 55 60
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
65 70 75 80
Ser Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Ser Arg
85 90 95
Asp Leu Pro Leu Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg
100 105 110
Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
115 120 125
Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
130 135 140
Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
145 150 155 160
Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
165 170 175
Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
180 185 190
His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
195 200 205
Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
210 215
<210> 91
<211> 584
<212> PRT
<213> 人工序列
<220>
<223> 合成的:派姆单抗类似物 IL-2-RAS-T3G, C125S
<400> 91
Gln Val Gln Leu Val Gln Ser Gly Val Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
20 25 30
Tyr Met Tyr Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Gly Ile Asn Pro Ser Asn Gly Gly Thr Asn Phe Asn Glu Lys Phe
50 55 60
Lys Asn Arg Val Thr Leu Thr Thr Asp Ser Ser Thr Thr Thr Ala Tyr
65 70 75 80
Met Glu Leu Lys Ser Leu Gln Phe Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Arg Asp Tyr Arg Phe Asp Met Gly Phe Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Thr Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125
Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala
130 135 140
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
145 150 155 160
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170 175
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190
Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys
195 200 205
Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro
210 215 220
Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu
260 265 270
Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350
Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly Gly Ser
435 440 445
Gly Gly Ser Ala Pro Gly Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln
450 455 460
Leu Glu Ala Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn
465 470 475 480
Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr
485 490 495
Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu
500 505 510
Glu Leu Lys Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn
515 520 525
Phe His Leu Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val
530 535 540
Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp
545 550 555 560
Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser
565 570 575
Gln Ser Ile Ile Ser Thr Leu Thr
580
<210> 92
<211> 611
<212> PRT
<213> 人工序列
<220>
<223> 合成的: NKp46-scFv xELL-杵状 Fc-IL-2-RAS-T3A, C125S
<400> 92
Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
Val Ile Asn Trp Gly Lys Gln Arg Ser Gly Gln Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Tyr Pro Gly Ser Gly Thr Asn Tyr Tyr Asn Glu Lys Phe
50 55 60
Lys Ala Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Asn Ile Ala Tyr
65 70 75 80
Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
85 90 95
Ala Arg Arg Gly Arg Tyr Gly Leu Tyr Ala Met Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Ser Val Thr Val Ser Ser Val Glu Gly Gly Ser Gly Gly Ser
115 120 125
Gly Gly Ser Gly Gly Ser Gly Gly Val Asp Asp Ile Gln Met Thr Gln
130 135 140
Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser
145 150 155 160
Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln
165 170 175
Lys Pro Asp Gly Thr Val Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu
180 185 190
His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
195 200 205
Tyr Ser Leu Thr Ile Asn Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr
210 215 220
Phe Cys Gln Gln Gly Asn Thr Arg Pro Trp Thr Phe Gly Gly Gly Thr
225 230 235 240
Lys Leu Glu Ile Lys Pro Gly Gly Gly Gly Asp Lys Thr His Thr Cys
245 250 255
Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
260 265 270
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
275 280 285
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
290 295 300
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
305 310 315 320
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
325 330 335
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
340 345 350
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
355 360 365
Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu
370 375 380
Leu Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr
385 390 395 400
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
405 410 415
Asn Tyr Asp Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
420 425 430
Leu Tyr Ser Asp Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
435 440 445
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn Arg Tyr Thr
450 455 460
Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Ser Gly Gly Ser Ala Pro
465 470 475 480
Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala Leu Leu
485 490 495
Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys Asn Pro
500 505 510
Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys Lys Ala
515 520 525
Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys Arg Leu
530 535 540
Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu Arg Pro
545 550 555 560
Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu Lys Gly
565 570 575
Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala Thr Ile
580 585 590
Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile Ile Ser
595 600 605
Thr Leu Thr
610
<210> 93
<211> 474
<212> PRT
<213> 人工序列
<220>
<223> 合成的: NKp46-scFv xELL-臼状 Fc
<400> 93
Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
Val Ile Asn Trp Gly Lys Gln Arg Ser Gly Gln Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Tyr Pro Gly Ser Gly Thr Asn Tyr Tyr Asn Glu Lys Phe
50 55 60
Lys Ala Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Asn Ile Ala Tyr
65 70 75 80
Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
85 90 95
Ala Arg Arg Gly Arg Tyr Gly Leu Tyr Ala Met Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Ser Val Thr Val Ser Ser Val Glu Gly Gly Ser Gly Gly Ser
115 120 125
Gly Gly Ser Gly Gly Ser Gly Gly Val Asp Asp Ile Gln Met Thr Gln
130 135 140
Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser
145 150 155 160
Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln
165 170 175
Lys Pro Asp Gly Thr Val Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu
180 185 190
His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
195 200 205
Tyr Ser Leu Thr Ile Asn Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr
210 215 220
Phe Cys Gln Gln Gly Asn Thr Arg Pro Trp Thr Phe Gly Gly Gly Thr
225 230 235 240
Lys Leu Glu Ile Lys Pro Gly Gly Gly Gly Asp Lys Thr His Thr Cys
245 250 255
Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
260 265 270
Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
275 280 285
Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
290 295 300
Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
305 310 315 320
Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
325 330 335
His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
340 345 350
Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
355 360 365
Gln Pro Arg Glu Pro Gln Val Cys Thr Leu Pro Pro Ser Arg Asp Lys
370 375 380
Leu Thr Lys Asn Gln Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr
385 390 395 400
Pro Ser Asp Ile Ala Val Glu Trp Lys Ser Asn Gly Gln Pro Glu Asn
405 410 415
Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Lys Gly Ser Phe Phe
420 425 430
Leu Val Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
435 440 445
Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
450 455 460
Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
465 470
<210> 94
<211> 477
<212> PRT
<213> 人工序列
<220>
<223> 合成的: NKp46-scFv xELL-Fc
<400> 94
Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Met Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
Val Ile Asn Trp Gly Lys Gln Arg Ser Gly Gln Gly Leu Glu Trp Ile
35 40 45
Gly Glu Ile Tyr Pro Gly Ser Gly Thr Asn Tyr Tyr Asn Glu Lys Phe
50 55 60
Lys Ala Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Asn Ile Ala Tyr
65 70 75 80
Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
85 90 95
Ala Arg Arg Gly Arg Tyr Gly Leu Tyr Ala Met Asp Tyr Trp Gly Gln
100 105 110
Gly Thr Ser Val Thr Val Ser Ser Val Glu Gly Gly Ser Gly Gly Ser
115 120 125
Gly Gly Ser Gly Gly Ser Gly Gly Val Asp Asp Ile Gln Met Thr Gln
130 135 140
Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly Asp Arg Val Thr Ile Ser
145 150 155 160
Cys Arg Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn Trp Tyr Gln Gln
165 170 175
Lys Pro Asp Gly Thr Val Lys Leu Leu Ile Tyr Tyr Thr Ser Arg Leu
180 185 190
His Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp
195 200 205
Tyr Ser Leu Thr Ile Asn Asn Leu Glu Gln Glu Asp Ile Ala Thr Tyr
210 215 220
Phe Cys Gln Gln Gly Asn Thr Arg Pro Trp Thr Phe Gly Gly Gly Thr
225 230 235 240
Lys Leu Glu Ile Lys Pro Gly Gly Gly Gly Asp Lys Thr His Thr Cys
245 250 255
Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu
260 265 270
Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
275 280 285
Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys
290 295 300
Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
305 310 315 320
Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
325 330 335
Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
340 345 350
Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
355 360 365
Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
370 375 380
Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
385 390 395 400
Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
405 410 415
Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
420 425 430
Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
435 440 445
Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
450 455 460
His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
465 470 475
<210> 95
<211> 587
<212> PRT
<213> 人工序列
<220>
<223> 合成的: LAG3-MAb xELL-杵状 Fc-IL-2-RAS-TGCS
<400> 95
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Asn Ala Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Ile Tyr Asp Ser Ser Asp Gln Leu Asn Val Trp Gly Gln
100 105 110
Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125
Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
130 135 140
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
145 150 155 160
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170 175
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190
Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
195 200 205
Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp
210 215 220
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
260 265 270
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu
355 360 365
Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
435 440 445
Gly Gly Ser Gly Gly Ser Ala Pro Gly Ser Ser Ser Thr Lys Lys Thr
450 455 460
Gln Leu Gln Leu Glu Ala Leu Leu Leu Asp Leu Gln Met Ile Leu Asn
465 470 475 480
Gly Ile Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr Phe
485 490 495
Lys Phe Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln Cys
500 505 510
Leu Glu Glu Glu Leu Lys Arg Leu Glu Glu Val Leu Asn Leu Ala Gln
515 520 525
Ser Lys Asn Phe His Leu Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn
530 535 540
Val Ile Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys Glu
545 550 555 560
Tyr Ala Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp Ile
565 570 575
Thr Phe Ser Gln Ser Ile Ile Ser Thr Leu Thr
580 585
<210> 96
<211> 447
<212> PRT
<213> 人工序列
<220>
<223> 合成的: LAG3-MAb xELL-臼状 Fc
<400> 96
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Asn Ala Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Ile Tyr Asp Ser Ser Asp Gln Leu Asn Val Trp Gly Gln
100 105 110
Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125
Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
130 135 140
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
145 150 155 160
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170 175
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190
Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
195 200 205
Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp
210 215 220
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser Val
225 230 235 240
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Arg Ser Arg Thr
245 250 255
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
260 265 270
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
290 295 300
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile
325 330 335
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Cys Thr Leu Pro
340 345 350
Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Ser Cys Ala
355 360 365
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400
Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val Asp Lys Ser Arg
405 410 415
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440 445
<210> 97
<211> 214
<212> PRT
<213> 人工序列
<220>
<223> 合成的: LAG3-MAb轻链
<400> 97
Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly
1 5 10 15
Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Tyr
20 25 30
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45
Tyr Asp Ala Ser Asn Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Glu Pro
65 70 75 80
Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ala Ser Ile Trp Pro Leu
85 90 95
Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala
100 105 110
Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly
115 120 125
Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala
130 135 140
Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln
145 150 155 160
Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser
165 170 175
Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr
180 185 190
Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser
195 200 205
Phe Asn Arg Gly Glu Cys
210
<210> 98
<211> 450
<212> PRT
<213> 人工序列
<220>
<223> 合成的: LAG3-MAb IgG1
<400> 98
Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr
20 25 30
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
35 40 45
Gly Trp Ile Asn Ala Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe
50 55 60
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr
65 70 75 80
Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Arg Asp Ile Tyr Asp Ser Ser Asp Gln Leu Asn Val Trp Gly Gln
100 105 110
Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val
115 120 125
Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala
130 135 140
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser
145 150 155 160
Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
165 170 175
Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro
180 185 190
Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
195 200 205
Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp
210 215 220
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly
225 230 235 240
Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile
245 250 255
Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu
260 265 270
Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His
275 280 285
Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg
290 295 300
Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys
305 310 315 320
Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu
325 330 335
Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr
340 345 350
Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu
355 360 365
Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp
370 375 380
Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val
385 390 395 400
Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp
405 410 415
Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His
420 425 430
Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro
435 440 445
Gly Lys
450
<210> 99
<211> 492
<212> PRT
<213> 人工序列
<220>
<223> 合成的: LAG3-VHH xELL-杵状 Fc-IL-2-RAS-TGCS
<400> 99
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Trp Gln Pro Gly Gly Ser
1 5 10 15
Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Asp Tyr Val
20 25 30
Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala
35 40 45
Ala Ile Ser Glu Ser Gly Gly Arg Thr His Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Leu Tyr Tyr Cys Ala
85 90 95
Thr Thr Leu Leu Trp Trp Thr Ser Glu Tyr Ala Pro Ile Lys Ala Asn
100 105 110
Asp Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Lys Pro Gly
115 120 125
Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly
130 135 140
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
145 150 155 160
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
165 170 175
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
180 185 190
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
195 200 205
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
210 215 220
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
225 230 235 240
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
245 250 255
Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
260 265 270
Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
275 280 285
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
290 295 300
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
305 310 315 320
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
325 330 335
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
340 345 350
Pro Gly Gly Ser Gly Gly Ser Ala Pro Gly Ser Ser Ser Thr Lys Lys
355 360 365
Thr Gln Leu Gln Leu Glu Ala Leu Leu Leu Asp Leu Gln Met Ile Leu
370 375 380
Asn Gly Ile Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr
385 390 395 400
Phe Lys Phe Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln
405 410 415
Cys Leu Glu Glu Glu Leu Lys Arg Leu Glu Glu Val Leu Asn Leu Ala
420 425 430
Gln Ser Lys Asn Phe His Leu Arg Pro Arg Ser Leu Ile Ser Asn Ile
435 440 445
Asn Val Ile Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys
450 455 460
Glu Tyr Ala Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp
465 470 475 480
Ile Thr Phe Ser Gln Ser Ile Ile Ser Thr Leu Thr
485 490
<210> 100
<211> 355
<212> PRT
<213> 人工序列
<220>
<223> 合成的: LAG3-VHH xELL-臼状 T366S, L368A, Y407V, H435R Fc
<400> 100
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Trp Gln Pro Gly Gly Ser
1 5 10 15
Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Asp Tyr Val
20 25 30
Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala
35 40 45
Ala Ile Ser Glu Ser Gly Gly Arg Thr His Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Leu Tyr Tyr Cys Ala
85 90 95
Thr Thr Leu Leu Trp Trp Thr Ser Glu Tyr Ala Pro Ile Lys Ala Asn
100 105 110
Asp Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Lys Pro Gly
115 120 125
Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly
130 135 140
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
145 150 155 160
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
165 170 175
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
180 185 190
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
195 200 205
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
210 215 220
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
225 230 235 240
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
245 250 255
Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
260 265 270
Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
275 280 285
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
290 295 300
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val
305 310 315 320
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
325 330 335
His Glu Ala Leu His Asn Arg Tyr Thr Gln Lys Ser Leu Ser Leu Ser
340 345 350
Pro Gly Lys
355
<210> 101
<211> 355
<212> PRT
<213> 人工序列
<220>
<223> 合成的: LAG3-VHH xELL-杵状 Fc
<400> 101
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Trp Gln Pro Gly Gly Ser
1 5 10 15
Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Thr Phe Ser Asp Tyr Val
20 25 30
Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val Ala
35 40 45
Ala Ile Ser Glu Ser Gly Gly Arg Thr His Tyr Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Asn Ser Leu Arg Pro Glu Asp Thr Ala Leu Tyr Tyr Cys Ala
85 90 95
Thr Thr Leu Leu Trp Trp Thr Ser Glu Tyr Ala Pro Ile Lys Ala Asn
100 105 110
Asp Tyr Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Lys Pro Gly
115 120 125
Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly
130 135 140
Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
145 150 155 160
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
165 170 175
Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
180 185 190
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
195 200 205
Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
210 215 220
Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
225 230 235 240
Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
245 250 255
Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
260 265 270
Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
275 280 285
Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
290 295 300
Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
305 310 315 320
Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
325 330 335
His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
340 345 350
Pro Gly Lys
355
<210> 102
<211> 361
<212> PRT
<213> 人工序列
<220>
<223> 合成的: xELL-杵状 Fc-IL-2-RAS-M23A-T3A, C125S
<400> 102
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Ser Arg
20 25 30
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
35 40 45
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
50 55 60
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65 70 75 80
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
85 90 95
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
100 105 110
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
115 120 125
Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys
130 135 140
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
180 185 190
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Val His Glu Ala
195 200 205
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly
210 215 220
Ser Gly Gly Ser Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu
225 230 235 240
Gln Leu Glu Ala Leu Leu Leu Asp Leu Gln Ala Ile Leu Asn Gly Ile
245 250 255
Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe
260 265 270
Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu
275 280 285
Glu Glu Leu Lys Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys
290 295 300
Asn Phe His Leu Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile
305 310 315 320
Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala
325 330 335
Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe
340 345 350
Ser Gln Ser Ile Ile Ser Thr Leu Thr
355 360
<210> 103
<211> 361
<212> PRT
<213> 人工序列
<220>
<223> 合成的: xELL-杵状 Fc-IL-2-RAS-E95Q-T3A, C125S
<400> 103
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Ser Arg
20 25 30
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
35 40 45
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
50 55 60
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65 70 75 80
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
85 90 95
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
100 105 110
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
115 120 125
Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys
130 135 140
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
180 185 190
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Val His Glu Ala
195 200 205
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly
210 215 220
Ser Gly Gly Ser Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu
225 230 235 240
Gln Leu Glu Ala Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile
245 250 255
Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe
260 265 270
Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu
275 280 285
Glu Glu Leu Lys Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys
290 295 300
Asn Phe His Leu Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile
305 310 315 320
Val Leu Gln Leu Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala
325 330 335
Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe
340 345 350
Ser Gln Ser Ile Ile Ser Thr Leu Thr
355 360
<210> 104
<211> 361
<212> PRT
<213> 人工序列
<220>
<223> 合成的: xELL-杵状 Fc-IL-2-RAS-M23A-E95Q-T3A, C125S
<400> 104
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Tyr Ile Ser Arg
20 25 30
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
35 40 45
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
50 55 60
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65 70 75 80
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
85 90 95
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
100 105 110
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
115 120 125
Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys
130 135 140
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
180 185 190
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Val His Glu Ala
195 200 205
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly
210 215 220
Ser Gly Gly Ser Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu
225 230 235 240
Gln Leu Glu Ala Leu Leu Leu Asp Leu Gln Ala Ile Leu Asn Gly Ile
245 250 255
Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe
260 265 270
Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu
275 280 285
Glu Glu Leu Lys Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys
290 295 300
Asn Phe His Leu Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile
305 310 315 320
Val Leu Gln Leu Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala
325 330 335
Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe
340 345 350
Ser Gln Ser Ile Ile Ser Thr Leu Thr
355 360
<210> 105
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3G-C125S
<400> 105
Ala Pro Gly Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 106
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-E61R-P65R-C125S
<400> 106
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 107
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-R38A-P65R-C125S
<400> 107
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 108
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-C125S
<400> 108
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 109
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-R38A-P65R-D84S-C125S
<400> 109
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 110
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19A-P65R-D84S-C125S
<400> 110
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Ala Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 111
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-P65R-D84S-N88S-C125S
<400> 111
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Ser Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 112
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-P65R-D84S-E95Q-C125S
<400> 112
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 113
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23A-P65R-D84S-C125S
<400> 113
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 114
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23A-P65R-D84S-E95Q-C125S
<400> 114
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 115
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19A-E61R-P65R-D84S-C125S
<400> 115
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Ala Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 116
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23A-E61R-P65R-D84S-E95Q-C125S
<400> 116
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 117
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23A-E61R-P65R-D84S-N88S-C125S
<400> 117
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Ser Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 118
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-N88S-E95Q-C125S
<400> 118
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Ser Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 119
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23A-E61R-P65R-D84S-N88S-E95Q-C125S
<400> 119
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Ser Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 120
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19A-R38A-P65R-D84S-C125S
<400> 120
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Ala Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 121
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23A-R38A-P65R-D84S-E95Q-C125S
<400> 121
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 122
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23A-R38A-P65R-D84S-N88S-C125S
<400> 122
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Ser Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 123
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-R38A-P65R-D84S-N88S-E95Q-C125S
<400> 123
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Ser Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 124
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23A-R38A-P65R-IL-2-D84S-N88S-E95Q-C125S
<400> 124
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Ser Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 125
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19N-P65R-D84S-C125S
<400> 125
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Asn Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 126
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19S-P65R-D84S-C125S
<400> 126
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Ser Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 127
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19T-P65R-D84S-C125S
<400> 127
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Thr Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 128
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19V-P65R-D84S-C125S
<400> 128
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Val Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 129
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19N-M23A-E61R-P65R-D84S-E95Q-C125S
<400> 129
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Asn Asp Leu Gln Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Gln Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 130
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19N-M23A-R38A-P65R-D84S-E95Q-C125S
<400> 130
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Asn Asp Leu Gln Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 131
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19N-M23A-R38A-P65R-D84S-C125S
<400> 131
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Asn Asp Leu Gln Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 132
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19N-R38A-P65R-D84S-E95Q-C125S
<400> 132
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Asn Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 133
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19N-R38A-P65R-D84S-C125S
<400> 133
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Asn Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 134
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19N-E61R-P65R-D84S-C125S
<400> 134
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Asn Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 135
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19N-E61R-P65R-D84S-E95Q-C125S
<400> 135
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Asn Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 136
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19N-M23A-E61R-P65R-D84S-C125S
<400> 136
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Asn Asp Leu Gln Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 137
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19N-Q22A-E61R-P65R-D84S-C125S
<400> 137
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Asn Asp Leu Ala Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 138
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19N-E61R-P65R-D84S-R120A-C125S
<400> 138
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Asn Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Ala Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 139
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19N-E61R-P65R-D84S-C125S-Q126A
<400> 139
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Asn Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Ala Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 140
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16S-L19N-E61R-P65R-D84S-C125S
<400> 140
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ser
1 5 10 15
Leu Leu Asn Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 141
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16T-L19N-E61R-P65R-D84S-C125S
<400> 141
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Thr
1 5 10 15
Leu Leu Asn Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 142
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16V-L19N-E61R-P65R-D84S-C125S
<400> 142
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Val
1 5 10 15
Leu Leu Asn Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 143
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16N-L19N-E61R-P65R-D84S-C125S
<400> 143
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Asn
1 5 10 15
Leu Leu Asn Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 144
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19N-E61R-P65R-D84T-C125S
<400> 144
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Asn Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Thr Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 145
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19N-E61R-P65R-D84V-C125S
<400> 145
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Asn Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Val Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 146
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-D20S-E61R-P65R-D84S-C125S
<400> 146
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Ser Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 147
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-D20T-E61R-P65R-D84S-C125S
<400> 147
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Thr Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 148
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-D20N-E61R-P65R-D84S-C125S
<400> 148
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asn Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 149
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-D20A-E61R-P65R-D84S-C125S
<400> 149
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Ala Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 150
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19N-E61R-P65R-D84N-C125S
<400> 150
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Asn Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asn Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 151
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-N88T-C125S
<400> 151
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Thr Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 152
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-N88A-C125S
<400> 152
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Ala Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 153
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16P-L19A-E61R-P65R-D84S-C125S
<400> 153
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Pro
1 5 10 15
Leu Leu Ala Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 154
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19H-E61R-P65R-D84S-C125S
<400> 154
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu His Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 155
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19P-E61R-P65R-D84S-C125S
<400> 155
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Pro Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 156
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19Q-E61R-P65R-D84S-C125S
<400> 156
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Gln Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 157
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19Y-E61R-P65R-D84S-C125S
<400> 157
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Tyr Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 158
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19A-E61R-P65R-D84P-C125S
<400> 158
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Ala Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Pro Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 159
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19A-E61R-P65R-D84V-C125S
<400> 159
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Ala Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Val Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 160
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19A-E61R-P65R-D84Y-C125S
<400> 160
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Ala Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Tyr Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 161
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23A-E61R-P65R-D84S-E95H-C125S
<400> 161
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu His Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 162
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23A-E61R-P65R-D84S-E95N-C125S
<400> 162
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Asn Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 163
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23A-E61R-P65R-D84S-E95P-C125S
<400> 163
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Pro Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 164
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23A-E61R-P65R-D84S-E95S-C125S
<400> 164
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Ser Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 165
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23A-E61R-P65R-D84S-E95T-C125S
<400> 165
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Thr Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 166
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23A-E61R-P65R-D84S-E95V-C125S
<400> 166
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Val Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 167
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23A-E61R-P65R-D84S-E95Y-C125S
<400> 167
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Tyr Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 168
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19A-E61A-P65R-D84S-C125S
<400> 168
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Ala Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Ala Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 169
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19A-E61G-P65R-D84S-C125S
<400> 169
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Ala Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Gly Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 170
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19A-E61H-P65R-D84S-C125S
<400> 170
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Ala Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu His Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 171
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19A-E61N-P65R-D84S-C125S
<400> 171
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Ala Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Asn Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 172
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19A-E61P-P65R-D84S-C125S
<400> 172
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Ala Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Pro Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 173
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19A-E61Q-P65R-D84S-C125S
<400> 173
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Ala Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Gln Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 174
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19A-E61S-P65R-D84S-C125S
<400> 174
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Ala Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Ser Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 175
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19A-E61T-P65R-D84S-C125S
<400> 175
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Ala Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Thr Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 176
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19A-E61V-P65R-D84S-C125S
<400> 176
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Ala Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Val Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 177
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19A-E61Y-P65R-D84S-C125S
<400> 177
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Ala Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Tyr Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 178
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23D-E61R-P65R-D84S-E95Q-C125S
<400> 178
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Asp Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 179
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23E-E61R-P65R-D84S-E95Q-C125S
<400> 179
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Glu Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 180
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23G-E61R-P65R-D84S-E95Q-C125S
<400> 180
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Gly Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 181
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23I-E61R-P65R-D84S-E95Q-C125S
<400> 181
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Ile Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 182
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23K-E61R-P65R-D84S-E95Q-C125S
<400> 182
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Lys Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 183
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23L-E61R-P65R-D84S-E95Q-C125S
<400> 183
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Leu Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 184
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23N-E61R-P65R-D84S-E95Q-C125S
<400> 184
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Asn Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 185
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23P-E61R-P65R-D84S-E95Q-C125S
<400> 185
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Pro Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 186
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23Q-E61R-P65R-D84S-E95Q-C125S
<400> 186
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Gln Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 187
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23R-E61R-P65R-D84S-E95Q-C125S
<400> 187
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Arg Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 188
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23T-E61R-P65R-D84S-E95Q-C125S
<400> 188
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Thr Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 189
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23V-E61R-P65R-D84S-E95Q-C125S
<400> 189
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Val Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 190
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-Q22A-E61R-P65R-D84S-C125S
<400> 190
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Ala Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 191
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-Q22D-E61R-P65R-D84S-C125S
<400> 191
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Asp Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 192
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-Q22E-E61R-P65R-D84S-C125S
<400> 192
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Glu Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 193
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-Q22G-E61R-P65R-D84S-C125S
<400> 193
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gly Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 194
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-Q22H-E61R-P65R-D84S-C125S
<400> 194
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu His Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 195
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-Q22K-E61R-P65R-D84S-C125S
<400> 195
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Lys Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 196
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-Q22N-E61R-P65R-D84S-C125S
<400> 196
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Asn Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 197
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-Q22P-E61R-P65R-D84S-C125S
<400> 197
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Pro Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 198
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-Q22R-E61R-P65R-D84S-C125S
<400> 198
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Arg Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 199
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-Q22S-E61R-P65R-D84S-C125S
<400> 199
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Ser Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 200
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-Q22T-E61R-P65R-D84S-C125S
<400> 200
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Thr Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 201
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-Q22V-E61R-P65R-D84S-C125S
<400> 201
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Val Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 202
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-Q22Y-E61R-P65R-D84S-C125S
<400> 202
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Tyr Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 203
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-R120A-C125S
<400> 203
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Ala Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 204
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-R120D-C125S
<400> 204
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Asp Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 205
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-R120E-C125S
<400> 205
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Glu Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 206
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-R120F-C125S
<400> 206
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Phe Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 207
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-R120G-C125S
<400> 207
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Gly Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 208
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-R120H-C125S
<400> 208
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn His Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 209
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-R120K-C125S
<400> 209
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Lys Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 210
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-R120N-C125S
<400> 210
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Asn Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 211
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-R120P-C125S
<400> 211
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Pro Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 212
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-R120Q-C125S
<400> 212
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Gln Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 213
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-R120S-C125S
<400> 213
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Ser Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 214
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-R120T-C125S
<400> 214
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Thr Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 215
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-R120V-C125S
<400> 215
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Val Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 216
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-R120Y-C125S
<400> 216
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Tyr Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 217
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-T123D-C125S
<400> 217
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Asp Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 218
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-T123E-C125S
<400> 218
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Glu Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 219
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-T123H-C125S
<400> 219
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile His Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 220
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-T123K-C125S
<400> 220
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Lys Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 221
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-T123N-C125S
<400> 221
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Asn Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 222
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-T123Q-C125S
<400> 222
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Gln Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 223
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-T123R-C125S
<400> 223
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Arg Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 224
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-C125S-S130D
<400> 224
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Asp Thr Leu Thr
130
<210> 225
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-C125S-S130E
<400> 225
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Glu Thr Leu Thr
130
<210> 226
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-C125S-S130K
<400> 226
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Lys Thr Leu Thr
130
<210> 227
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-C125S-S130N
<400> 227
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Asn Thr Leu Thr
130
<210> 228
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-C125S-S130Q
<400> 228
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Gln Thr Leu Thr
130
<210> 229
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-C125S-S130R
<400> 229
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Arg Thr Leu Thr
130
<210> 230
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-C125S-S127D
<400> 230
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Asp Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 231
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-C125S-S127E
<400> 231
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Glu Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 232
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-C125S-S127H
<400> 232
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln His Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 233
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-C125S-S127P
<400> 233
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Pro Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 234
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-C125S-S127Q
<400> 234
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Gln Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 235
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-C125S-S127R
<400> 235
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Arg Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 236
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19A-Q22A-R38A-P65R-D84S-C125S
<400> 236
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Ala Asp Leu Ala Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 237
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19A-R38A-P65R-D84S-R120A-C125S
<400> 237
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Ala Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Ala Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 238
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19A-Q22A-R38A-P65R-D84S-R120A-C125S
<400> 238
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Ala Asp Leu Ala Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Ala Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 239
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-Q22A-M23A-R38A-P65R-D84S-E95Q-C125S
<400> 239
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Ala Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 240
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23A-R38A-P65R-D84S-E95Q-R120A-C125S
<400> 240
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Ala Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 241
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的:
IL-2-T3A-H16A-Q22A-M23A-R38A-P65R-D84S-E95Q-R120A-C125S
<400> 241
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Ala Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Ala Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 242
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19N-Q22A-R38A-P65R-D84S-C125S
<400> 242
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Asn Asp Leu Ala Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 243
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19N-R38A-P65R-D84S-R120A-C125S
<400> 243
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Asn Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Ala Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 244
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19N-Q22A-R38A-P65R-D84S-R120A-C125S
<400> 244
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Asn Asp Leu Ala Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Ala Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 245
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的:
IL-2-A1G-P2G-T3S-S4G-S5G-H16A-L19A-R38A-P65R-D84S-C125S
<400> 245
Gly Gly Ser Gly Gly Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Ala Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 246
<211> 128
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-del1-5-H16A-L19A-R38A-P65R-D84S-C125S
<400> 246
Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala Leu Leu Ala Asp Leu
1 5 10 15
Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys Asn Pro Lys Leu Thr
20 25 30
Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys Lys Ala Thr Glu Leu
35 40 45
Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys Arg Leu Glu Glu Val
50 55 60
Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu Arg Pro Arg Ser Leu
65 70 75 80
Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu Lys Gly Ser Glu Thr
85 90 95
Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala Thr Ile Val Glu Phe
100 105 110
Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile Ile Ser Thr Leu Thr
115 120 125
<210> 247
<211> 128
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-del1-5-H16A-L19A-R38A-P65R-D84S-C125V
<400> 247
Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala Leu Leu Ala Asp Leu
1 5 10 15
Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys Asn Pro Lys Leu Thr
20 25 30
Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys Lys Ala Thr Glu Leu
35 40 45
Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys Arg Leu Glu Glu Val
50 55 60
Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu Arg Pro Arg Ser Leu
65 70 75 80
Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu Lys Gly Ser Glu Thr
85 90 95
Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala Thr Ile Val Glu Phe
100 105 110
Leu Asn Arg Trp Ile Thr Phe Val Gln Ser Ile Ile Ser Thr Leu Thr
115 120 125
<210> 248
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-L19N-R38A-P65R-D84S-C125S
<400> 248
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Asn Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 249
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19N-R38A-P65R-C125S
<400> 249
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Asn Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 250
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-L19N-Q22A-R38A-P65R-D84S-C125S
<400> 250
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Asn Asp Leu Ala Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 251
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19N-Q22A-R38A-P65R-C125S
<400> 251
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Asn Asp Leu Ala Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 252
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-L19N-Q22A-R38A-P65R-D84S-R120A-C125S
<400> 252
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Asn Asp Leu Ala Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Ala Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 253
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19N-Q22A-R38A-P65R-R120A-C125S
<400> 253
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Asn Asp Leu Ala Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Ala Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 254
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-Q22A-M23A-R38A-P65R-D84S-E95Q-C125S
<400> 254
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Ala Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 255
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-Q22A-M23A-R38A-P65R-E95Q-C125S
<400> 255
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Ala Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 256
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-Q22A-M23A-R38A-P65R-D84S-E95Q-R120A-C125S
<400> 256
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Ala Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Ala Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 257
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-Q22A-M23A-R38A-P65R-E95Q-R120A-C125S
<400> 257
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Ala Ala Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Ala Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 258
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-L19A-Q22A-R38A-P65R-D84S-C125S
<400> 258
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Ala Asp Leu Ala Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 259
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19A-Q22A-R38A-P65R-C125S
<400> 259
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Ala Asp Leu Ala Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 260
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-L19A-Q22A-R38A-P65R-D84S-R120A-C125S
<400> 260
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Ala Asp Leu Ala Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Ala Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 261
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19A-Q22A-R38A-P65R-R120A-C125S
<400> 261
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Ala Asp Leu Ala Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Ala Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 262
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-C125S-I129A
<400> 262
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ala Ser Thr Leu Thr
130
<210> 263
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-C125S-I129H
<400> 263
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
His Ser Thr Leu Thr
130
<210> 264
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-C125S-I129R
<400> 264
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Arg Ser Thr Leu Thr
130
<210> 265
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-C125S-I129S
<400> 265
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ser Ser Thr Leu Thr
130
<210> 266
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-C125C-Q126N
<400> 266
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Asn Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 267
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-C125C-Q126Y
<400> 267
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Tyr Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 268
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-C125C-S127N
<400> 268
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Asn Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 269
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84S-C125C-S130P
<400> 269
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Pro Thr Leu Thr
130
<210> 270
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84Y-C125S
<400> 270
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Tyr Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 271
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23T-E61R-P65R-D84Y-E95Q-C125S
<400> 271
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Thr Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Tyr Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 272
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19N-E61R-P65R-D84Y-C125S
<400> 272
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Asn Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Tyr Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 273
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19N-M23T-E61R-P65R-D84Y-E95Q-C125S
<400> 273
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Asn Asp Leu Gln Thr Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Tyr Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 274
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-E61R-P65R-D84Y-C125S-S127D
<400> 274
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Tyr Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Asp Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 275
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-M23T-E61R-P65R-D84Y-E95Q-C125S-S127D
<400> 275
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Thr Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Tyr Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Asp Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 276
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-L19N-E61R-P65R-D84Y-C125S-S127D
<400> 276
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Asn Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Tyr Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Asp Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 277
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的:
IL-2-T3A-H16A-L19N-M23T-E61R-P65R-D84Y-E95Q-C125S-S127D
<400> 277
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Asn Asp Leu Gln Thr Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Tyr Leu Ile Ser Asn Ile Asn Val Ile Val Leu Gln Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Asp Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 278
<211> 132
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-delta-F42-P65R-D84S-C125S
<400> 278
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Lys Phe Tyr Met Pro Lys Lys
35 40 45
Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys Arg
50 55 60
Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu Arg
65 70 75 80
Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu Lys
85 90 95
Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala Thr
100 105 110
Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile Ile
115 120 125
Ser Thr Leu Thr
130
<210> 279
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-K43E-Y45R-P65R-D84S-C125S
<400> 279
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Glu Phe Arg Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 280
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-K43E-P65R-D84S-C125S
<400> 280
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Glu Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 281
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-P65R-D84S-I114F-C125S
<400> 281
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Phe Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 282
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-H16A-F42R-P65R-D84S-C125S
<400> 282
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Arg Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 283
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-K43E-Y45R-C125S
<400> 283
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Glu Phe Arg Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 284
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-E61R-C125S
<400> 284
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 285
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-I114F-C125S
<400> 285
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Phe Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 286
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-K43E-C125S
<400> 286
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Glu Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 287
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-P65R-I114F-C125S
<400> 287
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Phe Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 288
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-K43E-P65R-C125S
<400> 288
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Glu Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 289
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-K43E-Y45R-P65R-C125S
<400> 289
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Glu Phe Arg Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 290
<211> 133
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-2-T3A-R38A-C125S
<400> 290
Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu His
1 5 10 15
Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys
20 25 30
Asn Pro Lys Leu Thr Ala Met Leu Thr Phe Lys Phe Tyr Met Pro Lys
35 40 45
Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Glu Glu Leu Lys
50 55 60
Pro Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu
65 70 75 80
Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu
85 90 95
Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala
100 105 110
Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile
115 120 125
Ile Ser Thr Leu Thr
130
<210> 291
<211> 115
<212> PRT
<213> 人工序列
<220>
<223> 合成的: IL-15 WT
<400> 291
Met Asn Trp Val Asn Val Ile Ser Asp Leu Lys Lys Ile Glu Asp Leu
1 5 10 15
Ile Gln Ser Met His Ile Asp Ala Thr Leu Tyr Thr Glu Ser Asp Val
20 25 30
His Pro Ser Cys Lys Val Thr Ala Met Lys Cys Phe Leu Leu Glu Leu
35 40 45
Gln Val Ile Ser Leu Glu Ser Gly Asp Ala Ser Ile His Asp Thr Val
50 55 60
Glu Asn Leu Ile Ile Leu Ala Asn Asn Ser Leu Ser Ser Asn Gly Asn
65 70 75 80
Val Thr Glu Ser Gly Cys Lys Glu Cys Glu Glu Leu Glu Glu Lys Asn
85 90 95
Ile Lys Glu Phe Leu Gln Ser Phe Val His Ile Val Gln Met Phe Ile
100 105 110
Asn Thr Ser
115
<210> 292
<211> 223
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 xELL P329G 杵状结构
<400> 292
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
20 25 30
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
35 40 45
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
50 55 60
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65 70 75 80
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
85 90 95
Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro Ile Glu Lys Thr
100 105 110
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
115 120 125
Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys
130 135 140
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
180 185 190
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
195 200 205
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
210 215 220
<210> 293
<211> 223
<212> PRT
<213> 人工序列
<220>
<223> 合成的: Fc区 xELL P329G, H435R 臼状结构
<400> 293
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
20 25 30
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
35 40 45
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
50 55 60
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65 70 75 80
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
85 90 95
Lys Cys Lys Val Ser Asn Lys Ala Leu Gly Ala Pro Ile Glu Lys Thr
100 105 110
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Cys Thr Leu
115 120 125
Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Ser Cys
130 135 140
Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175
Ser Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val Asp Lys Ser
180 185 190
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
195 200 205
Leu His Asn Arg Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly
210 215 220
<210> 294
<211> 361
<212> PRT
<213> 人工序列
<220>
<223> 合成的: xELL-杵状 Fc IL-2-RAS-T3G, C125S
<400> 294
Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser
1 5 10 15
Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg
20 25 30
Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro
35 40 45
Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala
50 55 60
Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val
65 70 75 80
Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr
85 90 95
Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr
100 105 110
Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu
115 120 125
Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys
130 135 140
Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser
145 150 155 160
Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp
165 170 175
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser
180 185 190
Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala
195 200 205
Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly
210 215 220
Ser Gly Gly Ser Ala Pro Gly Ser Ser Ser Thr Lys Lys Thr Gln Leu
225 230 235 240
Gln Leu Glu Ala Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile
245 250 255
Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe
260 265 270
Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu
275 280 285
Glu Glu Leu Lys Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys
290 295 300
Asn Phe His Leu Arg Pro Arg Ser Leu Ile Ser Asn Ile Asn Val Ile
305 310 315 320
Val Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala
325 330 335
Asp Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe
340 345 350
Ser Gln Ser Ile Ile Ser Thr Leu Thr
355 360
<210> 295
<211> 358
<212> PRT
<213> 人工序列
<220>
<223> 合成的: gdTCR 5C8 VHH-xELL- 臼状 T366S, L368A, Y407V, H435R Fc
<400> 295
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Pro Phe Ser Asn Tyr
20 25 30
Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val
35 40 45
Ala Ala Ile Ser Trp Ser Gly Gly Ser Thr Ser Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr
65 70 75 80
Leu Gln Met Asn Ser Pro Lys Pro Glu Asp Thr Ala Ile Tyr Tyr Cys
85 90 95
Ala Ala Gln Phe Ser Gly Ala Asp Tyr Gly Phe Gly Arg Leu Gly Ile
100 105 110
Arg Gly Tyr Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val
115 120 125
Lys Pro Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro
130 135 140
Ala Pro Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
145 150 155 160
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
165 170 175
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
180 185 190
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
195 200 205
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
210 215 220
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
225 230 235 240
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
245 250 255
Pro Gln Val Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn
260 265 270
Gln Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile
275 280 285
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
290 295 300
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys
305 310 315 320
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
325 330 335
Ser Val Met His Glu Ala Leu His Asn Arg Tyr Thr Gln Lys Ser Leu
340 345 350
Ser Leu Ser Pro Gly Lys
355
<210> 296
<211> 495
<212> PRT
<213> 人工序列
<220>
<223> 合成的: gdTCR 5C8 VHH-xELL-杵状 Fc-IL-2-T3A-H16A-
E61R-P65R-D84Y-C125S
<400> 296
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Arg Pro Phe Ser Asn Tyr
20 25 30
Ala Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val
35 40 45
Ala Ala Ile Ser Trp Ser Gly Gly Ser Thr Ser Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Tyr
65 70 75 80
Leu Gln Met Asn Ser Pro Lys Pro Glu Asp Thr Ala Ile Tyr Tyr Cys
85 90 95
Ala Ala Gln Phe Ser Gly Ala Asp Tyr Gly Phe Gly Arg Leu Gly Ile
100 105 110
Arg Gly Tyr Glu Tyr Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val
115 120 125
Lys Pro Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro Pro Cys Pro
130 135 140
Ala Pro Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
145 150 155 160
Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp
165 170 175
Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly
180 185 190
Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn
195 200 205
Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp
210 215 220
Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro
225 230 235 240
Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu
245 250 255
Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu Thr Lys Asn
260 265 270
Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
275 280 285
Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr
290 295 300
Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
305 310 315 320
Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys
325 330 335
Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu
340 345 350
Ser Leu Ser Pro Gly Gly Ser Gly Gly Ser Ala Pro Ala Ser Ser Ser
355 360 365
Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala Leu Leu Leu Asp Leu Gln
370 375 380
Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg
385 390 395 400
Met Leu Thr Phe Lys Phe Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys
405 410 415
His Leu Gln Cys Leu Glu Arg Glu Leu Lys Arg Leu Glu Glu Val Leu
420 425 430
Asn Leu Ala Gln Ser Lys Asn Phe His Leu Arg Pro Arg Tyr Leu Ile
435 440 445
Ser Asn Ile Asn Val Ile Val Leu Glu Leu Lys Gly Ser Glu Thr Thr
450 455 460
Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala Thr Ile Val Glu Phe Leu
465 470 475 480
Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile Ile Ser Thr Leu Thr
485 490 495
<210> 297
<400> 297
000
<210> 298
<211> 488
<212> PRT
<213> 人工序列
<220>
<223> 合成的: gdTCR 6C4 VHH-xELL-杵状 Fc-IL-2- T3A-H16A-
E61R-P65R-D84Y-C125S
<400> 298
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Val Ser Val Arg Thr Phe Ser Asp Tyr
20 25 30
Arg Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val
35 40 45
Ser Thr Ile Ser Trp Ser Gly Gly Leu Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Ala Gly Gly Gly Tyr Ala Gly Gly Thr Tyr Tyr His Pro Glu Glu
100 105 110
Trp Gly Gln Gly Thr Gln Val Thr Val Lys Pro Gly Gly Gly Gly Asp
115 120 125
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser Val
130 135 140
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
145 150 155 160
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
165 170 175
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
180 185 190
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
195 200 205
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
210 215 220
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile
225 230 235 240
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
245 250 255
Pro Cys Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Trp Cys Leu
260 265 270
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
275 280 285
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
290 295 300
Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
305 310 315 320
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
325 330 335
His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Gly Ser
340 345 350
Gly Gly Ser Ala Pro Ala Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln
355 360 365
Leu Glu Ala Leu Leu Leu Asp Leu Gln Met Ile Leu Asn Gly Ile Asn
370 375 380
Asn Tyr Lys Asn Pro Lys Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr
385 390 395 400
Met Pro Lys Lys Ala Thr Glu Leu Lys His Leu Gln Cys Leu Glu Arg
405 410 415
Glu Leu Lys Arg Leu Glu Glu Val Leu Asn Leu Ala Gln Ser Lys Asn
420 425 430
Phe His Leu Arg Pro Arg Tyr Leu Ile Ser Asn Ile Asn Val Ile Val
435 440 445
Leu Glu Leu Lys Gly Ser Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp
450 455 460
Glu Thr Ala Thr Ile Val Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser
465 470 475 480
Gln Ser Ile Ile Ser Thr Leu Thr
485
<210> 299
<211> 351
<212> PRT
<213> 人工序列
<220>
<223> 合成的: gdTCR 6C4 VHH-xELL-臼状 T366S, L368A, Y407V H435R Fc
<400> 299
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Ala Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Val Ser Val Arg Thr Phe Ser Asp Tyr
20 25 30
Arg Met Gly Trp Phe Arg Gln Ala Pro Gly Lys Glu Arg Glu Phe Val
35 40 45
Ser Thr Ile Ser Trp Ser Gly Gly Leu Thr Tyr Tyr Ala Asp Ser Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80
Leu Gln Met Asn Ser Leu Lys Pro Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95
Ala Ala Gly Gly Gly Tyr Ala Gly Gly Thr Tyr Tyr His Pro Glu Glu
100 105 110
Trp Gly Gln Gly Thr Gln Val Thr Val Lys Pro Gly Gly Gly Gly Asp
115 120 125
Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Gly Gly Pro Ser Val
130 135 140
Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
145 150 155 160
Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
165 170 175
Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
180 185 190
Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
195 200 205
Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
210 215 220
Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile
225 230 235 240
Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Cys Thr Leu Pro
245 250 255
Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Ser Cys Ala
260 265 270
Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
275 280 285
Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
290 295 300
Asp Gly Ser Phe Phe Leu Val Ser Lys Leu Thr Val Asp Lys Ser Arg
305 310 315 320
Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
325 330 335
His Asn Arg Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
340 345 350
<210> 300
<211> 345
<212> PRT
<213> 人工序列
<220>
<223> 合成的: 410A9v1(非靶向)VHH-xELL-臼状 T366S, L368A, Y407V
H435R Fc
<400> 300
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Glu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Asn Ser Ile Asn
20 25 30
Val Met Glu Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Asp Leu Val
35 40 45
Ala Gly Ile Thr Ser Asp Gly Asp Thr Asn Tyr Ala Glu Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Arg
85 90 95
Ala Arg Asp Trp Gly Ser Leu Thr Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110
Val Thr Val Lys Pro Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro
115 120 125
Pro Cys Pro Ala Pro Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
130 135 140
Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
145 150 155 160
Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
165 170 175
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
180 185 190
Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
195 200 205
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
210 215 220
Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
225 230 235 240
Pro Arg Glu Pro Gln Val Cys Thr Leu Pro Pro Ser Arg Asp Glu Leu
245 250 255
Thr Lys Asn Gln Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro
260 265 270
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
275 280 285
Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
290 295 300
Val Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
305 310 315 320
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn Arg Tyr Thr Gln
325 330 335
Lys Ser Leu Ser Leu Ser Pro Gly Lys
340 345
<210> 301
<211> 482
<212> PRT
<213> 人工序列
<220>
<223> 合成的: 410A9v1(非靶向)VHH- xELL-杵状 Fc- IL-2-T3A-H16A-
E61R-P65R-D84Y-C125S
<400> 301
Glu Val Gln Leu Val Glu Ser Gly Gly Gly Glu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Ser Ile Asn Ser Ile Asn
20 25 30
Val Met Glu Trp Tyr Arg Gln Ala Pro Gly Lys Glu Arg Asp Leu Val
35 40 45
Ala Gly Ile Thr Ser Asp Gly Asp Thr Asn Tyr Ala Glu Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr Leu
65 70 75 80
Gln Met Ser Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys Arg
85 90 95
Ala Arg Asp Trp Gly Ser Leu Thr Asp Tyr Trp Gly Gln Gly Thr Leu
100 105 110
Val Thr Val Lys Pro Gly Gly Gly Gly Asp Lys Thr His Thr Cys Pro
115 120 125
Pro Cys Pro Ala Pro Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
130 135 140
Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
145 150 155 160
Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr
165 170 175
Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
180 185 190
Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
195 200 205
Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
210 215 220
Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln
225 230 235 240
Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Cys Arg Asp Glu Leu
245 250 255
Thr Lys Asn Gln Val Ser Leu Trp Cys Leu Val Lys Gly Phe Tyr Pro
260 265 270
Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn
275 280 285
Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
290 295 300
Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val
305 310 315 320
Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln
325 330 335
Lys Ser Leu Ser Leu Ser Pro Gly Gly Ser Gly Gly Ser Ala Pro Ala
340 345 350
Ser Ser Ser Thr Lys Lys Thr Gln Leu Gln Leu Glu Ala Leu Leu Leu
355 360 365
Asp Leu Gln Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys Asn Pro Lys
370 375 380
Leu Thr Arg Met Leu Thr Phe Lys Phe Tyr Met Pro Lys Lys Ala Thr
385 390 395 400
Glu Leu Lys His Leu Gln Cys Leu Glu Arg Glu Leu Lys Arg Leu Glu
405 410 415
Glu Val Leu Asn Leu Ala Gln Ser Lys Asn Phe His Leu Arg Pro Arg
420 425 430
Tyr Leu Ile Ser Asn Ile Asn Val Ile Val Leu Glu Leu Lys Gly Ser
435 440 445
Glu Thr Thr Phe Met Cys Glu Tyr Ala Asp Glu Thr Ala Thr Ile Val
450 455 460
Glu Phe Leu Asn Arg Trp Ile Thr Phe Ser Gln Ser Ile Ile Ser Thr
465 470 475 480
Leu Thr
Claims (188)
1.一种包含修饰的IL-2的多肽,其中所述修饰的IL-2包含D84Y取代。
2.根据权利要求1所述的多肽,其中相比于野生型IL-2,所述修饰的IL-2具有降低的对CD122的亲和力。
3.根据权利要求1-2中任一项所述的多肽,其中所述修饰的IL-2在至少一个选自H16、L19、M23、N88和E95的氨基酸位置处包含至少一个取代。
4.根据权利要求3所述的多肽,其中所述修饰的IL-2在氨基酸位置H16处包含取代。
5.根据权利要求4所述的多肽,其中所述取代选自H16A、H16N、H16V和H16T。
6.根据权利要求1-5中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置L19处包含取代。
7.根据权利要求6所述的多肽,其中所述取代选自L19A、L19P、L19Q、L19Y、L19N、L19S、L19T、L19V。
8.根据权利要求1-7中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置M23处包含取代。
9.根据权利要求8所述的多肽,其中所述取代选自M23A、M23G、M23S、M23T、M23V、M23D、M23E、M23I、M23K、M23L、M23N、M23Q、M23R和M23Y。
10.根据权利要求1-9中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置N88处包含取代。
11.根据权利要求10所述的多肽,其中所述取代选自N88T、N88A和N88S。
12.根据权利要求1-11中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置E95处包含取代。
13.根据权利要求12所述的多肽,其中所述取代选自E95Q、E95G、E95T、E95V、E95P、E95H、E95N和E95Y。
14.根据权利要求1-13中任一项所述的多肽,其中相比于野生型IL-2,所述修饰的IL-2包含至少一个降低对CD132的亲和力的取代。
15.根据权利要求1-14中任一项所述的多肽,其中所述修饰的IL-2在至少一个选自Q22、R120、T123、Q126、S127、I129和S130的氨基酸位置处包含至少一个取代。
16.根据权利要求15所述的多肽,其中所述修饰的IL-2在氨基酸位置Q22处包含取代。
17.根据权利要求16所述的多肽,其中所述取代选自Q22A、Q22D、Q22G、Q22H、Q22K、Q22N、Q22R、Q22S、Q22T、Q22V和Q22Y。
18.根据权利要求15-17中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置R120处包含取代。
19.根据权利要求18所述的多肽,其中所述取代选自R120A、R120D、R120E、R120F、R120G、R120H、R120K、R120N、R120Q、R120S、R120V和R120Y。
20.根据权利要求15-19中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置T123处包含取代。
21.根据权利要求20所述的多肽,其中所述取代选自T123D、T123E、T123H、T123K、T123N、T123Q和T123R。
22.根据权利要求15-21中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置Q126处包含取代。
23.根据权利要求22所述的多肽,其中所述取代选自Q126N、Q126A和Q126Y。
24.根据权利要求15-23中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置S127处包含取代。
25.根据权利要求24所述的多肽,其中所述取代选自S127D、S127E、S127H、S127K、S127N、S127P和S127R。
26.根据权利要求15-25中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置I129处包含取代。
27.根据权利要求26所述的多肽,其中所述取代选自I129A、I129H、I129R和I129S。
28.根据权利要求15-27中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置S130处包含取代。
29.根据权利要求28所述的多肽,其中所述取代选自S130E、S130K、S130N、S130P、S130Q和S130R。
30.一种包含修饰的IL-2的多肽,其中所述修饰的IL-2在选自Q22、R120、T123、S127和S130的至少一个氨基酸位置处包含至少一个取代。
31.根据权利要求30所述的多肽,其中相比于野生型IL-2,所述修饰的IL-2具有降低的对CD132的亲和力。
32.根据权利要求30-31中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置Q22处包含取代。
33.根据权利要求32所述的多肽,其中所述取代选自Q22A、Q22D、Q22E、Q22G、Q22H、Q22K、Q22N、Q22P、Q22R、Q22S、Q22T、Q22V和Q22Y。
34.根据权利要求30-33中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置R120处包含取代。
35.根据权利要求34所述的多肽,其中所述取代选自R120A、R120D、R120E、R120F、R120G、R120H、R120K、R120N、R120P、R120Q、R120S、R120V和R120Y。
36.根据权利要求30-35所述的多肽,其中所述修饰的IL-2在氨基酸位置T123处包含取代。
37.根据权利要求36所述的多肽,其中所述取代选自T123D、T123E、T123H、T123K、T123N、T123Q和T123R。
38.根据权利要求30-37中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置S127处包含取代。
39.根据权利要求38所述的多肽,其中所述取代选自S127D、S127E、S127H、S127K、S127N、S127P、S127Q和S127R。
40.根据权利要求30-39中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置S130处包含取代。
41.根据权利要求40所述的多肽,其中所述取代选自S130D、S130E、S130H、S130K、S130N、S130P、S130Q和S130R。
42.根据权利要求30-41中任一项所述的多肽,其中相比于野生型IL-2,所述修饰的IL-2包含至少一个降低对CD122的亲和力的取代。
43.根据权利要求42所述的多肽,其中所述修饰的IL-2在至少一个选自H16、L19、M23、D84、N88和E95的氨基酸位置处包含至少一个取代。
44.根据权利要求43所述的多肽,其中所述修饰的IL-2在氨基酸位置H16处包含取代。
45.根据权利要求44所述的多肽,其中所述取代选自H16A、H16T、H16V和H16N。
46.根据权利要求43-45中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置L19处包含取代。
47.根据权利要求46所述的多肽,其中所述取代选自L19A、L19P、L19Q、L19Y、L19N、L19S、L19T、L19V。
48.根据权利要求43-47中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置M23处包含取代。
49.根据权利要求48所述的多肽,其中所述取代选自M23A、M23G、M23S、M23T、M23V、M23D、M23E、M23I、M23K、M23L、M23N、M23Q、M23R和M23Y。
50.根据权利要求43-49中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置D84处包含取代。
51.根据权利要求50所述的多肽,其中所述取代选自D84S、D84G、D84A、D84T、D84V、D84Y和D84N。
52.根据权利要求43-51中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置N88处包含取代。
53.根据权利要求52所述的多肽,其中所述取代选自N88T、N88A和N88S。
54.根据权利要求43-53中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置E95处包含取代。
55.根据权利要求54所述的多肽,其中所述取代选自E95Q、E95G、E95T、E95V、E95P、E95H、E95N和E95Y。
56.根据权利要求1-55中任一项所述的多肽,其中相比于野生型IL-2,所述修饰的IL-2包含至少一个降低对CD25的亲和力的取代。
57.根据权利要求1-56中任一项所述的多肽,其中所述修饰的IL-2在至少一个选自K43、Y45、E61、I114、P65、F42、R38和L72的氨基酸位置处包含至少一个取代,和/或其中所述修饰的IL-2包含氨基酸F42的缺失。
58.根据权利要求57所述的多肽,其中所述修饰的IL-2在氨基酸F42处包含取代或包含氨基酸F42的缺失。
59.根据权利要求58所述的多肽,其中所述修饰的IL-2在氨基酸位置F42处包含选自F42K、F42A、F42R、F42G、F42S和F42T的取代。
60.根据权利要求58所述的多肽,其中所述修饰的IL-2包含氨基酸位置F42的缺失。
61.根据权利要求57-60中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置K43处包含取代。
62.根据权利要求61所述的多肽,其中所述取代选自K43E和K43D。
63.根据权利要求57-62中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置Y45处包含取代。
64.根据权利要求63所述的多肽,其中所述取代选自Y45R和Y45K。
65.根据权利要求57-64中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置E61处包含取代。
66.根据权利要求65所述的多肽,其中所述取代选自E61R、E61G、E61H、E61N、E61P、E61S、E61T、E61Y、E61A、E61Q和E61K。
67.根据权利要求57-66中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置I114处包含取代。
68.根据权利要求67所述的多肽,其中所述取代是I114F、I114Y或I114W。
69.根据权利要求57-68中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置P65处包含取代。
70.根据权利要求69所述的多肽,其中所述取代选自P65R、P65E、P65K、P65H、P65Y、P65Q、P65D和P65N。
71.根据权利要求57-70中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置R38处包含取代。
72.根据权利要求71所述的多肽,其中所述在R38处的取代选自R38A和R38G。
73.根据权利要求57-72中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置L72处包含取代。
74.根据权利要求73所述的多肽,其中所述在L72处的取代是L72G。
75.根据权利要求1-74中任一项所述的多肽,其中所述修饰的IL-2包含取代Q22A或取代R120A、或取代Q22A和R120A。
76.根据权利要求1-75中任一项所述的多肽,其中所述修饰的IL-2包含取代P65R和R38A或取代P65R和E61R。
77.根据权利要求1-76中任一项所述的多肽,其中所述修饰的IL-2包含至少一个选自H16A、L19A、L19N、M23A、D84S或D84Y、N88S和E95Q的取代。
78.根据权利要求1-77中任一项所述的多肽,其中所述修饰的IL-2在氨基酸位置P65、H16和D84处包含取代。
79.根据权利要求78所述的多肽,其中所述修饰的IL-2包含取代P65R、H16A和D84S或取代P65R、H16A和D84Y。
80.根据权利要求1-79中任一项所述的多肽,其中所述修饰的IL-2在至少一个选自T3和C125的氨基酸位置处包含至少一个取代和/或包含IL-2的前五个氨基酸的缺失。
81.根据权利要求80所述的多肽,其中所述修饰的IL-2包含至少一个选自T3A、C125A、C125V和C125S的取代。
82.根据权利要求81所述的多肽,其中所述修饰的IL-2包含T3A和C125S取代或T3A和C125V取代。
83.根据权利要求81所述的多肽,其中所述修饰的IL-2包含IL-2的前五个氨基酸的缺失和C125S取代或C125V取代。
84.根据前述权利要求中任一项所述的多肽,其中所述修饰的IL-2包含选自以下的取代组:[T3A、H16A、E61R、P65R、D84Y、C125S]、[T3A、H16A、M23T、E61R、P65R、D84Y、E95Q、C125S]、[T3A、H16A、L19N、E61R、P65R、D84Y、C125S]、[T3A、H16A、L19N、M23T、E61R、P65R、D84Y、E95Q、C125S]、[T3A、H16A、E61R、P65R、D84Y、C125S、S127D]、[T3A、H16A、M23T、E61R、P65R、D84Y、E95Q、C125S、S127D]、[T3A、H16A、L19N、E61R、P65R、D84Y、C125S、S127D]以及[T3A、H16A、L19N、M23T、E61R、P65R、D84Y、E95Q、C125S、S127D]。
85.一种包含修饰的IL-2的修饰的多肽,其中所述修饰的IL-2包含选自以下的取代组:[T3A、H16A、E61R、P65R、D84Y、C125S]、[T3A、H16A、M23T、E61R、P65R、D84Y、E95Q、C125S]、[T3A、H16A、L19N、E61R、P65R、D84Y、C125S]、[T3A、H16A、L19N、M23T、E61R、P65R、D84Y、E95Q、C125S]、[T3A、H16A、E61R、P65R、D84Y、C125S、S127D]、[T3A、H16A、M23T、E61R、P65R、D84Y、E95Q、C125S、S127D]、[T3A、H16A、L19N、E61R、P65R、D84Y、C125S、S127D]以及[T3A、H16A、L19N、M23T、E61R、P65R、D84Y、E95Q、C125S、S127D]。
86.根据前述权利要求中任一项所述的多肽,其中所述修饰的IL-2包含所指示的取代,并且不包含任何另外的取代。
87.根据前述权利要求中任一项所述的多肽,其中所述修饰的IL-2是修饰的人IL-2。
88.根据前述权利要求中任一项所述的多肽,其中所述氨基酸位置对应于SEQ ID NO:1中的氨基酸位置。
89.根据前述权利要求中任一项所述的多肽,其中所述修饰的IL-2包含与SEQ ID NO:84至少90%、91%、92%、93%、94%、95%、96%、97%、98%或99%相同并且包含选自SEQID NO:105-290的氨基酸序列的对应取代的氨基酸序列。
90.根据前述权利要求中任一项所述的多肽,其中所述修饰的IL-2包含与选自SEQIDNO:270-277的氨基酸序列至少90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或100%相同的氨基酸序列并且包含取代D84Y。
91.根据前述权利要求中任一项所述的多肽,其中所述修饰的IL-2包含选自SEQ IDNO:105-290的氨基酸序列。
92.根据前述权利要求中任一项所述的多肽,其中所述修饰的IL-2包含选自SEQ IDNO:270-277的氨基酸序列。
93.根据前述权利要求中任一项所述的多肽,其中所述多肽包含Fc区。
94.根据权利要求93所述的多肽,其中所述修饰的IL-2与所述Fc区的N端或C端融合。
95.根据权利要求93或权利要求94所述的多肽,其中所述Fc区在Kabat氨基酸位置T366处包含取代。
96.根据权利要求95所述的多肽,其中所述Fc区包含T366W取代。
97.根据权利要求93或权利要求94所述的多肽,其中所述Fc区在至少一个选自T366、L368和Y407的Kabat氨基酸位置处包含至少一个取代。
98.根据权利要求108所述的多肽,其中所述Fc区包含T366S、L368A和Y407V突变。
99.根据权利要求93-98中任一项所述的多肽,其中所述Fc区在选自S354和Y349的Kabat位置处包含取代。
100.根据权利要求99所述的多肽,其中所述Fc区包含S354C或Y349C取代。
101.根据权利要求93-100中任一项所述的多肽,其中所述Fc区在Kabat氨基酸位置H435处包含取代。
102.根据权利要求101所述的多肽,其中所述Fc区包含选自H435R和H435K的取代。
103.根据权利要求93-102中任一项所述的多肽,其中所述Fc区在至少一个选自M252和M428的Kabat氨基酸位置处包含至少一个取代。
104.根据权利要求103所述的多肽,其中所述Fc区包含M252Y和M428V取代。
105.根据权利要求93-104中任一项所述的多肽,其中所述Fc区包含Kabat氨基酸E233、L234和L235的缺失。
106.根据权利要求93-104中任一项所述的多肽,其中所述Fc区在选自L234、L235和P329的至少一个氨基酸位置处包含至少一个取代。
107.根据权利要求106所述的多肽,其中所述Fc区包含L234A、L235A和P329G取代。
108.根据权利要求93-107中任一项所述的多肽,其中所述Fc区包含与选自SEQ ID NO:47-83、292和293的氨基酸序列至少90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或100%相同的氨基酸序列。
109.根据权利要求93-108中任一项所述的多肽,其中所述Fc区是重链恒定区的一部分。
110.根据权利要求109所述的多肽,其中所述重链恒定区是IgG恒定区。
111.根据权利要求110所述的多肽,其中所述重链恒定区是IgG1、IgG2、IgG3或IgG4恒定区。
112.根据权利要求93-111中任一项所述的多肽,其中所述修饰的IL-2与所述Fc区或重链恒定区的C端融合。
113.根据权利要求112所述的多肽,其中所述修饰的IL-2经由包含1-20个氨基酸的接头与所述Fc区或重链恒定区的C端融合。
114.根据权利要求113所述的多肽,其中所述接头包含甘氨酸氨基酸。
115.根据权利要求114所述的多肽,其中所述接头包含甘氨酸和丝氨酸氨基酸。
116.根据权利要求113-115中任一项所述的多肽,其中所述接头中的大部分或全部氨基酸是甘氨酸和丝氨酸。
117.根据权利要求93-116中任一项所述的多肽,其中所述多肽包含选自SEQ ID NO:105-290的氨基酸序列以及选自SEQ ID NO:48、64、292和293的氨基酸序列。
118.根据前述权利要求中任一项所述的多肽,其中所述多肽包含至少一个抗原结合结构域。
119.根据权利要求118所述的多肽,其中所述多肽包含两个、三个或四个抗原结合结构域。
120.根据权利要求118或权利要求119所述的多肽,其中至少一个抗原结合结构域特异性结合T细胞抗原或自然杀伤细胞抗原。
121.根据权利要求118-120中任一项所述的多肽,其中至少一个抗原结合结构域特异性结合CD4+T细胞抗原或CD8+T细胞抗原。
122.根据权利要求121所述的多肽,其中所述至少一个抗原结合结构域特异性结合激活的CD4+T细胞或激活的CD8+T细胞上的抗原。
123.根据权利要求118-122中任一项所述的多肽,其中至少一个抗原结合结构域是激动剂。
124.根据权利要求118-122中任一项所述的多肽,其中所述抗原结合结构域是拮抗剂。
125.根据权利要求118-124中任一项所述的多肽,其中至少一个抗原结合结构域特异性结合PD-1、CTLA-4、LAG3、TIM3、4-1BB、OX40、GITR、CD8a、CD8b、CD4、NKp30、NKG2A、TIGIT、TGFβR1、TGFβR2、Fas、NKG2D、NKp46、PD-L1、CD107a、ICOS、TNFR2、CD16a或γδTCR。
126.根据权利要求118-124中任一项所述的多肽,其中至少一个抗原结合结构域特异性结合PD-1。
127.根据权利要求118-126中任一项所述的多肽,其中至少一个抗原结合结构域是人或人源化抗原结合结构域。
128.根据权利要求127所述的多肽,其中每个抗原结合结构域独立地是人或人源化抗原结合结构域。
129.根据权利要求118-128中任一项所述的多肽,其中至少一个抗原结合结构域包含VHH结构域。
130.根据权利要求129所述的多肽,其中每个抗原结合结构域包含VHH结构域。
131.根据权利要求118-128中任一项所述的多肽,其中至少一个抗原结合结构域包含VH结构域和VL结构域。
132.根据权利要求131所述的多肽,其中至少一个抗原结合结构域包含选自以下的抗体的VH结构域和VL结构域:派姆单抗、纳武单抗、AMP-514、TSR-042、STI-A1110、伊匹单抗、曲美目单抗、乌瑞鲁单抗、乌托鲁单抗、阿特珠单抗和度伐鲁单抗。
133.根据权利要求131或132所述的多肽,其中所述至少一个抗原结合结构域包含单链Fv(scFv)。
134.根据权利要求131或132所述的多肽,其中所述多肽包含重链恒定区,其中所述VH结构域与所述重链恒定区融合,并且其中所述VL结构域与所述VH结构域缔合。
135.根据权利要求134所述的多肽,其中所述VL结构域与轻链恒定区融合。
136.根据权利要求135所述的多肽,其中所述轻链恒定区选自κ和λ。
137.根据权利要求118-136中任一项所述的多肽,其中每个所述抗原结合结构域是相同的。
138.根据权利要求118-137中任一项所述的多肽,其中每个所述抗原结合结构域特异性结合相同的抗原。
139.根据权利要求118-136中任一项所述的多肽,其中至少一个所述抗原结合结构域与至少一个其他抗原结合结构域特异性结合不同的抗原。
140.根据权利要求139所述的多肽,其中至少一个抗原结合结构域特异性结合PD-1,并且至少一个其他抗原结合结构域特异性结合除PD-1之外的T细胞抗原或自然杀伤细胞抗原。
141.根据权利要求118-140中任一项所述的多肽,其中至少一个抗原结合结构域结合PD-1、CTLA-4、LAG3、TIM3、4-1BB、OX40、GITR、CD8a、CD8b、CD4、NKp30、NKG2A、TIGIT、TGFβR1、TGFβR2、Fas、NKG2D、NKp46、PD-L1、CD107a、ICOS、TNFR2、CD16a、DNAM1或γδTCR(Vγ9、Vγ2、Vδ1)。
142.根据权利要求93-141中任一项所述的多肽,其中所述多肽在生理条件下形成同二聚体。
143.根据前述权利要求中任一项所述的多肽,其中与人野生型IL-2对于IL-2R的亲和力相比,所述修饰的IL-2以低至少2倍、3倍、4倍、5倍、6倍、7倍、8倍、9倍、至少10倍、至少20倍、至少30倍、至少50倍或至少100倍的亲和力结合人IL-2R。
144.一种包含第一多肽和第二多肽的复合物,其中所述第一多肽是根据前述权利要求中任一项所述的多肽。
145.根据权利要求144所述的复合物,其中所述第一多肽包含第一Fc区并且所述第二多肽包含第二Fc区。
146.根据权利要求144或145所述的复合物,其中每个Fc区是选自人IgG1、IgG2、IgG3、IgG4的同种型的。
147.根据权利要求146所述的复合物,其中每个Fc区是人IgG1的。
148.根据权利要求144-147中任一项所述的复合物,其中每个Fc区包含氨基酸E233、L234和L235的缺失。
149.根据权利要求144-148中任一项所述的复合物,其中每个Fc区包含H435R或H435K突变。
150.根据权利要求155-160中任一项所述的复合物,其中所述Fc区包含突变M252Y和M428L或突变M252Y和M428V。
151.根据权利要求144-150中任一项所述的复合物,其中所述第一Fc区或所述第二Fc区包含T366W突变,并且另一个Fc区包含突变T366S、L368A和Y407V。
152.根据权利要求151所述的复合物,其中所述第一Fc区或所述第二Fc区包含S354C突变。
153.根据权利要求144-152中任一项所述的复合物,其中每个Fc区独立地包含与选自SEQ ID NO:47-83、292和293的氨基酸序列至少90%、91%、92%、93%、94%、95%、96%、97%、98%、99%或100%相同的氨基酸序列。
154.根据权利要求144-153中任一项所述的复合物,其中所述第二多肽不包含修饰的IL-2。
155.根据权利要求144-154中任一项所述的复合物,其中所述第一多肽包含至少一个抗原结合结构域。
156.根据权利要求144-155中任一项所述的复合物,其中所述第二多肽包含至少一个抗原结合结构域。
157.根据权利要求144-156中任一项所述的复合物,其中所述第一多肽包含第一抗原结合结构域、Fc区和修饰的IL-2。
158.根据权利要求157所述的复合物,其中所述第一抗原结合结构域与所述Fc区的N端融合,并且所述修饰的IL-2与所述Fc区的C端融合。
159.根据权利要求157或158所述的复合物,其中所述第二多肽包含第二抗原结合结构域和Fc区。
160.根据权利要求159所述的复合物,其中所述第一抗原结合结构域和所述第二抗原结合结构域是相同或不同的。
161.根据权利要求160所述的复合物,其中:
a)所述第一抗原结合结构域和所述第二抗原结合结构域均结合PD-1;
b)所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合LAG3;
c)所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合CTLA-4;
d)所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合4-1BB;
e)所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合OX40;
f)所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合GITR;
g)所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合CD8a;
h)所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合CD8b;
i)所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合CD4;j)所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合NKp30;k)所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合NKG2A;
l)所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合TIGIT;
m)所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合NKG2D;
n)所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合TGFBR2;
o)所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合Fas;
p)所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合CD107a;
q)所述第一抗原结合结构域结合PD-1,并且所述第二抗原结合结构域结合NKp46;
r)所述第一抗原结合结构域结合CD8a,并且所述第二抗原结合结构域结合TGFRβR2;
s)所述第一抗原结合结构域结合CD8a,并且所述第二抗原结合结构域结合Fas;
t)所述第一抗原结合结构域结合NKG2D,并且所述第二抗原结合结构域结合TGFRβR2;
u)所述第一抗原结合结构域结合NKG2D,并且所述第二抗原结合结构域结合Fas;
v)所述第一抗原结合结构域结合NKG2A,并且所述第二抗原结合结构域结合TGFRβR2;
w)所述第一抗原结合结构域结合NKG2A,并且所述第二抗原结合结构域结合Fas;
x)所述第一抗原结合结构域结合NKp46,并且所述第二抗原结合结构域结合TGFRβR2;
y)所述第一抗原结合结构域结合NKp46,并且所述第二抗原结合结构域结合Fas;
z)所述第一抗原结合结构域结合CTLA-4,并且所述第二抗原结合结构域结合LAG3;
aa)所述第一抗原结合结构域结合CTLA-4,并且所述第二抗原结合结构域结合Tim3;
bb)所述第一抗原结合结构域结合CTLA-4,并且所述第二抗原结合结构域结合OX40;
cc)所述第一抗原结合结构域结合CTLA-4,并且所述第二抗原结合结构域结合GITR;
dd)所述第一抗原结合结构域结合CTLA-4,并且所述第二抗原结合结构域结合CD107a;
ee)所述第一抗原结合结构域结合CTLA-4,并且所述第二抗原结合结构域结合NKp46
ff)所述第一抗原结合结构域结合ICOS,并且所述第二抗原结合结构域结合TNFR2;gg)所述第一抗原结合结构域结合γδTCR,并且所述第二抗原结合结构域结合NKG2D;
hh)所述第一抗原结合结构域结合γδTCR,并且所述第二抗原结合结构域结合DNAM1;
ii)所述第一抗原结合结构域结合γδTCR,并且所述第二抗原结合结构域结合TIGIT;
jj)所述第一抗原结合结构域结合γδTCR,并且所述第二抗原结合结构域结合4-1BB;
kk)所述第一抗原结合结构域结合γδTCR,并且所述第二抗原结合结构域结合Fas;ll)所述第一抗原结合结构域结合γδTCR,并且所述第二抗原结合结构域结合NKG2A;或
mm)所述第一抗原结合结构域结合γδTCR,并且所述第二抗原结合结构域结合CD16a。
162.根据权利要求144-161中任一项所述的复合物,其中与人野生型IL-2对于IL-2R的亲和力相比,所述修饰的IL-2以低至少2倍、3倍、4倍、5倍、6倍、7倍、8倍、9倍、至少10倍、至少20倍、至少30倍、至少50倍或至少100倍的亲和力结合人IL-2R。
163.一种药物组合物,其包含根据权利要求1-154中任一项所述的多肽或根据权利要求144-162中任一项所述的复合物和药学上可接受的载体。
164.一种分离的核酸,其编码根据权利要求1-143中任一项所述的多肽或根据权利要求144-162中任一项所述的复合物。
165.一种表达载体,其包含根据权利要求164所述的核酸。
166.一种分离的宿主细胞,其包含根据权利要求164所述的核酸或根据权利要求165所述的表达载体。
167.一种分离的宿主细胞,其表达根据权利要求1-143中任一项所述的多肽或根据权利要求144-162中任一项所述的复合物。
168.一种产生根据权利要求1-143中任一项所述的多肽或根据权利要求144-162中任一项所述的复合物的方法,其包括在适合表达所述多肽或复合物的条件下孵育根据权利要求166或权利要求167所述的宿主细胞。
169.根据权利要求168所述的方法,其还包括分离所述多肽或复合物。
170.一种增加CD4+和/或CD8+T细胞增殖的方法,其包括使T细胞与根据权利要求1-154中任一项所述的多肽或根据权利要求144-162中任一项所述的复合物接触。
171.根据权利要求170所述的方法,其中所述CD4+和/或CD8+T细胞在体外。
172.根据权利要求170所述的方法,其中所述CD4+和/或CD8+T细胞在体内。
173.根据权利要求170-172中任一项所述的方法,其中所述增加为至少1.5倍、至少2倍、至少3倍或至少5倍。
174.一种增加NK细胞增殖的方法,其包括使NK细胞与根据权利要求1-143中任一项所述的多肽或根据权利要求144-162中任一项所述的复合物接触。
175.根据权利要求174所述的方法,其中所述增加为至少1.5倍、至少2倍、至少3倍或至少5倍。
176.一种治疗癌症的方法,其包括向患有癌症的受试者施用药学有效量的根据权利要求1-143中任一项所述的多肽或根据权利要求144-162中任一项所述的复合物或根据权利要求163所述的药物组合物。
177.根据权利要求176所述的方法,其中所述癌症选自基底细胞癌;胆道癌;膀胱癌;骨癌;脑和中枢神经系统癌症;乳腺癌;腹膜癌;宫颈癌;绒毛膜癌;结直肠癌;结缔组织癌;消化系统癌症;子宫内膜癌;食道癌;眼癌;头颈癌;胃癌;胃肠癌;胶质母细胞瘤;肝癌;肝肿瘤;上皮内瘤;肾脏癌或肾癌;喉癌;肝脏癌症;肺癌;小细胞肺癌;非小细胞肺癌;肺腺癌;肺鳞癌;黑色素瘤;骨髓瘤;神经母细胞瘤;口腔癌;卵巢癌;胰腺癌;前列腺癌;视网膜母细胞瘤;横纹肌肉瘤;直肠癌;呼吸系统癌症;唾液腺癌;肉瘤;皮肤癌;鳞状细胞癌;胃癌;睾丸癌;甲状腺癌;子宫或子宫内膜癌;泌尿系统癌症;外阴癌;淋巴瘤;霍奇金淋巴瘤;非霍奇金淋巴瘤;B细胞淋巴瘤;低分级/滤泡性非霍奇金淋巴瘤(NHL);小淋巴细胞(SL)NHL;中分级/滤泡性NHL;中分级弥漫性NHL;高分级免疫母细胞NHL;高分级淋巴母细胞NHL;高分级小非裂解细胞NHL;大肿块NHL;套细胞淋巴瘤;艾滋病相关淋巴瘤;华氏巨球蛋白血症;慢性淋巴细胞白血病(CLL);急性成淋巴细胞性白血病(ALL);毛细胞白血病;和慢性成髓细胞性白血病。
178.根据权利要求176或177所述的方法,其还包括施用另外的治疗剂。
179.根据权利要求178所述的方法,其中所述另外的治疗剂是抗癌剂。
180.根据权利要求179所述的方法,其中所述抗癌剂选自化疗剂、抗癌生物制剂、放射疗法、CAR-T疗法和溶瘤病毒。
181.根据权利要求179或权利要求180所述的方法,其中所述另外的治疗剂是抗癌生物制剂。
182.根据权利要求181所述的方法,其中所述抗癌生物制剂是抑制PD-1和/或PD-L1的药剂。
183.根据权利要求181所述的方法,其中所述抗癌生物制剂是抑制VISTA、gpNMB、B7H3、B7H4、HHLA2、CTLA4或TIGIT的药剂。
184.根据权利要求179-183中任一项所述的方法,其中所述抗癌剂是抗体。
185.根据权利要求181所述的方法,其中所述抗癌生物制剂是细胞因子。
186.根据权利要求179所述的方法,其中所述抗癌剂是CAR-T疗法。
187.根据权利要求179所述的方法,其中所述抗癌剂是溶瘤病毒。
188.根据权利要求176-187中任一项所述的方法,所述方法还包括肿瘤切除术和/或放射疗法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063047681P | 2020-07-02 | 2020-07-02 | |
US63/047,681 | 2020-07-02 | ||
PCT/US2021/040061 WO2022006380A2 (en) | 2020-07-02 | 2021-07-01 | Polypeptides comprising modified il-2 polypeptides and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116615440A true CN116615440A (zh) | 2023-08-18 |
Family
ID=77127075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180053315.0A Pending CN116615440A (zh) | 2020-07-02 | 2021-07-01 | 包含修饰的il-2多肽的多肽及其用途 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230235005A1 (zh) |
EP (1) | EP4175979A2 (zh) |
JP (1) | JP2023532904A (zh) |
KR (1) | KR20230035076A (zh) |
CN (1) | CN116615440A (zh) |
AR (1) | AR122863A1 (zh) |
AU (1) | AU2021299552A1 (zh) |
CA (1) | CA3184618A1 (zh) |
IL (1) | IL299542A (zh) |
MX (1) | MX2022016532A (zh) |
TW (1) | TW202216745A (zh) |
WO (1) | WO2022006380A2 (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202233673A (zh) | 2020-10-23 | 2022-09-01 | 美商雅雪生物治療公司 | 含調節免疫細胞功能之cd8抗原結合分子之融合物 |
WO2023133393A1 (en) * | 2022-01-05 | 2023-07-13 | Inhibrx, Inc. | Gamma delta t-cell-targeted modified il-2 polypeptides and uses thereof |
WO2023151661A1 (zh) * | 2022-02-11 | 2023-08-17 | 江苏恒瑞医药股份有限公司 | 免疫缀合物及其用途 |
WO2023212056A2 (en) * | 2022-04-27 | 2023-11-02 | Asher Biotherapeutics, Inc. | Combination of cytokine fusion proteins with cd8 antigen binding molecules |
TW202402784A (zh) * | 2022-07-06 | 2024-01-16 | 中國商科望(上海)生物醫藥科技有限公司 | Il2突變蛋白及其用途 |
CN116041539B (zh) * | 2022-10-31 | 2023-07-21 | 山东博安生物技术股份有限公司 | Il-2突变体免疫缀合物 |
WO2024165500A1 (en) * | 2023-02-06 | 2024-08-15 | Merck Patent Gmbh | Vhh-based nkp46 binders |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
DK2330201T3 (en) | 2003-10-22 | 2017-07-24 | Keck Graduate Inst | PROCEDURES FOR SYNTHESIS OF HEATER-MULTIMATE POLYPEPTIDES WHEN USING A HAPLOID COUPLE STRATEGY |
AU2005227263A1 (en) * | 2004-03-05 | 2005-10-06 | Novartis Vaccines And Diagnostics, Inc. | In vitro test system for predicting patient tolerability of therapeutic agents |
JP5128935B2 (ja) | 2004-03-31 | 2013-01-23 | ジェネンテック, インコーポレイテッド | ヒト化抗TGF−β抗体 |
EP3134102B1 (en) * | 2014-04-24 | 2019-07-03 | The Board of Trustees of The Leland Stanford Junior University | Superagonists, partial agonists and antagonists of interleukin-2 |
AU2017379900A1 (en) * | 2016-12-22 | 2019-06-13 | Cue Biopharma, Inc. | T-cell modulatory multimeric polypeptides and methods of use thereof |
JP2021528105A (ja) * | 2018-06-22 | 2021-10-21 | キュージーン インコーポレイテッドCugene Inc. | インターロイキン−2バリアントおよびその使用方法 |
US20220089667A1 (en) * | 2019-01-07 | 2022-03-24 | Inhibrx, Inc. | Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof |
-
2021
- 2021-07-01 AR ARP210101857A patent/AR122863A1/es unknown
- 2021-07-01 IL IL299542A patent/IL299542A/en unknown
- 2021-07-01 CN CN202180053315.0A patent/CN116615440A/zh active Pending
- 2021-07-01 MX MX2022016532A patent/MX2022016532A/es unknown
- 2021-07-01 WO PCT/US2021/040061 patent/WO2022006380A2/en active Application Filing
- 2021-07-01 CA CA3184618A patent/CA3184618A1/en active Pending
- 2021-07-01 AU AU2021299552A patent/AU2021299552A1/en active Pending
- 2021-07-01 KR KR1020237003798A patent/KR20230035076A/ko unknown
- 2021-07-01 TW TW110124255A patent/TW202216745A/zh unknown
- 2021-07-01 EP EP21748720.6A patent/EP4175979A2/en active Pending
- 2021-07-01 US US18/002,613 patent/US20230235005A1/en active Pending
- 2021-07-01 JP JP2022580769A patent/JP2023532904A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3184618A1 (en) | 2022-01-06 |
AR122863A1 (es) | 2022-10-12 |
TW202216745A (zh) | 2022-05-01 |
JP2023532904A (ja) | 2023-08-01 |
IL299542A (en) | 2023-02-01 |
KR20230035076A (ko) | 2023-03-10 |
WO2022006380A2 (en) | 2022-01-06 |
WO2022006380A3 (en) | 2022-02-24 |
AU2021299552A1 (en) | 2023-02-02 |
EP4175979A2 (en) | 2023-05-10 |
MX2022016532A (es) | 2023-04-12 |
US20230235005A1 (en) | 2023-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220089667A1 (en) | Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof | |
US20230235005A1 (en) | Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof | |
JP7462611B2 (ja) | Ox40結合性ポリペプチド及びその使用 | |
CN114040926A (zh) | 结合cd123的多肽及其用途 | |
TW202328171A (zh) | 靶向NKp46之經修飾之IL-2多肽及其用途 | |
JP2024526835A (ja) | Cd8結合ポリペプチド及びその使用 | |
JP2024534838A (ja) | NKp46結合ポリペプチド及びその使用 | |
WO2023004305A1 (en) | Cd8-targeted modified il-2 polypeptides and uses thereof | |
RU2802070C2 (ru) | Ох40-связывающие полипептиды и их применение | |
KR20240130130A (ko) | 감마 델타 t 세포 결합 폴리펩티드 및 그의 용도 | |
TW202334193A (zh) | 靶向γδ T細胞之經修飾IL-2多肽及其用途 | |
CN117980335A (zh) | Cd8结合多肽及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20240924 Address after: California, USA Applicant after: Yinxibi Bioscience Co.,Ltd. Country or region after: U.S.A. Address before: California, USA Applicant before: INHIBRX L.P. Country or region before: U.S.A. |